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Expanding the functional CD8+ T cell repertoire reduces HSV-1 reactivation from 
latency in sensory ganglia 
 
Anthony St. Leger, Ph.D. 
University of Pittsburgh, 2012
  
Following corneal infection, herpes simplex virus (HSV)-1 establishes latency in sensory 
neurons of the trigeminal ganglia (TG). In humans, spontaneous and recurrent reactivation of 
HSV-1 from latency has the potential to cause lesions on the gums (stomatitis), lips (cold sores, 
fever blisters), cornea (stromal keratitis), and brain (encephalitis). Latently infected neurons were 
once thought be largely ignored by the host immune system. Existing evidence shows that not 
only do HSV-specific CD8 T cells recognize latently infected neurons; they actively maintain 
viral latency using proinflammatory cytokines and lytic granules containing granzymes. The 
premise of this study further characterized the nature of the CD8 T cell response. Previous 
studies displayed that in the C57BL/6 mouse; CD8 T cells infiltrate the TG and become situated 
in direct apposition to infected neurons. It was known that 50 % of the CD8 T cells recognized 
the immunodominant epitope on glycoprotein B (gB) while the specificities of the remaining 
CD8 T cells were undefined. In this study, we observed that the non-gB CD8 T cell repertoire 
was confined to 18 epitopes on 11 viral proteins. During acute infection, these cells, similar to 
gB498-505-specific CD8 T cells, readily produce cytokines and release lytic granules upon 
stimulation. Conversely, during latency, even though these cells remain in the TG, they lose the 
ability to produce cytokines and release lytic granules upon stimulation suggesting functional 
compromise, unlike gB498-505-specific CD8 T cells. We show that the immunosuppressive 
cytokine, IL-10, preferentially suppresses the non-gB498-505-specific CD8 T cell population. Upon 
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administration of an antibody against the IL-10 receptor, we see a dramatic increase in functional 
non-gB498-505-specific CD8 T cells without apparent effect in the gB498-505-specific CD8 T cell 
population. This increase in functional CD8 T cells leads to a 50% reduction in viral reactivation 
from latency suggesting the possibility of anti-IL10R as a treatment of recurrent reactivation of 
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1.0  INTRODUCTION 
1.1 HERPES SIMPLEX VIRUS TYPE 1 
1.1.1 Epidemiology 
The human herpes virus family contains nine structurally similar members that impose a 
significant burden on health systems. The two herpes simplex viruses (HSV) and varicella zoster 
virus (VZV) infect and enter latency in host sensory neurons. Typically, HSV-1 commonly 
associates with the orofacial region with a site of latency in the trigeminal ganglia (TG) while 
HSV-2 most prominently associates with the genital tract and sacral ganglia. As time progresses, 
these distinctions are becoming less pronounced as demonstrated by the increased cases of 
genital HSV-1 infection [1]. Herpes simplex virus (HSV) type 1 is estimated to affect at least 
58% of the population in the United States while reaching prevalence up to 98% in other areas 
[2-4]. Asymptomatic loss of viral control in host neurons, which is thought to occur at least once 
every thirty days in some individuals [5], leads to live virus formation and contributes to high 
frequencies of transmission in the population. Currently, much effort is directed towards 
investigating the immunological mechanisms maintaining viral latency and preventing viral 
spread in hopes of developing a more effective therapeutic treatment. 
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Pathogenesis associated with HSV infections include herpes labialis (cold sores/fever 
blisters), genital lesions, herpes simplex encephalitis (HSE) and herpes keratitis. HSE, though 
rare, affects 1 of every 250,000 individuals per year and is the most common cause of 
sporadically fatal viral encephalitis in the U.S. This is especially prevalent in neonates. The most 
severe form of HSV-mediated ocular disease, herpes stromal keratitis (HSK), involves the deep 
stromal layer of the cornea. Ocular HSV disease is thought to affect 150 out of 100,000 people 
[4]. In North America and Europe, it is estimated that each year up to 13 people per 100,000 
experience their first episode of ocular HSV [4,6-9]. Additionally, it is estimated that 10 million 
people have been affected by herpetic eye disease with 2 million of those people left with 
impaired vision. It is thought that more than 95% of these cases are directly attributed to HSV-1 
as opposed to other herpes viruses [10]. The corneal thinning, scarring, and neovascularization 
due to recurrent HSK is the leading cause of corneal blindness due to infectious origin and 
commonly results in keratoplasty.  
1.1.2 Virus Structure 
HSV-1 is a double stranded DNA virus that has a 152-kbp genome consists of 6 important 
regions encoding at least 84 viral proteins. During lytic infection, the viral genome is linear and 
becomes circularized upon entering latency with the help of “a” region located at the end of the 
linear DNA. Other important regions consist of the 9,000 bp long repeat (RL) (important for 
immediate early regulatory protein formation and latency associated transcripts), the 108-kbp 
long unique region (UL) (DNA replication enzymes and capsid proteins), the 6.6-kbp short 
repeats (RS) (the essential viral protein ICP4), the origins of replication (2 copies), and the 13-
kbp unique short region (US) (viral glycoproteins and response to host defense). The viral 
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genome is encased by an icosadeltahedral structure of viral capsid proteins. Outside of the 
capsid, there is another layer, tegument, which contains viral proteins that initiate viral gene 
transcription upon host cell infection. The outermost component of the virus consists of a lipid 
bilayer envelope that includes numerous viral glycoproteins [11]. These glycoproteins have 
functions that aid viral release from the infected host cell and entry into a new target host cell 
(Figure 1).  
 
 
                            
Figure 1. HSV-1 Structure 
Cartoon depiction of the size and structural components of the HSV-1 virion (Yale website). 
1.1.3 HSV-1 lytic and latent infection 
During lytic infection, herpes viruses are known to sequentially express viral gene 
products necessary for successful replication of infectious virus. Upon infection of permissive 
cells, the virus uses the host RNA polymerase II to transcribe immediate early (IE or α) genes 
within two hours of initial infection. IE genes encode six proteins, ICP0, ICP4, ICP22, ICP27, 
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ICP47, and US1.5. All of these genes except ICP47 encode proteins that transactivate and 
regulate the expression of the next set of genes called early (E or β). ICP47 encodes a protein 
that inhibits immune recognition of virally infected cells (discussed later). The β gene products 
act in concert to replicate viral DNA and allow for late (L or γ) gene expression. The γ class of 
viral genes can be experimentally defined into two categories. Leaky late (γ1) genes are 
expressed at very low levels prior to DNA synthesis and are rapidly upregulated after viral DNA 
synthesis. Conversely, γ2 (true late) genes are only expressed after viral DNA synthesis. Late 
gene products include tegument proteins as well as glycoproteins necessary for viral assembly 
and egress from the cell [11]. The completion of the sequential expression of lytic genes results 
in the formation and release of virions ultimately resulting in cell lysis and death (Figure 2). 
Proteins important for the focus of this dissertation are described in Table 1.  
 
Figure 2. Kinetics of gene expression during lytic infection 
Cartoon depiction of the kinetics of gene expression after a cell permissive for lytic infection is infected. 
Courtesy of Brian Sheridan, Ph.D. 
 
Following primary infection in abraded epithelia of the cornea, HSV gains access to sensory 
neurons and travels via retrograde axonal transport to the neuronal cell bodies in the ophthalmic 
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branch of the TG [12,13]. In the TG, the virus replicates briefly and enters into latency for the 
life of the host. The processes that drive HSV into latency are not well understood, but it is 
thought that the virus, the quiescent nature of the neurons, as well as the immune system play 
significant roles. HSV latency can be defined as the retention of episomal DNA in neuronal cell 
bodies without the production of infectious virions [14]. During this time, viral gene expression 
is largely suppressed except for the abundant expression of latency associated transcripts (LATs) 
in some neurons, which lack any detectable protein product. Much effort has been devoted to 
exploring LATs, however, there appears to be no consensus on the role these transcripts play in 
viral latency [15-17]. Even though these transcripts have been shown to be expendable in the 
establishment and reactivation from latency, there have been studies showing that LATs inhibit 
neuronal apoptosis, thus aiding in the survival of the virus in the host [18-21]. LATs also help 
determine the subsets of neurons HSV will latently infect [22]. Lastly, microRNAs within the 
LAT gene are thought to regulate viral reactivation from latency by impairing the expression of 
ICP0 [23-25], which has been shown in culture. 
The propensity of HSV to exit latency and enter into a productive lytic infection is also 
not well understood. This reactivation event produces live virus particles that travel back down 
neuronal axons and are released at the site of primary infection (cornea) leading to possible 
disease. Sensitive PCR methods have determined the precise numbers of viral genomes per 
infected neuron. Numbers range in orders of tens to thousands in mice while humans average 11 
HSV DNA copies per neuron [26,27]. These data are of importance to reactivation studies 
because the number of HSV-1 genome copies per ganglia directly correlates with the virus’ 
ability to reactivate from latency [28,29]. Many factors are attributed to increased rates of viral 
reactivation from latency which includes immunocompromise, UV-B irradiation, hypothermia, 
 5 
hyperthermia, invasive surgery, psychological stress, and others [31-33]. It was originally 
thought that these factors modified neuronal physiology leading to reduced neuronal control of 
viral reactivation. While the effects of these factors on neuronal physiology have not been 
discredited and do contribute, our lab and others have shown that these stressors also greatly 
affect the function of the immune system, a component of the host absolutely essential in 
controlling viral reactivation from latency [31,34]. 
Epigenetic modifications of the latent HSV-1 genome that include histone methylation 
and acetylation influence the transition from latent to lytic infection. During latency, lytic gene 
promoters are associated with methylated histones, which entail a state of gene inactivity [35]. 
Conversely, the LAT enhancer region during latency is acetylated suggesting active chromatin 
[35-38]. When reactivation is induced in ganglionic cultures, the ICP0 promoter region becomes 
acetylated and allows for production of ICP0 mRNA. Concurrently, the LAT region of HSV-1 
becomes deacetylated during this process. To further support this concept, the histone 
deacetylase inhibitor, sodium butyrate, induces reactivation from latency by modifying DNA-









Table 1. Summary of Select Viral Gene Products 
Gene Product Class Characteristics Ref 
ICP0 α -A nonessential protein at high MOI 
-Required for efficient reactivation 
-Increased expression can induce reactivation from 
latency 
-IFN-γ prevents gene expression  
[11,30,40,41] 
ICP4 α -An essential transactivator of β and γ genes 
-Cleaved by CD8 T cell effector molecule, 
granzyme B 
[11,42,43] 
ICP8 β -An essential viral protein  
-Single-stranded DNA binding protein 
-Binds to the viral DNA and stimulates the viral 
DNA polymerase 
[11,44-47] 
ICP47 α -An nonessential viral protein 
-Binds to host TAP proteins to prevent MHC class I 
presentation of viral antigens 
-Binds with 100X more affinity in humans 




β -A nonessential viral protein 
-Aids in the synthesis of deoxyribonucleotides from 
ribonucleotides for viral DNA proliferation 
-Contains a known subdominant epitope 
-Target for human CD8 T cell response 
[11,50-52] 
Glycoprotein B γ1 -An essential viral protein 
-Required for fusion and entry 
-Expressed at low levels before DNA synthesis and 
much higher after DNA synthesis 
-Contains the immunodominant eptiope 
[11,53-55] 
Glycoprotein C γ2 -A nonessential protein 
-Involved in cell attachment 
-Target for antibody generating vaccines 
-Expression inhibited by IFN-γ 
[41,56-59] 
LATs - -A nonessential viral transcript 
-Accumulates to large levels in latently infected 
neuronal nuclei 
-Prevents neuronal apoptosis 
[18,19,21,60,61] 
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1.2 THE INITIAL IMMUNE RESPONSE TO HSV-1 INFECTION 
1.2.1 Cornea 
Cells of the innate immune system rapidly respond to the infection from a never-before-seen 
pathogen. In our mouse model of HSV ocular infection of C57BL/6 (B6) mice, this response 
begins in the corneal epithelia. While not a classical immune cell, epithelial cells containing toll-
like receptors (TLRs) recognize highly conserved patterns on HSV-1 and secrete type I 
interferons [62,63]. These factors seek to inhibit viral protein translation in infected cells, inhibit 
infection of neighboring uninfected cells, upregulate MHC class I molecules, attract innate 
lymphoid cells such as polymorphonuclear (PMN) neutrophils, natural killer (NK) cells, and γδ 
T cell receptor (TCR) cells. In addition to epithelial cells, corneal resident dendritic cells (DCs) 
migrate to the site of infection and are thought to secrete chemokines creating a chemotactic 
gradient for the recruitment of NK cells to the site of initial infection [64]. The role DCs play in 
the initiation of the adaptive immune response remains controversial and is under extensive 
investigation, but it is known that the innate immune response is absolutely essential for the 
initial control of HSV-1 replication in the cornea and the priming of the adaptive response 
against HSV-1 [65,66].  
1.2.2 Trigeminal Ganglion 
Even though the innate immune response begins in a matter of hours, it is not sufficient to 
prevent the virus from gaining access to axons innervating the cornea. Once in the axons, the 
virus reaches the neuronal cell bodies of the ophthalmic branch of the TG. Here, the virus 
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replicates from 4 to 8 days post infection. Macrophages, γδ T cells, and NK cells infiltrate the 
TG upon replication of the virus [65,67,68]. Nitric Oxide (NO) and tumor necrosis factor (TNF) 
produced by macrophages and granzyme A presumably made by NK cells is thought to limit 
spread of virus to neighboring neurons in the TG [68,69]. During initial infection in the TG, γδ T 
cells and NK cells produce most of the IFN-γ, which has antiviral properties (discussed below) 
and can activate macrophages to produce NO and TNF. Depletion of γδ T cells and macrophages 
during acute infection significantly increases HSV-1 replication. Therefore, innate immune 
function in the TG is critical for the early control of viral replication in the TG. However, a 
functional adaptive immune response is required for complete elimination of replicating virus. 
Mice lacking an adaptive immune system, (severe combined immune deficiency or SCID) 
establish HSV-1 latency similar to wild-type mice, but eventually succumb to viral encephalitis 
due to a loss of viral control [70]. 
1.3 ADAPTIVE IMMUNE RESPONSE TO HSV-1 
After initial infection, DCs present viral antigens to naïve B cells, CD4 and CD8 T cells in the 
draining lymph nodes (DLN). While B cells cannot directly prevent viral reactivation, they do 
help prevent the spread of infectious virus through production of neutralizing antibodies [71]. 
Studies have shown that the transfer of neutralizing antibodies to a non-immune B cell deficient 
host will confer better protection compared to control mice. CD4 T cells infiltrate both the 
cornea and TG after infection [72-75]. In the TG, CD4 T cells do not appear to play a direct role 
in maintaining viral latency, but aid in the functionality of HSV-specific CD8 T cells before the 
establishment of latency [76]. In the cornea, however, CD4 T cells are the main adaptive immune 
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cell that mediates the HSV related immunopathology, HSK [77,78]. While the exact epitopes 
these CD4 T cells recognize have not been elucidated, evidence suggests cornea-resident CD4 T 
cells are stimulated to produce chemokines that recruit PMNs and other cells to the cornea. The 
continual recruitment of inflammatory cells followed by resolution of inflammation eventually 
leads to the disruption of the corneal collagen stratification and ultimate corneal opacity. 
Prevention of CD4 stimulation in the cornea is thought to be attributed by the effective control of 
viral reactivation by CD8 T cells in the TG.  
1.3.1 CD8 T cell recognition and response to virally infected cells  
Host cells constantly break down proteins in the cytosol via proteasomes into small peptides that 
are transported into the endoplasmic reticulum via the transporter associated with antigen 
processing (TAP). Once in the endoplasmic reticulum (ER), the peptides are loaded into the 
peptide groove of MHC class I molecules. MHC class I molecules are shuttled to the surface to 
allow for recognition by CD8 T cells. During viral infection, viral peptides are loaded into MHC 
class I molecules and are shuttled to the surface. Each CD8 T cell clone specific for viral 
peptides bears a unique T cell receptor (TCR) that recognizes a specific peptide/MHC interaction 
(epitope) [79]. Upon initial recognition of the cognate antigen in the draining lymph node, CD8 
T cells respond by proliferating. Interestingly, the epitopes targeted fall into a dominance 
hierarchy consisting of one or a few dominant epitopes (recognized by a large frequency of 
virus-specific CD8 T cells) and several other subdominant epitopes (recognized by a smaller 
frequency of virus-specific CD8 T cells) [80]. Several factors contribute to the dominance 
hierarchy of viral epitopes. These include the efficiency of peptide generation by proteasomes 
[81], kinetics of gene expression [80], the peptide binding affinity to MHC [82], the epitope 
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affinity for TCR, the frequency of epitope-specific CD8 T cell precursors [83,84], and the ability 
of epitope-specific CD8 T cell precursors to expand and survive. Uniquely, in the B6 mouse 
model of HSV-1 infection, there is a single immunodominant epitope on HSV-1 glycoprotein B 
(gB498-505). In the flank infection, an estimated 70% of virus-specific CD8 T cells recognize this 
epitope [53], while 50% of virus-specific CD8 T cells recognize the epitope in the ocular 
infection [85] suggesting the route of infection may also play a role in the immunodominance 
hierarchy. Another unique aspect of the immunodominance hierarchy in ocular HSV-1 infection 
is that a 1:1 ratio of gB498-505-specific CD8 T cell:non-gB498-505-specific  CD8 T cells maintained 
in the TG throughout latency (Figure 3) while immunodominant CD8 T cells are eventually lost 
from the ganglia in the flank infection model [85]. Another subdominant epitope was identified 
on ribonucleotide reductase 1 (RR1822-829), which is recognized in both models of HSV-1 
infection [50,86].  
 
Figure 3 The 1:1 ratio of gB498-505-specifc CD8 T cell:non-gB498-505-specific  CD8 T cell is maintained 
in the TG through latency 
The kinetics of the CD8 T cell response was determined using fluorescently conjugated tetramer labeling of 
gB498-505-specific CD8 T cells [85].  
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During viral infections, a diverse CD8 T cell response has been attributed to a more 
effective viral clearance [87,88]. The term “elite controllers” has been used to describe humans 
that can generate robust T cell responses while also maintaining low viral loads during chronic 
infections such as HIV [89,90]. A characteristic of these elite controllers is the breadth of their 
CD8 T cell response. In the mouse model of CMV and macaque model of SIV infection, 
subdominant T cells directly correlate with better viral control [91]. This is attributed to the 
potential for mutational loss of immunodominant epitopes. In the event of an immunodominant 
epitope mutation, a highly functional subdominant CD8 T cell population would provide the best 
mode of viral control. Additionally, mobilization of the subdominant CD8 T cell response via 
immunization before lethal viral infections have led to better viral control and less mortality 
[92,93]. This concept is especially pertinent in our model of HSV-1 infection where at least 50% 
of CD8 T cell recognizes the immunodominant epitope on glycoprotein B. While subdominant 
epitopes found in mouse or macaque studies may not directly correlate with human epitopes, 
subdominant epitopes found in animal models may act as a guide to target specific viral proteins 
in the development of human vaccines.  
A major hurdle to identifying subdominant CD8 T cell specificities is the low frequency 
among the virus-specific and whole CD8 T cell population. To make matters more complicated, 
expression of activation markers, CD69 and CD44, have proved to be ineffective at definitively 
demarcating viral specific CD8 T cells. Therefore, studies detecting T cell epitopes would rely 
on CD8 T cell stimulation with an array of viral peptides generated by plasmids or synthesized in 
laboratories. To get an effective assessment of the complete viral-specific CD8 T cell repertoire, 
overlapping peptide sequences needed to span the entire virus proteome, which becomes costly 
and time consuming as viruses reach the size of HSV-1, which contains over 80 ORFs [11]. 
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Fortunately, the developments of the Immune Epitope Database and Analysis Resource (IEDB) 
and other epitope databases have alleviated some of the effort needed to identify CD8 T cell 
epitopes [94]. These databases keep records of known T- and B- cell epitopes from various 
infectious and animal models as well as experimental data detailing the specific interactions of 
peptide/MHC/TCR interactions. Algorithms can predict the probability a viral peptide sequence 
would also be a T cell epitope by assessing each amino acid’s ability to bind to specific parts of 
the MHC molecule [82,95]. Epitope prediction resources do not eliminate the need for 
experimental stimulation data, but they do reduce the number of potential candidates. For the 
studies of this dissertation, with the collaboration of Sette’s group, the number of potential 
epitope candidates was reduced from over 72,000 to just 376 peptides [96].   
Upon CD8 T cell recognition of antigen, the TCR transmits a signal to activate effector 
function. Effector function of CD8 T cells consists of the secretion of antiviral cytokines, IFNγ 
and TNF α, which inhibit the transcription of viral genes. IFNγ is also known to increase MHC 
class I expression on host cells allowing for a greater opportunity for CD8 T cell recognition of 
infected cells. Additionally, CD8 T cell release lytic granules containing perforin and 11 
granzymes. The mechanism by which granyzmes enter the cytosol in a perforin dependent 
manner is not definitively known. Once these serine proteases enter the cytosol, they cleave host 
proteins leading to programmed cell death or apoptosis. The most well characterized granzyme is 
granzyme B, which induces apoptosis in a variety of ways. It can directly activate caspase 8 
triggering the apoptosis inducing caspase cascade. Also, granzyme B can cleave BID to tBID, 
which is inserted into the mitochondrial membrane. Insertion of tBID into the mitochondrial 
membrane allows the release of cytochrome c, which can also activate the apoptosis caspase 
cascade. Granzyme A possesses capabilities to induce apoptosis by cleaving proteins associated 
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with the SET complex releasing the protein, Granzyme A-Activated Deoxyribonuclease 
(GAAD). GAAD then gains access to the nucleus and induces apoptosis by creating single-
stranded DNA nicks that cannot be repaired [97]. 
1.3.2 CD8 T cell response to HSV-1 infection 
After an ocular infection, around 6 dpi, HSV-specific CD8 T cells begin to infiltrate the TG, 
peak in numbers by 8 dpi, and contract to a stable memory population for the life of the animal. 
A requirement for entry into the TG during acute infection is CD8 T cell activation. During this 
time OT-I specific CD8 T cells, which are superfluous to HSV-1 infection, that are activated by 
peptide pulsed DCs enter the TG at a high frequency but are eventually lost due to a lack of 
apparent antigenic stimulation [85]. Human and mouse studies show that TG-resident CD8 T cell 
are maintained in direct apposition to infected neurons and exhibit an activation phenotype 
[12,85,98]. Additionally in mice, gB498-505-specific CD8 T cells were shown to form 
immunological synapses with infected neurons, providing confirmation that HSV-1 does not hide 
from the immune system, but rather is constantly surveyed by CD8 T cells for transition from the 
latent cycle to lytic cycle [86].  
Unique to the TG during HSV latency, CD8 T cells exist independent of memory 
cytokines IL-7 and IL-15. Typically, in IL-7 and IL-15 KO mice, CD8 T cell memory would be 
detrimentally affected and effectively lost, which was observed in the spleens of HSV-1 infected 
IL-15 KO mice. Yet, in the same KO mice, HSV-specific CD8 T cells are maintained and remain 
functional in the TG [99]. This observation led to the hypothesis that the maintenance and 
function of TG-resident CD8 T cells is influenced by latent HSV rather than usual memory 
cytokines. In other words, we proposed that antigenic stimulation of TG-resident CD8 T cells 
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maintained the population independent of other factors. To support this, our lab showed that cells 
entering the TG that recognize an irrelevant peptide are eventually lost from the TG during 
latency while viral specific cells are maintained. We concluded from this that retention of CD8 T 
cells in the TG requires antigenic stimulation from latent virus [85]. This then led to the 
hypothesis that the remaining 50% of CD8 T cells (non-gB498-505-specific CD8 T cells) in the TG 
during acute infection and through latency were specific for HSV antigens.  
The ability to prevent viral reactivation has been shown to be dependent on the CD8 T 
cell response. Whenever TGs are explanted and dispersed into ex vivo cultures, HSV [29,100] 
will spontaneously reactivate from a small number of infected neurons. Depletion of CD45+ cells 
from these cultures exacerbates reactivation frequency while the addition of recombinant IFN-γ 
to depleted cultures restores a level of protection equal to 50% of control treated groups [101]. 
By inhibiting CD8 and/or CD4 T cell function, our lab revealed that the main producer of IFN-γ 
was CD8 T cells [41]. Later studies indicated that CD8 T cells also prevent viral reactivation in a 
perforin dependent manner without depleting the pool of latently infected neurons, which 
suggested an exciting possibility that CD8 T cells use lytic granules in a noncytolytic manner (as 
compared to the description above) to prevent viral reactivation. Indeed, our lab displayed that 
CD8 T cells release lytic granules containing granzyme B into latently infected neurons. Rather 
than inducing apoptosis, it was shown that granzyme B cleaves ICP4, an essential viral protein 
needed for viral gene expression. These findings suggest a complex interplay between CD8 T 
cell effector function, sensory neurons, and HSV-1 that permits the retention of latent virus 
without expanse damage to host neurons [43](Figure 4). 
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 Figure 4. Cartoon rendition of CD8 T cell maintenance of latency in sensory ganglia 
CD8 T cells recognize viral antigen presented by MHC class I molecules on latently infected neurons. IFN-
γ inhibits viral gene expression while granzyme B cleavage of apoptosis inducing caspases is inhibited by 
ICP4 and LATs. 
1.3.3 Immune suppression during chronic antigenic stimulation 
In chronic viral infections such as LCMV, HCV, and HIV, long term antigenic stimulation from 
persistent infection correlates with loss of CD8 T cell functionality and a failure to eliminate the 
virus [102-105]. In LCMV clone 13 infections, loss of CD8 T cell functionality due to 
overstimulation, considered functional exhaustion, has been characterized by a serial loss of IL-
2, TNF α, IFN-γ, and granzyme B [106]. Most severe cases of exhaustion end in CD8 T cell 
deletion. Loss of functionality typically results from the acquisition of inhibitory receptors and 
the production of immunosuppressive cytokines.  
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Functionally exhausted cells express an array of inhibitory receptors such as Tim-3, 
CD160, cytotoxic T-lymphocyte antigen (CTLA)-4, lymphocyte-activation gene (LAG)-3, and 
the most extensively studied, programmed death (PD)-1 [103,106-108]. PD-1 expression can be 
induced on CD4 T cells, CD8 T cells, NK cells, and B cells upon antigenic stimulation as well as 
activated monocytes. PD-1 has two ligands; PD-L1 (B7-H1), which is expressed on both 
hematopoietic and non-hematopoietic cells and can be induced with type I and II interferons, and 
PD-L2, which is selectively expressed on DCs an macrophages [109]. Interaction of PD-1 on T 
cells and PD-L1 on antigen presenting cells dampens and regulates the T cell response by 
initiating the recruitment of phosphatases, SHP-1 and SHP-2, to the immunological synapse. 
This results in the dephosphorylation of the signaling intermediates, CD3ε, ZAP70, and PKCθ, 
which are necessary for transmitting signals for effector T cell function. The PD-1/PD-L1 
pathway continues to be a necessary mechanism in the prevention of autoimmunity, but when 
this pathway results in a dampened immune response to infection, prolonged pathogen 
persistence occurs [110]. Active studies in our lab are investigating the nature of CD8 T cell 
exhaustion due to PD-1/PD-L1 interactions. 
In addition to inhibitory receptors, soluble mediators such as IL-10 contribute to the CD8 
T cell exhaustion phenotype. Increased levels of IL-10 have been detected in chronic viral 
infections as well as some cancers. Studies using LCMV have shown that DCs and CD4 T cells 
are main sources of IL-10 during persistent infection [111-114]. More recent studies have shown 
that viral specific CD8 T cells have the potential to produce IL-10 as well [115]. After IL-10 
binds its receptor, activated Janus Kinase (JAK)-1 and Tyrosine Kinase (TYK)-2 phosphorylate 
STAT3, which in turn homodimerizes, enters the nucleus, and initiates synthesis of suppressor of 
cytokine signaling (SOCS)-3. SOCS3 is known to inhibit the translation of TNF α, which is one 
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of the first effectors lost during functional exhaustion. Additionally, reports show that IL-10 
signaling leads to reduced IFN-γ production and reduced expression of the costimulatory 
molecules, CD80 and CD86 [112,116]. Recently, studies have neutralized the 
immunosuppressive effects of IL-10 by genetically knocking out the IL-10 allele or have 
administered antibodies that bind IL-10R preventing IL-10/IL-10R interaction and signaling. 
Pronounced effects of this treatment on partially exhausted cells include increased functionality 
and proliferation, which results in reduced or eliminated viral burden [117-119]. However, the 
effects of this treatment after the establishment of chronic infection and complete functional 
exhaustion have yet to be investigated.  
In herpesvirus infections, IL-10 is an attractive target for therapy due to the presence of 
IL-10 homologs encoded by Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), which are 
thought play a role in the persistence of the virus in the host [120,121]. Even though HSV-1 does 
not contain a gene that encodes a viral homolog of IL-10, IL-10 mRNA is produced in the 
sensory ganglia during latency [122]. Aspects of this study describe the striking role IL-10 plays 
in viral persistence during HSV-1 latent infection. 
1.3.4 Functionality of HSV-specific CD8 T cells 
Nearly all studies investigating the TG-resident CD8 T cell response draw on the observations 
from gB498-505-specific CD8 T cells. As stated above, these cells constantly survey the TG for the 
presentation of their cognate antigen on infected neurons. Interestingly, from the transition from 
acute infection to latent infection, these cells are considered to increase functionality [76]. In 
other words, these cells acquire the ability to produce multiple cytokines (IFN-γ and TNF α) 
contrasting what is observed in chronic infection models such as LCMV where antigen specific 
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cells lose the ability to produce cytokines and are eventually deleted. Potential explanations for 
this lack of exhaustion may include low level gene expression during latent infection as opposed 
to chronic infection. It appears that gB498-505-specific CD8 T cells do not receive constant 
stimulation, but do receive periodic stimulation as seen by in situ TCR polarization [86]. This 
low level stimulation appears to be enough to keep gB498-505-specific CD8 T cells from leaving 
the TG during latency while also preventing exhaustion. Support for this comes from the high 
level of granzyme B expression and concordant low level of PD-1 expression seen in gB498-505-
specific CD8 T cells throughout latency [76]. The high functionality of these cells is sufficient to 
prevent viral reactivation in vivo and in ex vivo TG cultures [100], but cannot eliminate the virus 
from the host. What is not known and what is described in this study is functionality of non-
gB498-505-specific CD8 T cells and their ability to prevent viral reactivation from latency. 
1.4 DOWNFALLS OF CURRENT TREATMENTS 
Most HSV-1 induced pathology is associated with recurrent viral shedding at the corneal surface 
induced by psychological and environmental stress, CD8 T cell depletion, ultraviolet light, 
increased female sex hormone, as well as other factors. Treatment of blindness due to HSV-1 
mediated pathology ultimately may require surgical transplantation of a donor cornea. 
Unfortunately, the success of these grafts is limited, which is thought to be due to subsequent 
recurrent reactivation events. Current vaccines aimed to prevent infection focus on enhancing the 
antibody response against HSV-1, but clinical trials have proven futile [123-125]. HSV-1 
antibodies help prevent primary infection and extracellular spread of the virus but appear to 
provide minimal benefits in preventing reactivation and host-to-host spread of the virus. Thus, 
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the development of a vaccine aimed at bolstering the TG-resident CD8 T cell response has 
garnered increasing interest. The studies in this dissertation first investigate the efficacy of a 
CD8 T cell adoptive transfer therapy. We then assess the use of antibody inhibition of 
suppressive cytokine signaling to prevent HSV-1 viral reactivation from latency. 
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2.0  SPECIFIC AIMS 
Many propose that therapeutic therapies for recurrent HSV-1 reactivation events would aim to 
enhance the CD8 T cell response maintaining viral latency in the trigeminal ganglion (TG). The 
aims of this study investigate various methods to increase the proficiency of the CD8 T cell 
response against HSV-1 to prevent viral reactivation from latency. To effectively do this, we first 
needed to identify the specificities of HSV-specific CD8 T cells. We then assessed the efficacy 
of an adoptive transfer of CD8 T cells and the manipulation of immune suppression to confer 
better protection of viral reactivation from latency.  
 
Identify the subdominant HSV-1 epitopes that are targeted by the CD8 T cells in acutely 
infected TG and trace their retention in latently infected TG.   
Our lab’s previous work displayed that antigenic stimulation was necessary for the 
retention of CD8 T cells in the latently infected TG. 50% of the TG-resident CD8 T cells from 
acute infection throughout latency recognize the immunodominant epitope, gB498-505. Therefore, 
we hypothesized that the remaining CD8 T cells in the TG would recognize subdominant 
epitopes on HSV-1 and would be maintained throughout latency.  
 
Assess the ability of HSV-specific CD8 T cells to migrate into a latently infected TG.  
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Studies show the prevalence of tissue-resident memory (Trm) populations in central 
nervous system tissue such as the brain. Trm populations do not receive replenishment of effector 
cells from the circulation. From this, we hypothesized that adoptively transferred effector or 
memory CD8 T cells would not gain access into the latently infected TG.  
 
Investigate the role of host suppression of the immune response in HSV-1 viral persistence. 
During chronic viral infections, IL-10 aids viral persistence by suppressing effector 
functions of viral specific CD8 T cells. Also, IL-10 has been detected in latently infected 
trigeminal ganglia leading to our hypothesis that IL-10 suppresses TG-resident CD8 T cells 
leading to the retention of HSV-1 in sensory ganglia. 
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3.0  MATERIALS AND METHODS 
3.1 MICE AND HSV-1 CORNEAL INFECTIONS 
Six- to 10-week-old female C57BL/6J (B6), B6.129S6-Il10tm1Flv/J and gB-TI.1β TG (gB-T; 
kindly provided by Dr. Francis R. Carbone, University of Melbourne) mice were used. Mice 
were anesthetized by intraperitoneal (i.p.) injection of 2.5 mg ketamine hydrochloride and 0.25 
mg of xylazine (Butler-Schein, Dublin, OH) in 0.2 mL of Hanks balanced salt solution 
(BioWhittaker, Walkersville, MD). The central cornea was scarified 16 times by forming a 
perpendicular meshwork using a sterile 30-gauge needle. The abraded corneas were then infected 
by topical application of 3 µL of RPMI (BioWhittaker) containing 1 x 105 plaque-forming units 
(PFU) of WT HSV-1 strain RE. Infection efficiency was determined by making a topical 
application of fluorescein (Akorn, Abita Springs, LA) directly onto the cornea 2 days post 
infection (dpi) and observed under a slit-lamp microscope. All animal experiments were 
conducted in accordance with guidelines established by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
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3.2 VIRUS 
HSV-1 strain RE was grown in Vero cells. Intact virions were isolated from cell supernatants and 
purified on Optiprep gradients according to manufacturer’s instructions (Accurate Chemical and 
Scientific Corp., Westbury, NY). PFU were determined using a standard plaque assay on a 
monolayer of Vero cells.  
3.3 REAGENTS FOR FLOW CYTOMETRY 
PE-conjugated H-2Kb tetramers complexed with the gB498–505, RR1982–989, RR1822–829, or ICP8876–
883, peptides and PE-conjugated H-2Db tetramers complexed with the ICP8168–176, RR1372–380, or 
ribonucleotide reductase 2 (RR2279–287) peptide were provided by the National Institute of 
Allergy and Infectious Diseases Tetramer Core Facility (Emory University Vaccine Center, 
Atlanta, GA). Purified or Fluorochrome-conjugated antibodies specific for surface markers, 
CD16/CD32 (Fc block; 2.4G2), CD45 (30-F11), CD8α (clone 53-6.7), CD4 (RM4-5), VLA-4 
(RI-2), LFA-1 (2D7), CD69 (H1.2 F3), CD90.1 (OX-7), CD90.2 (53.21), CD45.1 (A20), CD279 
(RPM1-30), CD107a (1d45) and CD45.2 (I04) were purchased from BD Pharmingen, and 
Biolegend (CD279) (San Diego, CA). Fluorchrome-conjugated antibodies specific for 
intracellular IFN-γ (XMG1.2), TNF (MP6-XT22), and 5-bromo-2-deoxyuridine (BrdU Flow Kit; 
3D4) were purchased from BD Pharmingen. APC-conjugated antibody specific for intracellular 
antigen human granzyme B (GB11; cross reacts with murine granzyme B) was purchase from 
Invitrogen (Carlsbad, CA). The appropriate isotype control antibodies were purchased from BD 
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Pharmingen, Biolegen, and Millipore. All flow samples were collected on a FACSAria 
cytometer and analyzed by FACSDiva software (BD Biosciences).  
3.4 TISSUE HARVEST 
At the indicated dpi, anesthetized mice were injected with 0.3 ml heparin 1000 U/ml and 
euthanized by exsanguination or intracardial perfusion with 20 ml of 1X PBS. Trigeminal 
ganglia (TG) or lungs were harvested and digested in 100 μl (gangion) or 1 ml (lungs) of DMEM 
(BioWhittaker) containing 10% FCS and 400 U/ml collagenase type I (Sigma-Aldrich) for 1 h at 
37°C. TG were dispersed into single-cell suspensions by trituration through a 200 μl pipette tip. 
Spleens were dispersed mechanically and treated with RBC lysis buffer prior to use. Tissue 
harvest and preparation were performed under sterile conditions.  
3.5 MOUSE TREATMENTS 
3.5.1 TAK-779 treatment 
Where indicated, mice were treated subcutaneously with 150 µg TAK-779, a dose previously 
shown to effectively inhibit the function of CCR5 and CXCR3 in vivo [126]. Control mice 
received a subcutaneous injection of the vehicle (PBS). 
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3.5.2 5-Bromo-2-deoxyuridine (BrdU) administration  
At specified dpi, 1 mg of BrdU was given i.p. daily for two days prior to mouse sacrifice 
(proliferation after stress) or once 4 hours prior to mouse sacrifice (in situ proliferation after 
antiIL-10R treatment). 
3.5.3 Corticosterone treatment  
For 4 consecutive days beginning at various times after infection, mice were supplied with 400 
μg/ml corticosterone (MP Biomedicals, Irvine, CA) in the drinking water. Freshly made 
corticosterone was re-supplied every other day. Corticosterone was dissolved in 30% (2-
hydroxypropyl)-β-cyclodextrin (HBC; Sigma-Aldrich), prepared by dissolving 9 g HBC in 30 ml 
H
2
O. 100 mg corticosterone was then dissolved in 5 ml HBC and brought to 250 ml with H
2
O 
per treated group. Thus, if two treated groups were required, 200 mg corticosterone was 
dissolved in 10 ml HBC and brought to 500 ml with H
2
O. 
3.5.4 Antibody treatment 
Mice were depleted of CD4+ T cells by i.p. injection of 0.15 mg of anti-CD4 antibody (clone 
GK1.5) at times described in the text. Systemic IL-10 signaling was inhibited by intraperitoneal 
(i.p.) injections of 250 ug of anti-IL-10R mAb (1B1.3A) every 3 days for up to 21 days. Control 
mice were treated with i.p. injection of PBS because we demonstrated in a previous study that 
similar treatment with a rat antibody of irrelevant specificity did not affect the CD8+ T cell 
infiltrate in HSV-1 infected TG (Sheridan et al., 2009). 
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3.5.5 Saporin conjugated gB-tetramer 
Biotinylated H-2Kb monomers complexed with the gB498-505 peptide were provided by the 
National Institute of Allergy and Infectious Diseases Tetramer Core Facility (Emory University 
Vaccine Center, Atlanta, GA). Streptavidin conjugated saporin (SA-ZAP) was purchased from 
Advanced Targeting (San Diego, CA). To complex the monomers and SA-ZAP, we added 4X 
molar quantities of monomers to 1X molar quantities of SA-ZAP. Specifically, we would add 
1/10 the necessary quantity of toxin to the monomers every 10 min at room temperature for 100 
min. To deplete gB498-505-specific CD8 T cells in vivo, 30 pmol of the complexed toxin was 
intravenously (i.v.) injected at specified times.  
3.6 QUANTITATIVE REAL TIME PCR 
Total DNA was isolated from tissue using Qiagen DNeasy spin columns (Qiagen, Valencia, CA) 
and quantified by spectophotometry. Viral DNA was detected using primers specific for the 
HSV-1 glycoprotein H (gH): forward primer (5'-CGACCACCAGAAAACCCTCTTT-3'), 
reverse primer (5'ACGCTCTCGTCTAGATCAAAGC-3') and probe 
[5'(FAM)TCCGGACCATTTTC(NFQ)-3'. The PCR reaction was carried out as previously 
described [127]. 
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3.7 IN VITRO ACTIVATION OF GB498-505-SPECIFIC CD8 T CELLS 
Naive gBT-I transgenic spleen cells were coated for 1 h at 37°C with 1 μM gB peptide. Cells 
were then washed twice in HEPES-buffered Earles medium containing 2.5% (vol/vol) FCS 
before being cultured at a density of 1.7 × 105 cells per ml in complete medium (mouse tonicity 
RPMI 1640 medium: RPMI 1640 medium containing 10% (vol/vol) FCS, 2 U/ml IL-2, 50 M -
mercaptoethanol, 2 mM L-glutamine, 100 U/ml of penicillin and 100 g/ml of streptomycin). 
After 2 d, cells were washed and IL-2 was replaced with recombinant human IL-15 (20 ng/ml; 
R&D Systems). Complete medium containing human IL-15 was replaced every 3-4 d, and cells 
were used between 10 and 14 d after initiation of the culture [128]. 
3.8 EPITOPE PREDICTION 
The entire HSV-1 proteome (GI 9629378) was scanned using algorithms for peptide sequences 
predicted to have a high-affinity binding capacity for the MHC class I molecules H-2 Kb or H-2 
Db. According to the reported peptide length preference of these MHC molecules, peptides 
comprising 8 and 9 amino acids were analyzed for H-2 Kb and H-2 Db binding, respectively. For 
both H-2 alleles, the ANN and SMM binding prediction methods available from the Immune 
Epitope Database (http://www.iedb.org) were used along with matrices derived from 
combinatorial peptide libraries reported by Udaka et al. [129]. Each method assigns a score to a 
peptide based on its sequence that predicts its binding affinity for the respective MHC molecule. 
For each prediction method, the peptides were ranked corresponding to their predicted binding 
capacity. To construct a consensus from the prediction methods, the median rank of each peptide 
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for all applicable prediction methods was taken. Finally, for each allele, the 188 peptides with the 
highest median ranks, corresponding with the top 0.5% scoring peptides, were selected for 
screening.  
Peptides used in the HSV screening studies were synthesized as crude material by Mimotopes 
(Clayton, VIC, Australia). Peptides used as radiolabeled ligands for binding assays, were 
synthesized by A and A Labs (San Diego, CA), and purified to >95% homogeneity by reverse-
phase HPLC. Purity of these peptides was determined using analytical reverse-phase HPLC and 
amino acid analysis, sequencing, and/or mass spectrometry. Peptides were radiolabeled with the 
chloramine T method, as described elsewhere.  
3.9 MHC PEPTIDE BINDING ASSAYS 
 
MHC purification, and quantitative assays to measure the binding affinity of peptides to purified 
H-2 Kb and H-2 Db molecules were performed as previously described [130]. Briefly, 1–10 nM 
of radiolabeled peptide was co-incubated at room temperature with 1 μM to 1 nM of purified 
MHC in the presence of 1–3 μM human β2-microglobulin (Scripps Laboratories, San Diego, CA) 
and a mixture of protease inhibitors. After a 2-d incubation, binding of the radiolabeled peptide 
to the corresponding MHC class I molecule was determined by capturing MHC–peptide 
complexes on Greiner Lumitrac 600 microplates (Greiner Bio-one, Longwood, FL) coated with 
either the Y3 (anti–H-2 Kb) or 28-14-8s (anti–H-2 Db, Ld, and Dq) Ab and measuring bound 
cpm using the TopCount microscintillation counter (Packard Instrument Co.).  
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For competition assays, the concentration of peptide yielding 50% inhibition of the binding of 
the radiolabeled peptide was calculated. Peptides were typically tested at six different 
concentrations covering a 100,000-fold dose range, and in three or more independent assays. 
Under the conditions used, where (label) < (MHC) and IC50 ≥ (MHC), the measured IC50 values 
are reasonable approximations of the true Kd values [131,132].  
3.10 TETRAMER RELEASE ASSAY 
Tetramer release assay was performed as described [133]. Single-cell TG suspensions were 
stained with gB498–505 or RR1982–989 for 1 h at 37°C, and the cells were washed and then 
incubated with anti–H-2Db/Kb Ab to avoid tetramer rebinding (28-8-6; BD Pharmingen) at 37°C 
for the designated times. Cells were then stained with anti-CD8 and anti-CD45 and analyzed via 
flow cytometry to observe loss of tetramer over time. 
3.11 IN VITRO STIMULATION AND INTRACELLULAR STAINING 
B6WT3 fibroblast targets were pulsed with individual or pooled peptides, RR1982-989, RR1822-829, 
RR1372-379, ICP8171-178, ICP8168-174 or ICP8876-883, at a concentration of 1.0 ug/mL for 45 min at 
37oC/5% CO2. Dispersed TG cells were stimulated with peptide pulsed fibroblasts in RPMI 1640 
containing 10% FBS, 50 uM 2-Mercaptoethanol (Fisher), anti-CD107a and Golgi-Plug (BD 
Biosciences) for 6 h at 37oC/5% CO2. After stimulation, cells were stained for surface expression 
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of CD8α, followed by intracellular staining for IFN-γ after permeabilization and fixation via 
Cytofix/Cytoperm (BD Biosciences).  
For granzyme B expression or BrdU incorporation, dispersed TGs were stained with anti-CD45, 
CD8α and gB498-505 tetramer for 1 h at room temperature. After incubation, cells were 
permeabilized and fixed with Cytofix/Cytoperm (BD Biosciences) and stained for intracellular 
granzyme B, or cells were fixed and stained for BrdU per manufacturer’s instructions using the 
BD Phamingen BrdU FITC Flow Kit (BD Phamigen). 
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4.0  DEFINING THE HSV-1 SPECIFIC CD8 T CELL REPERTOIRE IN C57BL/6 
MICE 
In mice and other species, viruses typically induce a CD8 T cell response that targets a very 
small fraction of the viral proteins and the potential epitopes they contain. Those viral epitopes 
that are targeted typically fall into a dominance hierarchy consisting of one or a few dominant 
epitopes and several other subdominant epitopes. From acute infection throughout latency in the 
C57BL/6 mouse model of HSV-1 ocular infection, 50% of TG-resident CD8 T cells recognize 
the immunodominant epitope on HSV-1 glycoprotein B (gB498-505) and about 5% of CD8 T cells 
recognize a previously defined subdominant epitope on ribonucleotide reductase I (RR1822-829) 
[50,85,86]. Upon investigating the kinetics of the CD8 T cell response during HSV-1 infection, 
our lab has shown that CD8 T cells peak in number by 8 dpi and contract to form a stable 
memory population by 35 dpi. Our previous studies also strongly suggested that cells infiltrating 
the TG at 8 dpi and persist through latency are indeed HSV-specific. To better characterize the 
CD8 T cell response in hopes of making it more effective against HSV-1 reactivation, our initial 
studies, in collaboration with Dr. Alessandro Sette’s laboratory, aimed at identifying the 
remaining epitopes that are recognized by non-gB498-505-specific CD8 T cells.  
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4.1 THE 8 DPI HSV-SPECIFIC CD8 T CELL REPERTOIRE 
After scanning the proteome of HSV-1 strain RE, the laboratory of Dr. Alessandro Sette used a 
combination of MHC binding algorithms as described in the Materials and Methods section of 
this dissertation to determine potential HSV-1 CD8 T cell epitopes. In total, 376 peptides 
representing the top 0.5% candidate peptides that bound strongly to Kb and Db MHC molecules 
were selected for analysis. We felt the best method of assessing potential candidates was to 
perform in vitro stimulations of tissues thought to contain viral-specific CD8 T cells with peptide 
pulsed B6WT3 fibroblasts. Eight days post infection (dpi) TG provided an environment highly 
enriched for HSV-specific CD8 T cells due to our previous studies suggesting that only HSV-
specific CD8 T cells enter the TG and peak in numbers at 8 dpi [85]. To initially narrow down 
the possible candidates, we pooled 25 candidate peptides and loaded B6WT3 fibroblasts with 
pools of peptides. We performed 6-h in vitro stimulations by incubating peptide pulsed 
fibroblasts with dispersed 8 dpi TG cells. Flow cytometric detection of intracellular IFN-γ 
identified pools of peptides containing HSV epitopes. After positive pools were identified, we 
loaded fibroblasts with individual peptides from positive pools. Again, after a 6-h in vitro 
stimulation of TG cells with fibroblasts, flow cytometric analysis resolved the frequency of CD8 
T cells responding to a single epitope by detecting the percentage of CD8 T cells with 
measurable amounts of intracellular IFN-γ. The screening of potential epitope candidates 
resulted in identifying 19 individual epitopes that included the immunodominant epitope, gB498-
505, the known subdominant epitope, RR1822-829, and 17 previously unidentified subdominant 
epitopes (Figure 5). In aggregate, 87.77 ± 9.22% of TG CD8 T cells responded to defined HSV-
epitopes.  
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Figure 5 One dominant and 18 subdominant epitopes define the HSV-specific CD8 T cell repertoire 
in the trigeminal ganglion (TG) of C57BL/6 (B6) mice 
TG from 8 dpi mice were dispersed into single-cell suspensions. Tissues were then incubated for 6 h with 
peptide-loaded B6WT3 fibroblasts in the presence of Golgi-Plug, followed by intracellular staining for 
IFN-γ. Bars represent the cumulative mean ± SEM percentage of TG-resident CD8 T cells that produce 
IFN-γ (total n=5, two experiments).  
To assess the HSV repertoire in lymphoid tissue, we performed in vitro stimulations (as 
described above) of dispersed 8 dpi spleen CD8 T cells with peptide pulsed fibroblasts (Figure 
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Figure 6 One dominant and 18 subdominant epitopes define the HSV-specific CD8 TCR repertoire in 
the spleen of C57BL/6 (B6) mice 
Spleens from 8 dpi mice were dispersed into single-cell suspensions. Tissues were then incubated for 6 h 
with peptide-loaded B6WT3 fibroblasts in the presence of Golgi-Plug, followed by intracellular staining for 
IFN-γ. Bars represent the cumulative mean ± SEM percentage of TG-resident CD8 T cells that produce 
IFN-γ (total n=5, two experiments).  
We next wanted to compare the frequencies of subdominant epitopes in the TG and the spleen to 
assess the possibility of preferential expansion or exclusion of CD8 T cells specific for 
subdominant epitopes in the TG. To start, 8 dpi TG and spleens were stimulated with HSV-
infected fibroblasts. After stimulation with HSV-infected fibroblasts, as many as 80% of CD8 T 
cells in TG produced IFN-γ. Additionally, 17.3 ± 2.0% of splenic CD8 T cells responded to 
HSV-1 infected fibroblasts. Due to the high frequency of TG-resident CD8 T cells stimulated by 
HSV-1 infected fibroblasts, and the fact that HSV-1 infected fibroblasts stimulated a nearly 
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identical frequency of splenic CD8 T cells as the cumulative frequency of CD8 T cells 
responding to HSV-epitopes, we presumed that the fibroblasts presented all the HSV-epitopes. 
Therefore, we could calculate the frequency splenic HSV-specific CD8 T cells specific for 
individual epitopes (Figure 7).    
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Figure 7 Comparison of HSV-specific CD8 T cells in the TG and spleen that respond to HSV-1 
epitopes 
Frequencies were calculated by dividing the % stimulation via HSV-infected fibroblasts by the % 
stimulation via peptide pulsed fibroblasts (Figure 4 &5) in the TG and spleen.  
With these analyses (Figure 5-7), we were able to make several conclusions that directed our 
future observations. First, we concluded that we identified the entire CD8 T cell repertoire during 
acute HSV-1 infection. Importantly, the repertoire is consistent between the site of infection 
(TG) and the peripheral lymphoid tissues (spleen), suggesting there is universal expansion of 
CD8 T cell specificities in the TG.  
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The HSV-specific CD8 T cell repertoire targets a restricted array of HSV-1 proteins that 
are derived from only 11 of approximately 84 HSV-1 proteins (Table 1). There appears to be no 
α gene products targeted, but 11 of 19 epitopes and 4 of 19 epitopes are derived from β or γ1 
gene products respectively. Thus, nearly 80% of the epitopes are derived from viral proteins that 
are expressed prior to DNA synthesis, which further supports the role these cells play in 
preventing viral reactivation from latency.  Even though HSV-specific CD8 T cells recognize 19 
epitopes on 11 proteins, nearly 75% of the CD8 T cell response is directed toward epitopes on 
three viral proteins:  gB (53.18% spleen/61.58% TG), RR1 (10.79% spleen/10.93% TG), and 
ICP8 (10.38% spleen/11.08% TG). 
Table 2 Epitopes recognized by HSV-specific CD8 T cells in spleens and TG 
      SPLEEN   
Sequence Pro Type Pos.1  


















SSIEFARL gB γ1 498 Kb 0.78 9.14 46.07 57.9 125.81 
YQPLLSNTL gB γ1 452 Db 5153 0.74 3.73 2.30 61.62 
SARMLGDVM gB γ1 560 Db 9206 0.67 3.38 1.32 39.05 
Total gB      10.55 53.18 61.58 115.80 
GAMRAVVPI gG γ1 4 Db 499 0.24 1.21 0.78 64.46 
Total γ1      10.79 54.39 62.36 114.65 
FAPLFTNL RR1 β 982 Kb <0.5 1.04 5.24 4.60 87.79 
QTFDFGRL RR1 β 822 Kb 2.1 0.7 3.53 4.19 118.70 
FGLLNYALV RR1 β 372 Db 1.0 0.4 2.02 2.14 105.94 
                                                 
1 Pos., starting amino acid position; Pro., protein; UL9, DNA replication origin-binding helicase; UL28, DNA replication origin-binding 
helicase; UL41, tegument host shutoff protein. 
2 The % of CD8 T cells stimulated by the epitope divided by the total % of CD8 T cells stimulated with all HSV epitopes (19.84%). 
3 The % of CD8+ T cells stimulated by the epitope divided by the total % of CD8+ T cells stimulated with all HSV epitopes (87.77%). 
4 % TG divided by % spleen. 
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Total RR1      2.14 10.79 10.93 101.30 
GAINFINL ICP8 β 876 Kb 6.2 0.82 4.13 3.74 90.56 
INNTFLHL ICP8 β 171 Kb 2.0 0.72 3.63 3.74 103.03 
AVCINNTFL ICP8 β 168 Db 450 0.52 2.62 3.60 137.41 
Total ICP8      2.06 10.38 11.08 106.74 
SFYRFLFA RR2 β 81 Kb 64 0.3 1.51 1.03 68.21 
YRFLFAFL RR2 β 83 Kb 5.4 0.14 0.71 0.89 125.35 
AAIENYVRF RR2 β 279 Db 38 0.2 1.01 0.52 51.49 
Total RR2      0.64 3.23 2.44 75.54 
FLPRLGTEL UL9 β 251 Db 3049 0.52 2.62 1.91 72.90 
LGYAYINS UL41 β 181 Kb 10 0.28 1.41 0.80 56.74 
Total β      5.64 28.43 27.16 95.53 
LAVVLWSLL gC γ2 8 Db 2781 1.62 8.17 4.51 55.20 
YSVENVGLL UL28 γ2 629 Db 1.9 0.93 4.69 3.42 72.92 
FAFVNAAHA gH γ2 391 Db 4.9 0.44 2.22 0.75 33.78 
WMKMNQTLL gK γ2 54 Db 131 0.42 2.12 1.80 84.91 
Total γ2      3.41 17.20 10.18 59.20 
Total subdom.      10.70 53.95 36.90 68.40 
Total      19.84 100.02 99.7  
 
4.2 EFFECTOR FUNCTIONS OF NON-GB498-505-SPECIFIC CD8 T CELLS 
Optimal control of viruses, including HSV-1, has been associated with CD8 T cell expression of 
granzyme B and production of IFN-γ and TNFα. Consistent with previous reports [76,85], nearly 
all of the CD8 effector T cells in the TG at 8 dpi that are specific for the immunodominant gB498–
505 epitope express granzyme B (Figure 8 A&B). To evaluate granzyme B expression in non-
gB498-505-specific CD8 T cells, the National Institute of Allergy and Infectious Diseases Tetramer 
Core Facility (Emory University Vaccine Center, Atlanta, GA) provided us with fluorescently 
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tagged tetramers complexed with 8 different subdominant HSV-1 epitopes. These reagents 
allowed us to measure intracellular granzyme B levels directly ex vivo in non-gB498-505-specific 
CD8 T cells using flow cytometric analysis. Our results showed that consistent with gB498-505-
specific CD8 T cells, non-gB498-505-specific CD8 T cells express high levels of granzyme B. 
Even though these cells express high levels of granzyme B during acute infection, the frequency 
of cells expressing granzyme B is slightly reduced compared to the immunodominant CD8 T 




                                        
Figure 8 CD8 T cells specific for subdominant epitopes from 8 dpi TG express granzyme B. 
(A&B) Dispersed TG were stained for 1 h at room temperature with αCD45, CD8α, and tetramers loaded 
with subdominant epitopes followed by intracellular staining for granzyme B expression. (A) 
Representative dot plots of granzyme B expression of select HSV-specific CD8 T cells. (B) Bars represent 
cumulative mean ± SEM percentage of peptide-specific CD8 T cells that express granzyme B (total n=4, 2 
experiments). Granzyme B expression is lower in non-gB-specific CD8 T cells compared with gB498-505-
specific CD8 T cells. The p value for all specificities is <0.025. 
Studies propose that CD8 T cells producing TNFα in coordination with IFN-γ are CD8 T 
cells best suited to combat viral infections. This is especially true for gB498-505-specific CD8 T 
cells that gain the ability to produce TNFα from acute infection to latency. With this, we wanted 
to assess the ability of non-gB498-505-specific CD8 T cells to produce multiple cytokines upon 
recognition of their cognate antigen. To compare the level of functionality of the CD8 T cells 
 40 
specific for immunodominant and subdominant epitopes, 8 dpi TG cells were stimulated for 6 h 
with targets pulsed with each of the 19 defined epitopes and stained for intracellular IFN-γ and 
TNFα. The frequency of multifunctional CD8 T cells that produced both IFN-γ and TNFα (as 
opposed to IFN-γ only) reactive to subdominant epitopes varied widely. CD8 T cells specific for 
some subdominant epitopes had a high frequency of multifunctional cells (≥60%), which is 
similar to the frequency of multifunctional cells among CD8 T cells specific for the 
immunodominant gB498–505 epitope (Figure 9A). The frequency of multifunctional cells among 
CD8 T cells specific for other subdominant epitopes were as low as 21.85%.  After plotting the 
percent of peptide-specific cells that were multifunctional against the frequency of that peptide-
specific cell, we observed a significant correlation between the frequency of CD8 T cells specific 
for a given subdominant epitope in the TG and the frequency of multifunctional cells within that 
population (Figure 9B). 
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Figure 9 Non-gB-specific CD8 T cells are multifunctional; multifunctionality correlates with 
immunodominance 
(A&B) TG from 8 dpi B6 mice were dispersed into single-cell suspensions. Tissues were then incubated 
for 6 h with peptide-loaded B6WT3 fibroblasts in the presence of Golgi-Plug, followed by intracellular 
staining for IFN-γ and TNFα. (A) Bars represent the cumulative mean ± SEM percentage of peptide-
specific CD8 T cells that secrete IFN-γ and TNF-α when stimulated in vitro (total n=4, 2 experiments). (B) 
Data points represent percentage abundance of individual epitopes in the TG at 8 dpi versus the percentage 
of epitope-specific cells that are multifunctional. Linear regression shows a significant correlation (p = 
0.0337) between the prevalence in the TG and multifunctionality. 
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4.3 IMMUNODOMINANCE OF HSV-1 CD8 T CELL EPITOPES IS NOT 
DETERMINED SOLELY BY TCR AFFINITY  
The correlation of multifunctionality with immunodominance directed our next set of studies 
looking at the determinants of immunodominance. Factors influencing the immunodominance 
hierarchy among T cell epitopes include MHC binding affinity of the epitope, TCR binding 
affinity, efficiency of peptide processing and loading on MHC, and the frequency of CD8 T cell 
precursors specific for a specific epitope. We ruled out MHC binding affinity as a crucial factor 
determining immunodominance, based on the fact that several peptides representing 
subdominant epitopes had MHC binding affinities that were as high as or higher than that of the 
immunodominant gB498–505 epitope (Table 2). To determine if TCR binding affinity is a critical 
element determining immunodominance, we used a tetramer release assay to compare the TCR 
affinity of the immunodominant gB498–505 epitope with that of one of the subdominant epitopes 
(RR1982–989). The two epitopes exhibited comparable TCR binding affinity as indicated by the 
fact that the slopes of the tetramer release curves were not significantly different (Figure 10).            
                                               
Figure 10 Immunodominance is not solely determined by TCR affinity for MHC–peptide complexes 
Dispersed TG were stained with gB498–505 or RR1982–989 tetramer for 1 h at 37°C. Anti–H-2Kb/H-2Db 
blocking Ab was added, and TG were incubated for the designated times at 37°C to observe tetramer 
dissociation. Data represent the cumulative mean ± SEM fluorescence intensity (MFI) of CD8+ tetramer+ 
cells as a percentage (n=3 representing data from 3 independent experiments) of the maximum MFI 
observed at time zero. Linear regression represents the slopes of both gB498–505 and RR1982–989. Data are 
representative of three independent experiments. 
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4.4 PRECURSOR FREQUENCY INFLUENCES IMMUNODOMINANCE 
Along with the affinity of peptide for MHC class I and TCR affinity of peptide/MHC class I 
complexes, precursor frequency has been shown to influence the immunodominance hierarchy of 
CD8 T cells. It is well documented that fluorescently conjugated tetramers effectively label 
antigen specific CD8 T cells after priming and expansion of the population from immunization 
or viral infections. Until recently, these reagents were somewhat poor at detecting antigen-
specific CD8 T cells in naïve mice due to the low frequency of precursors and the high 
background noise from analysis. Upon enrichment of these cells prior to analysis, resolution of 
antigen specific cells in naïve mice can occur [134]. Due to the drastic disparity in 
immunodominance during B6 HSV-1 infection, we hypothesized that precursor frequency 
played a role in this disparity.  Because previous studies have shown the greatest results with 
CD8 T cells that are higher in the immunodominance hierarchy [83,84,134] and are specific for 
peptides that bind strongest to MHC class I, we chose to compare gB498-505(immunodominant)- 
and RR1982-989(subdominant)-specific CD8 T cell precursor numbers. To do this, we first 
dispersed the spleen, cervical lymph nodes (LN), brachial LN, axillary LN, mesenteric LN, and 
inguinal LN from a naïve B6 mouse into single cell suspensions. We labeled whole cells from 
naïve mice with either gB498-505 or RR1982-989 tetramers conjugated to the fluorochrome PE. 
Magnetic isolation of the PE+ population and addition of APC-conjugated tetramer allowed for 
resolution of antigen specific CD8 T cells from unspecific cells using flow cytometric analysis 
(Figure 11A & B). CD8 T cell precursors specific for gB498-505 outnumber RR1982-989-specific 
CD8 T cell precursors by 3.7 fold (Figure 11B), which is less than the 10 fold difference 
observed during acute infection (Figure 4). The average number of gB498-505-specific CD8 T cells 
per mouse equates to 685 cells per mouse and a precursor frequency of 0.0052% (1 gB-cell in 
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every 19,124 CD8 T cells). There are 186 RR1982-989-specific CD8 T cells per mouse resulting in 
a precursor frequency of 0.0014% (1 RR1-cell in every 70,430 CD8 T cells). 
                  
Figure 11 CD8 T cell precursor numbers per naive mouse 
(A&B) CD8 T cells specific for gB498-505 or RR1982-989 were enumerated by magnetic separation for PE+ 
cells and flow cytometric analysis. (A) Representative dots plots showing precursor numbers. Cells binding 
PE and APC tetramer are considered precursors. (B) Data represent the cumulative mean ± SEM number of 
antigen-specific precursors per mouse (n = 3 per specificity). Experiment was repeated with similar results. 
p = 0.0019. 
4.5 DISCUSSION 
After infection at mucosal sites, HSV-1 is transported to the nuclei of sensory neurons where it 
establishes a latent infection. In humans and mice, CD8 T cells appear to play essential roles in 
preventing viral reactivation [12,41,43,98,100], and theories for future vaccines center around 
the idea of bolstering the TG-resident CD8 T cell population [125,135]. The studies of this 
dissertation sought to explore and enhance the nature of the CD8 T cell response in the B6 
mouse to better protect the host from viral reactivation from latency. Our initial study was 
 45 
undertaken to identify the specificities of CD8 T cells in acutely infected TG as well as attempt 
to identify factors influencing the CD8 T cell immunodominance hierarchy. We and others have 
demonstrated that only activated CD8 T cells infiltrate the TG of mice during the acute phase of 
corneal HSV-1 infection and remain closely associated with neuronal cell bodies as the virus 
enters a life-long latent state [86]. Half of the CD8 T cells in the infected TG throughout 
infection are specific for a strongly immunodominant epitope on HSV gB, and the remaining 
cells in the TG were thought to also be HSV-specific. Based on our previous findings, we 
anticipated that CD8 T cells in the acutely infected TG would represent a highly enriched source 
of HSV-specific CD8 T cells that could provide sensitive detection of HSV-1 CD8 T cell 
epitopes.  
The HSV-1 genome encodes at least 84 open reading frames [136]. Thus, the CD8 T cell 
response is highly selective, targeting only 19 epitopes on 11 viral proteins. The selective 
targeting of a minute portion of thousands of available peptide sequences is commonly seen in 
viral infections and other systems [82,83,137-139]. The mechanism of such selective targeting is 
unknown, but certain patterns emerge. For instance, viral immediate early genes are infrequent 
targets of CD8 T cells in mouse models of infection [80], consistent with our observation that no 
HSV-1 immediate early proteins are targeted. Previous studies revealed that 87% of vaccinia 
virus epitopes and a majority of CD8 T cell epitopes in human lesions are on proteins that are 
produced early in the viral life cycle [140,141]. This is consistent with our observation that 
?80% of the HSV-1 CD8 T cell epitopes are on proteins that are produced before viral DNA 
synthesis, and nearly 80% of HSV-specific CD8 T cells target these epitopes. The kinetic class 
of proteins that is most frequently targeted is the Early proteins that contain 58 and 65% of CD8 
T cell epitopes in HSV-1 and vaccinia virus, respectively. This is not a simple reflection of the 
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frequency of this class of genes in the viral genome because Early genes represent only 14.2% 
[11] and 35% of HSV-1 and vaccinia virus genes, respectively. Although the mechanism 
responsible for selective targeting of early genes is not known, the advantages to the host are 
obvious. Viral DNA can be infectious, and the HSV-1 genome copy number in latently infected 
sensory ganglia is directly correlated with reactivation frequency [29]. 
Recent studies have established that initial expansion of HSV-specific CD8 T cells in the 
draining LN of mice is induced by lymph node resident CD8α+ dendritic cells (DCs) [142-145]. 
Presumably these CD8α+ DCs cross-present viral Ags acquired from migratory DCs from the site 
of infection [146]. Both mature and immature DCs express HSV receptors nectin-1 and nectin-2 
and herpesvirus entry mediator and are susceptible to HSV infection [147-149]. However, only 
immature DCs are susceptible to productive infection. Moreover, productive infection of 
immature DCs leads to apoptosis that is dependent on both early and late HSV gene products 
[150]. Infection of mature DCs results in an abortive infection in which HSV-1 α, β, and γ1 
genes are expressed, but no infectious virions are produced [151]. HSV-1 infection of mature DC 
results in downregulation of CD83 expression and impaired T cell stimulatory capacity. These 
findings are consistent with a model in which DCs that are matured at sites of infection before 
being infected with HSV, are primarily responsible for transporting viral Ags to the lymph nodes 
for cross-presentation by CD8α+ DCs. Because these DCs permit only abortive HSV infections, 
the viral proteins they produce appear to be primarily those produced prior to viral DNA 
synthesis. Such a model would explain the fact that 80% of HSV-1 CD8 T cell epitopes are 
derived from viral proteins that are produced before HSV-1 DNA synthesis. At later stages of 
infection, DCs that infiltrate sites of the lesion might begin to phagocytose apoptotic or necrotic 
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parenchymal cells containing γ2 gene products, accounting for the small but significant response 
to several of these proteins. 
Several factors can potentially contribute to the dominance hierarchy of viral epitopes. 
These include the efficiency of peptide generation by proteasomes [81], viral gene expression 
[80], the peptide binding affinity for MHC [83], the epitope affinity for TCR, the frequency of 
epitope-specific CD8+ T cell precursors [83], and the ability of epitope-specific CD8+ T cell 
precursors to expand and survive. The strong immunodominance of the gB498–505 epitope cannot 
be attributed solely to the peptide affinity for MHC as several of the subdominant epitopes have 
similar or higher affinities. Moreover, a tetramer release assay demonstrated a similar TCR 
affinity for the immunodominant and subdominant RR1982–989 epitopes. Furthermore, magnetic 
bead enrichment and flow cytometric analysis of tetramer+ precursors from naïve B6 mice 
revealed that gB498-505-specific CD8 T cell precursors out number RR1982-989-specific CD8 T cells 
by 3.7 fold. Interestingly, the difference in precursor numbers does not account for the 
exaggerated immunodominance of gB498-505-specific CD8 T cells. These findings suggested that 
the determining factor in the dominance of gB498-505 over the RR1982-989 epitope is related either 
to efficiency of peptide generation or the proliferative capacity or survival characteristics of 
epitope-specific CD8 T cell precursors. Our results showing a consistent CD8 T cell repertoire 
between the acute TG and spleen as well as the latent TG suggest that priming of these cells 
should be investigated. For example, different clonotypes of CD8 T cell precursors may possess 
more proliferative potential compared to others, thus our precursor studies may conceal a greater 
divide between epitope-specific CD8 T cells. Also during priming, evidence shows that 
immunodominant CD8 T cells become armed with immunosuppressive cytokines such as 
interleukin (IL)-10 to suppress the proliferation/survival of subdominant CD8 T cells [115]. 
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Addressing the potential of gB498-505-specific CD8 T cells to suppress the subdominant CD8 T 
cell response may illuminate immunosuppressive targets to diversify the HSV-specific 
repertoire, which would confer better protection from viral reactivation from latency.  
Targeting 50% of the HSV-specific CD8 T cell repertoire to a single immunodominant epitope 
would seem to place the host at significant risk should that peptide be mutated. However, a 
recent study showed that a recombinant virus in which the gB498–505 epitope was mutated failed 
to expand gB498–505-specific CD8 T cells, but the magnitude of the HSV-specific CD8 T cell 
response and viral clearance were not altered [152]. In this study, we show that CD8 T cells 
specific for most of the subdominant epitopes exhibit functional characteristics similar to those 
reactive to the dominant epitope during acute infection. In other words, subdominant HSV-
specific CD8 T cells possess the mechanisms necessary to combat viral reactivation. 
Our initial studies have important implications for the development of HSV vaccines. 
Murine studies show that immunization with CD8 T cell epitopes generates effector and memory 
CD8 T cells and reduces HSV lethality and viral load in the CNS [153,154]. Although the exact 
epitopes recognized by human CD8 T cells will likely be different [52,155], our findings and the 
study from Laing et al. [52] suggest that generating CD8 T cells targeting β and γ1 proteins 
before infection might prove to be a good strategy for vaccine development. Moreover, although 
epitopes from HSV-1 γ2 proteins are recognized by only 20% of the HSV-specific CD8 T cell 
repertoire in mice, our previous findings suggest that IFN-γ can block HSV-1 reactivation from 
latency even at a point after γ2 gene expression [41]. Thus, targeting these gene products might 
also be useful in controlling both lytic infections and reactivation from latency.  
The practicality of immunizing humans prior to primary infection remains questionable 
due to the inability to diagnose primary infection. Therefore, a paramount vaccine would be a 
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therapeutic treatment enhancing the latent TG-resident CD8 T cell population either by 
increasing CD8 T cell numbers or by increasing functionality of the TG-resident CD8 T cell 
population. Knowing the specificities of all the CD8 T cells in the TG of B6 mice, we directed 
our next studies towards characterizing the latent CD8 T cell response.   
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5.0  THE HSV-SPECIFIC CD8 T CELL REPERTOIRE DURING LATENCY 
The ratio of gB498-505-specific CD8 T cells: non-gB498-505-specific CD8 T cells remains constant 
from acute infection throughout latency [85]. After our initial studies we recognized that even 
though the gB498-505-specific CD8 T cell population remains stable throughout infection, the non-
gB498-505-specific CD8 T cell population, comprised of 18 different specificities, may be altered 
during latency as seen in other models [137]. Additionally, gB498-505-specific CD8 T cells 
become more functional over time, producing multiple cytokines during latency, and can prevent 
viral reactivation in vivo and in ex vivo TG cultures. The extent of non-gB498-505-specific CD8 T 
cell functionality and the ability these cells to prevent viral reactivation has not been well 
defined. In the current study, we aimed to characterize the latent non-gB498-505-specific CD8 T 
cell population by identifying the TCR specificities, assessing CD8 T cell function, and the 
ability of non-gB498-505-specific CD8 T cells to prevent viral reactivation from latency.   
5.1 CD8 T CELLS SPECIFIC FOR SUBDOMINANT HSV-1 EPITOPES LOSE 
FUNCTIONALITY IN LATENTLY INFECTED TG 
CD8 effector T cells accumulate to peak levels in TG of C57BL/6 mice by 8 days post HSV-1 
corneal infection (dpi), and contract to form a stable memory population by 30 dpi [85].  Half of 
the CD8 T cells are specific for a single immunodominant epitope on gB as assessed by tetramer 
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staining, and all of these immunodominant cells maintain the ability to produce IFN-γ when 
stimulated with the gB498-505 epitope directly ex vivo [76].  Two subdominant epitopes on HSV-1 
ribonucleotide reductase1 (RR1982-989 and RR1822-829) and two on HSV-1 infected cell protein 8 
(ICP8171-178 and ICP8876-884) together represent 27.8% of the subdominant population at 8 dpi 
based on tetramer staining (Figure 12A). Tetramer staining tended to underestimate the 
frequency of epitope reactive cells during acute infection since the frequency based on tetramer 
staining was lower than the frequency based on intracellular staining for IFN-γ following epitope 
stimulation, though the difference was statistically significant only for ICP8876-883. Although 
there was some individual variation, the frequency of the subdominant CD8 T cell populations 
remained fairly constant during latency as assessed by tetramer staining, representing in 
aggregate 23.9% of the subdominant population at 30 dpi (Figure 12A).   
The TG-resident subdominant CD8 T cells did, however, exhibit a rather dramatic loss of 
functionality during latency as indicated by a significantly reduced frequency of IFN-γ producing 
cells relative to tetramer staining cells in latently infected TG (Figure 12A). This comparison 
might underestimate the functional impairment of the subdominant CD8 T cells, as some appear 
refractory to tetramer staining as noted above and discussed in Appendix A. Moreover, the 
frequency of multifunctional subdominant CD8 T cells (capable of producing IFN-γ, TNFα, and 
releasing lytic granules when stimulated directly ex vivo) was also significantly reduced in 
latently infected TG compared to acutely infected TG (Figure 12B).  No functional compromise 
was observed in the corresponding subdominant CD8 T cells in the spleen (data not shown).  In 
our model, HSV-1 latent infections are restricted to the TG and brainstem, suggesting that the 
functional compromise of TG-resident subdominant CD8 T cells likely requires antigenic 
exposure. Functional impairment was restricted to the subdominant population, since the TG-
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resident immunodominant gB498-505-specific cells showed a slight increase in multifunctional 
cells during latency in agreement with previous findings [76]. 
                     
Figure 12 Subdominant CD8 T cells become functionally compromised during latent HSV-1 infection 
(A&B) TG were obtained from HSV-1 infected mice during acute (8 dpi) or latent (30-35 dpi) infection, 
and the dispersed cells (A) were stained with H2-Kb tetramers containing peptides corresponding to 
subdominant epitopes on HSV-1 ribonucleotide reductase 1 (RR1) or infected cell protein 8 (ICP8); or 
were stimulated with B6WT3 fibroblasts pulsed with the same peptides, stained for intracellular IFN-γ, and 
analyzed by flow cytometry.  The bars represent the cumulative mean ± SEM percent of CD8 T cells that 
are tetramer positive during acute (2 experiments, total n = 8-10 per peptide) and latent (4 experiments, 
total n ≥ 20/peptide) infection, or frequency of CD8 T cells that are IFN-γ positive during acute or latent 
infection (2 experiments, n ≥ 8/peptide).  (B) TG cells were stimulated with B6WT3 fibroblasts pulsed with 
3 subdominant epitopes on RR1 (RR1982-989, RR1822-829, and RR1372-380) or on ICP8 (ICP8171-178, ICP8168-176 , 
and ICP8876-883) and monitored for surface CD107a (lytic granule release) and intracellular IFN-γ and TNFα 
by flow cytometry.  Bars represent the cumulative mean ± SEM frequency of multifunctional (IFN-γ+, 
TNFα+ and CD107a+) cells (2 experiments, n ≥ 9/peptide pool).  The p values were determined by a 
Student’s T test. 
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5.2 GB498-505-SPECIFIC CD8 T CELLS EXPRESS MORE GRANZYME B 
COMPARED TO SUBDOMINANT CD8 T CELLS 
Another anti-viral mechanism gB498-505-specific CD8 T cells use to prevent HSV-1 reactivation 
from latency is releasing lytic granules containing granzymes. With our next experiment, we 
examined in situ granzyme B expression in the non-gB498-505-specific CD8 T cell population. 
Similar to the results in Figure 12, there exists a disparity in the expression of the effector 
molecule, granzyme B, between gB498-505-specific CD8 T cells and non-gB498-505-specific CD8 T 
cells. With 70% of gB498-505-specific CD8 T cells expressing granzyme B and only 30% of non-
gB498-505-specific CD8 T cells expressing the serene protease, it initially appeared that gB498-505-
specific CD8 T cells were better equipped to prevent viral reactivation (Figure 13). However, 
other studies have used granzyme expression as a marker of stimulation rather than a marker of 
virucidal activity [98].   
 














Figure 13 Subdominant CD8 T cells express lower amounts of granzyme B during latent HSV-1 
infection. 
TG cells from latently infected mice were stained for CD8α, gB498-505 TCR, and granzyme B (GrzB) 
expression and analyzed by flow cytometry. Bars represent the cumulative mean ± SEM frequency of 
GrzB+ cells (1 experiment, n=3). This experiment was repeated 3 times with similar results.  
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5.3 NON-GB498-505-SPECIFIC CD8 T CELLS PROLIFERATE AT A HIGHER RATE 
AND EXPRESS HIGHER LEVELS OF PD-1 COMPARED TO GB498-505-SPECIFIC CD8 
T CELLS 
As stated above, CD8 T cells respond to antigenic stimulation by proliferating. In an attempt to 
identify the degree of antigenic stimulation of non-gB498-505-specific CD8 T cells, we next 
evaluated the rate of proliferation of the non-gB498-505 population as well as select specificities in 
the population, which include RR1982-989, RR1822-829, ICP8171-178, and ICP8876-883. Unexpectedly, 
after 2 daily injections of BrdU, we observed that the non-gB498-505-specific CD8 T population as 
a whole (22%) incorporated 2 times the amount of BrdU compared to their gB498-505 counterparts 
(11%). The four subdominant CD8 T cell specificities tested also incorporated BrdU at a higher 
rate compared to the immunodominant population albeit at varying degrees of incorporation 
(Figure 14A). Indeed, from these results, it appeared that subdominant CD8 T cells during latent 
infection are stimulated to a higher extent than gB498-505-specific CD8 T cells.  
We next investigated the expression of an activation marker as well as a known marker of 
exhaustion, programmed death (PD)-1 on subdominant CD8 T cells. When bound to its ligand, 
PD-L1, PD-1 recruits factors to the TCR synapse to dampen signaling through the TCR [110]. 
During acute viral infections, PD-1 upregulation is common due to the high degree of 
stimulation during the expansion phase of the CD8 T cell response [156]. After a virus is cleared 
and the memory population is fully developed, PD-1 will then only be upregulated in times of 
antigenic exposure such as secondary infections. Moreover, in models such as LCMV infection, 
continual antigenic stimulation correlates with increased levels of PD-1 and retention of live 
virus [102,157]. Combining our previous functional data with the fact that latent HSV-1 
genomes are never fully eliminated from the host, we hypothesized that subdominant CD8 T 
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cells are functionally compromised and thus would have increased expression of PD-1. Indeed, 
our results show that all specificities of subdominant CD8 T cells have increased levels of PD-1 
expression compared with the gB498-505-specific CD8 T cells. Similar to the BrdU incorporation 
data, subdominant CD8 T cells express varying levels of PD-1. Additionally, the non-gB498-505 
population (20.5%) expressed 3 fold more PD-1 as compared to the gB498-505 population (6.7%). 
Degrees of CD8 T cell exhaustion can also be characterized by comparing the mean fluorescence 
intensity of cells expressing PD-1. Non-gB498-505-specific CD8 T cells consistently express 33% 
more surface PD-1 expression per cell when compared with gB498-505-specific CD8 T cells from 




.   
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Figure 14 Non-gB498-505-specific CD8 T cells incorporate more BrdU and express more PD-1 when 
compared with gB498-505-specific CD8 T cells 
(A-D) Latently infected mice were given 100mg intraperitoneal (i.p.) injections of BrdU on 36 and 37 dpi. 
TG were dispersed into single-cell suspensions, stained for CD8α, gB498-505, RR1982-989, RR1822-829, ICP8171-
178, ICP8876-883 TCR, (A) BrdU and (B-D) PD-1 and analyzed by flow cytometry.  (A) Bars represent the 
cumulative mean ± SEM percentage of BrdU positive cells (2 experiments, total n=4-9). (B) Bars represent 
the cumulative mean ± SEM percentage of PD-1 positive cells (4 experiments, total n=19-24). (C) Bars 
represent the cumulative mean ± SEM mean fluorescence intensity of PD-1 positive cells (2 experiments, 
total n=7) (Contributed by Sophia Jeon). (D) Representative dot plots displaying PD-1 expression on gB498-
505 and non-gB498-505-specific CD8 T cells. *   p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.0005 
5.4 GB498-505-TOXIN COUPLED TETRAMER DEPLETES GB498-505-SPECIFIC CD8 T 
CELLS IN VIVO 
The functional compromise of non-gB498-505-specific CD8 T cells suggested an inability of these 
cells to prevent viral reactivation from latency. Described in an earlier study, we proposed to 
deplete gB498-505-specific CD8 T cells using tetrameric MHC class I molecules complexed with 
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gB498-505 peptide and conjugated to the toxin saporin. After conjugation, the toxin-coupled 
tetramer was then injected intravenously (i.v.) into latently infected mice. Upon specifically 
binding the gB498-505 TCR, the toxin/TCR complex was endocytosed giving saporin the ability to 
inactivate ribosomes, which led to cell death. Due to the specificity of TCR for MHC/peptide, 
the toxin depletes antigen specific CD8 T cells with minimal unspecific damage. We 
administered several doses of toxin-coupled tetramer and observed the most effective dose to be 
30 pmols. At this dosage, we achieved a two-fold reduction in TG-resident gB498-505-specific 
CD8 T cell numbers combined with a concurrent two-fold increase in non-gB498-505-specific CD8 
T cell numbers three days after administration of treatment (Figure 15A&B). We observed no 
change in the subdominant CD8 T cell population specific for the RR1822-829 peptide. By 6 days 
after dosage, the gB498-505-specific CD8 T cell numbers fully recovered, in fact, gB498-505-specific 
CD8 T cell numbers expanded to 1900 total cells per TG equating to a five-fold increase over the 
gB498-505-specific CD8 T cell numbers observed at 3 days after treatment. Non-gB498-505-specific 
CD8 T cell numbers did not change significantly between 3 and 6 days after treatment (Figure 
15C).  
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 Figure 15 gB498-505 toxin-coupled tetramer specifically depletes gB498-505-specific CD8 T cells in vivo 
(A-C) Latently infected mice were given intravenous (i.v.) injection of (A) 7 pmol, (A) 15 pmol, (A) 22 
pmol, (A) 25 pmol, (A-C) 30 pmol of gB498-505 tetramers conjugated to saporin. After (A-C) 3 days and (C) 
6 days, TG were dispersed into single-cell suspensions and stained for CD8α, gB498-505 TCR, and RR1822-829 
TCR and analyzed by flow cytometry. (A) Dots represent individual mice treated with gB498-505 tetramers 
conjugated to saporin (1 experiment, n=1). (B) Representative dot plots displaying reduced TG-resident 
gB498-505-specific CD8 T cell frequency and maintained TG-resident RR1822-829-specific CD8 T cell 
frequency. (C) Symbols represent the cumulative mean ± SEM number of gB498-505-specific or non-gB498-
505-specific CD8 T cells (2 experiments, n=6-7). This experiment was repeated once with similar results.  
5.5 REDUCTION IN GB498-505-SPECIFIC CD8 T CELL NUMBERS COMPROMISES 
MAINTENANCE OF VIRAL LATENCY 
After observing a reduction in gB498-505-specific CD8 T cell numbers, we next asked if this 
reduction correlates with viral reactivation from latency. Due to the rapid effects of toxin-
tetramer treatment, the most accurate assessment of viral reactivation would be to quantify viral 
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genomes from infected ganglia between untreated and toxin-tetramer treated mice. After three 
days of treatment, when gB498-505-specific CD8 T cell numbers are lowest, we observed a 60% 
increase in viral genome copy number. Re-establishment of viral control was achieved once 
gB498-505-specific CD8 T cell numbers were restored (Figure 16A). Due to the high limit of 
detection of live virus formation and/or the high affinity HSV-1 neutralizing antibody make 
detecting live virus difficult, we decided to support our claim of viral reactivation with CD8 T 
cell activation phenotypes. We hypothesized that loss of viral control would correlate with 
increased viral gene expression as well as increased antigenic stimulation of CD8 T cells. As 
mentioned earlier, CD8 T cells proliferate upon antigenic stimulation. Therefore, we assessed 
BrdU incorporation into proliferating CD8 T cells as a measure of increased antigenic 
stimulation. Concurrent with increased copy number after toxin treatment, we observed 
significant increases in the frequency of CD8 T cells incorporating BrdU three days after toxin 
treatment. Immunodominant gB498-505-specific CD8 T cells had a 5.5 fold increase in the rate of 
BrdU incorporation while non-gB498-505-specific CD8 T cells as a population only increased 
BrdU incorporation by a factor of 2.4.  However, the largest change in BrdU incorporation 
occurred in the RR1822-829-specific CD8 T cell population, which increased by a factor of 6.2 
(Figure 16B). This would suggest different populations of CD8 T cells receive varying degrees 
of stimulation during a reactivation event. Furthermore, we supported our claim by assessing 
PD-1 expression on different specificities of CD8 T cells as a dynamic marker for antigenic 
stimulation. Indeed, the frequencies of PD-1 expressing cells in the gB498-505 and non-gB498-505 
CD8 T cell populations increased from the starting frequencies of 10% and 20% respectively to 
30% at 3 days after toxin-couple tetramer administration. Levels were restored to steady-state 
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latency levels by 6 days after treatment. This pattern paralleled with the amplified then 
contracted viral genome copy numbers observed after treatment administration (Figure 16C).  
   
 
Figure 16 gB498-505 toxin-coupled tetramer induces viral reactivation from latency 
(A-C) Latently infected mice were given intravenous (i.v.) injection of 30 pmol of gB498-505 tetramers 
conjugated to saporin. Two days after toxin injection, mice were given an intraperitoneal (i.p.) injection of 
100mg of BrdU. On days (A-C) 3 and (A&C) 6 days after toxin injection, TG were dispersed into single-
cell suspensions and (A) were assessed for viral genome copies by performing Real Time-PCR of DNA 
extracted from ganglia or (B&C) were for CD8α, gB498-505 TCR, (B) RR1822-829 TCR, (B) BrdU (C) PD-1 
and analyzed by flow cytometry. (A) Symbols represent the cumulative mean ± SEM number of gH copies 
per ganglion (2 experiments, total n=6-8). (B) Symbols represent individual mice and error bars represent 
cumulative mean ± SEM frequency of individual T cell specificities positive for BrdU incorporation (1 
experiment, n=6-7). (C) Symbols represent cumulative mean ± SEM frequency of gB498-505 or non-gB498-505 




Recent evidence from several laboratories suggests that strategies aimed at augmenting the TG-
resident CD8 T cell population could inhibit HSV-1 reactivation from latency, potentially 
reducing the frequency of recurrent disease. To ensure proper development of this type of 
strategy, it is essential to fully characterize the CD8 T cell response. My initial studies defined 
the acute HSV-1 CD8 T cell repertoire, but it is well documented that in chronic viral infections, 
the CD8 T cell repertoire is prone to changes [103]. Since the likelihood of identifying a primary 
HSV-1 infection is quite rare, characterization of the latent CD8 T cell response was necessary 
for the development of a CD8 T cell therapy.  
The unusually strong immunodominance of the gB498-505 epitope in B6 mice is well 
documented [53,85,152].  These cells represent 50% of the HSV-1 specific CD8 T cell repertoire 
in spleens as well as in both acutely and latently infected TG.  The remaining 50% of CD8 T 
cells in acutely infected TG are also HSV-1 specific as demonstrated by their ability to produce 
cytokines (IFN-γ and TNF α) when stimulated with 18 different HSV-1 subdominant epitopes 
[50,96].  Using tetramers containing four of the subdominant epitopes that together constitute 
approximately 30% of the subdominant population; we demonstrate little if any change in the 
CD8 T cell repertoire within the memory population that is retained in the TG during viral 
latency.  However, in contrast to the immunodominant CD8 T cells that retain full functionality 
during latency, those specific for subdominant epitopes exhibit a dramatic loss of functionality.   
We next explored the cause for functional compromise in subdominant CD8 T cells. It 
was possible that cells were losing functionality due to the lack of antigenic stimulation or over 
stimulation resulting in functional exhaustion. A previous study from our lab suggested that only 
cells stimulated in the TG are maintained in the TG during latency [85]. Therefore, we 
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hypothesized that subdominant CD8 T cells in the TG are over simulated during latency leading 
to exhaustion and an inability to produce effector molecules. Reliably detecting lytic viral gene 
expression remains elusive due to the limits of detection of current assays, so we were unable to 
correlate the level of gene expression to the degree of functional compromise CD8 T cells. 
However, our previous study exhibiting the polarization of the gB498-505 TCR on CD8 T cells 
towards latently infected neurons [86] displayed heightened sensitivity of CD8 T cells. Likewise, 
we used CD8 T cell responses to antigen as a measure of the degree of stimulation received 
during latency. In our study, we assessed proliferation rates and the levels of PD-1 expression on 
CD8 T cells during latency. We observed that during latency, non-gB498-505-specific CD8 T cells 
incorporate more BrdU over time and express more PD-1 than their gB498-505-specific CD8 T cell 
counterparts. This would suggest that even in the absence of detectable viral gene expression, 
non-gB498-505-specific CD8 T cells do receive more antigenic stimulation than gB498-505-specific 
CD8 T cells. When the non-gB498-505-specific CD8 T cell population was further delineated into 
individual peptide-specific populations, we observed that specificities appear to receive varying 
levels of stimulation during latency.  
Though no substantial evidence exists showing viral gene expression during the transition 
from latent to lytic infection in neuronal tissue, our results suggest that the stochastic model of 
viral gene expression may apply [158,159]. From our results, RR1- and ICP8-specific CD8 T 
cells appear to be stimulated to a higher degree than gB498-505-specific CD8 T cells. Furthermore 
in the stochastic model of gene expression, it is well documented that the β genes coding the 
RR1 and ICP8 proteins are abundantly expressed before DNA synthesis [50] while gB 
expression is fully expressed only after DNA synthesis [160]. This would suggest that if HSV-1 
persistently attempts to escape latency while CD8 T cells constantly prevent escape from latency, 
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early gene CD8 T cells (RR1 and ICP8) would encounter more antigenic stimulation, while 
leaky-late CD8 T cells (gB) would encounter less antigenic stimulation. From this, we propose a 
possible “Goldilocks” model of CD8 T cell stimulation during latency. Cells that receive little to 
no antigenic stimulation during latency are eventually lost during latency, as described in our 
previous studies. Cells (RR1- and ICP8-specific CD8 T cells) overly stimulated during latency 
are maintained in the TG, but eventually lose the ability to produce effector molecules capable of 
preventing viral reactivation from latency. Lastly, cells that receive optimal antigenic stimulation 
(gB498-505-specific CD8 T cells) are maintained in the TG and increase functionality through 
latent infection.          
Functionally exhausted cells are significantly impaired in the ability to control viral 
infections [103,106,110]. We knew that the TG-resident non-gB498-505-specific CD8 T cell 
population contained a large number of functionally exhausted cells, so we wanted examine if 
the limited number of functional cells in the population could maintain viral latency in vivo. To 
do this, we used a recently developed technique that uses saporin-conjugated tetramers 
complexed with a viral antigen of interest to systemically deplete antigen-specific CD8 T cells 
[161]. Initial assessments of depletion showed that we do get effective depletion of up to 50% of 
gB498-505-specific CD8 T cells without observable effects on the non-gB498-505 population. In fact 
three days after treatment administration, we observed a significant increase in the non-gB498-505-
specific population bringing the total number of TG-resident CD8 T cells to typical levels 
noticed during latent infection. By 6 days after toxin administration, gB498-505-specific CD8 T 
cell numbers recovered to levels 3 fold higher than expected. We concluded from this that the 
recovery could be due to residual amounts of toxin-coupled tetramer binding the TCR of gB498-
505-specific CD8 T cells in amounts that were not enough to cause apoptotic death but was 
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enough to stimulate CD8 T cell function. It was also possible that viral reactivation from latency 
in response to the drastic reduction in functional CD8 T cell numbers could stimulate the 
remaining cells increasing the CD8 T cell population days after toxin-treatment. 
 Inhibition of CD8 T cell function and depletion of CD8 T cells in vivo results in viral 
reactivation from latency 3 days after inhibition/depletion. Even though we did not alter total 
CD8 T cell numbers, the 50% reduction in gB498-505-specific CD8 T cell numbers resulted in a 2-
fold increase in viral genome copy number. Additionally, the increased antigenic stimulation of 
CD8 T cells led to higher rates of proliferation as well as upregulation of PD-1 in all populations 
of CD8 T cells. Importantly, the observed increase in viral genome copies resolved once the 
gB498-505-specific CD8 T cell population was restored to steady state latency numbers.  We 
concluded from these observations that during the depletion of gB498-505-specific CD8 T cells, 
non-gB498-505-specific CD8 T cells essentially replace the lost population through proliferation. 
However, due to the high functionality of gB498-505-specific CD8 T cells and the compromised 
nature of non-gB498-505-specfic CD8 T cells, we actually observed a net loss in the total numbers 
of functioning cells in the latent ganglia. After 3 days of treatment, the virus finally overcame 
CD8 T cell control progressing to the stage of DNA synthesis. Three days later, the gB498-505-
specific CD8 T cell population was restored and reclaimed control over the virus reducing copy 
number and the level of CD8 T cell stimulation (reduced PD-1 expression).  
The impacts of these studies provided important observations that should be taken into 
consideration when considering therapies to prevent HSV-1 reactivation. First, we have shown 
from this study that non-gB498-505-specific CD8 T cells do not possess the antiviral power that 
their immunodominant counterparts own. This poses a problem in the event of a mutation in the 
immunodominant epitope that renders immunodominant CD8 T cells useless. Therefore, a 
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possible strategy would be to develop a therapy that targets exhaustion markers to increase 
functionality (actively studied in our lab). Additionally, the development of a tactic that boosts 
the subdominant response while maintaining the gB498-505-specific CD8 T cell response may 
provide benefit.  As we examined in our study, whenever we sacrifice immunodominant CD8 T 
cells to increase subdominant CD8 T cells, viral reactivation occurs. Lastly, due to the efficiency 
of gB498-505-specific CD8 T cells at preventing viral reactivation, a therapy that aims to increase 
the efficacy or numbers of those cells may be beneficial. Rather than attempting to resuscitate 
subdominant CD8 T cells from an exhausted state, our next study focused on increasing the pool 






6.0  CIRCULATING HSV-1-SPECIFIC CD8 T CELLS DO NOT ACCESS HSV-1 
LATENTLY INFECTED TG 
Recurrences of herpetic disease are associated with exposure to stressors known to compromise 
T cell function. Therapeutic vaccines can be designed to enhance existing T cell memory 
populations for increased protection against re-infection. In the case of HSV-1, recurrent disease 
results from reactivation of latent virus in sensory ganglia, which is controlled in part by a 
ganglia-resident HSV-specific memory CD8 T cell population. Recent data suggested that the 
CD8 T cell population in HSV-1 latently infected sensory ganglia may be compartmentalized 
and not replenished from the periphery, a feature ascribed to tissue resident memory (Trm) CD8 T 
cells. Evidence to support this comes from the establishment of an HSV-specific memory 
population in IL-15-/- mice, suggesting that the population can be maintained without 
replenishment from the periphery [99]. Also, when DRG from 2 different congenic strains of 
mice infected with HSV-1 are transplanted under the kidney capsule of another mouse, CD8 T 
cells are first lost inducing HSV-1 reactivation from latency. Following reactivation, the CD8 T 
cell populations were restored expressing the congenic marker of the original DRG donor with 
no apparent infiltration of blood circulating CD8 T cells. The goal of this study was to 
investigate the maintenance of the TG–resident memory CD8 T cell population at the true 
orthotopic site as well as bolster it through adoptive transfer of effector and memory HSV-
specific CD8 T cells.  
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Based on our previous studies, non-gB498-505-specific CD8 T cells did not appear to be a 
worthwhile target for an adoptive cell transfer vaccine due to the significant loss of functionality 
and ability to prevent viral reactivation during latent infection. Therefore, we focused our efforts 
on boosting the immunodominant gB498-505-specific CD8 T cell population. These cells retain 
high levels of functionality through latent infection and can protect from viral reactivation from 
latency without the help of subdominant CD8 T cells. These studies were aided by the 
availability of gBTI-1 mice that allowed for the harvesting of a large number of gB498-505-specific 
CD8 T cells.  
6.1 BLOCKING THE CHEMOKINE RECEPTORS CXCR3 AND CCR5 REDUCES 
CD8 T CELL INFILTRATION INTO GANGLIA DURING ACUTE HSV-1 INFECTION 
Mice received a single subcutaneous injection of TAK-779 at 6 dpi to inhibit the activity of both 
CXCR3 and CCR5 [162] during the initial CD8 T cell infiltration of the TG that occurs 6-8 days 
after HSV-1 corneal infection. Total CD8 T cells and gB498-505-specific CD8 T cells were 
quantified by flow cytometry on dispersed cells from individual TG at 8 dpi (Figure 17 A & B). 
The TAK-779 treatment significantly reduced the CD8 T cell population in the TG compared to 
mock treated (PBS) controls, while not altering the frequency of gB498-505-specific CD8 T cells. 
The reduced CD8 T cell population in TAK-779 treated mice did not affect the HSV-1 viral 
burden in the TG (Figure 17C), which is largely controlled by the innate immune system prior to 




           
 
Figure 17 Effect of systemic TAK-779 treatment on CD8 T cell infiltration into HSV-1-infected 
ganglia 
(A-C) Six days following corneal HSV-1 infection, B6 mice were treated subcutaneously with 150 
μg/mouse TAK-779 or with an equal volume of PBS. Two days following treatment, TG were excised and 
dispersed into single cells. The cells were stained for surface CD8α, CD45, and gB-specific T cell receptor, 
and analyzed by flow cytometry. Data represent the cumulative mean ± SEM of total CD8 T cells (A) or 
gB-CD8 (B) per TG from three experiments involving a total of 6 PBS-treated and 11 TAK-779 treated 
mice. (C) DNA extracted from dispersed TG cells and analyzed by real-time PCR for the number of viral 
glycoprotein H (gH) gene copies revealed no significant group differences. A two-tailed Students t test was 
used for all statistical analyses. Experiments were performed by Susanne Himmelein, PhD with repeats 
performed by Anthony St. Leger.  
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6.2 CXCR3 AND CCR5 ARE NOT REQUIRED TO MAINTAIN THE MEMORY CD8 
T CELL POPULATION WITHIN LATENTLY INFECTED TG  
The CD8 effector T cells in the acutely infected TG undergo contraction and establish a 
stable memory population by 30 dpi [86]. To interrogate the role of CXCR3 and CCR5 in 
maintaining the memory CD8 T cell population in latently infected TG, mice were treated with 
TAK-779 or PBS as a control at 30, 32, and 34 dpi, and total CD8 T cells and gB498-505-specific 
CD8 T cells were quantified in the TG at 36 dpi. As illustrated in Figure 18, TAK-779 treatment 
did not influence the size of the total CD8 T cell population (Figure 18A) in the TG, or the 
frequency of gB498-505-specific CD8 T cells (Figure 18B). Thus, the chemokine receptors CXCR3 
and CCR5 do not appear to be required to maintain the CD8 T cell population within HSV-1 
latently infected TG, at least for the 6 day observation period employed. CD8 T cells in latently 
infected TG of both mice and humans tend to cluster around latently infected neurons, some 
forming immunological synapses with the neurons, and most expressing an activated phenotype. 
Mechanisms governing the attraction of CD8 T cells to infected neurons and their activation 
status are unknown. Here we show that blocking CXCR3 and CCR5 with TAK-779 for 6 days 
did not alter the activation phenotype of TG-resident CD8 T cells (Figure 18C). 
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Figure 18 Effect of TAK-779 treatment during HSV-1 latency on size and activation of memory 
CD8+ T cell population 
(A-C) HSV-1-infected mice were treated with TAK-779 or PBS at 30, 32 and 34 days post-infection (dpi). 
TG were excised 36 dpi, dispersed into single cells, stained for CD45, CD8α, and gB498-505-specific T cell 
receptor, total CD8 T cells (A) or gB498-505-specific CD8 T cells (B) per TG are presented. Data represent 
the cumulative mean ± SEM of cells in the TG (total n=8-9, 2 experiments performed by Anthony St. 
Leger). (C) Alternatively dispersed TG cells were stained for activation markers, CD69 and granzyme B 
(GrB). Bars represent cumulative mean ± SEM frequency of CD8 T cells that expressed CD69 and GrzB 
(n=4 from experiments performed by Susanne Himmelein, PhD). Students t test revealed no statistical 
difference between the groups.  
6.3 HSV-SPECIFIC CD8 T CELLS IN THE PERIPHERAL BLOOD DO NOT 
MIGRATE INTO HSV-INFECTED GANGLIA DURING VIRAL LATENCY  
It has recently been suggested that the CD8 T cell population within HSV-1-infected ganglia is 
compartmentalized, self-sustainable, and does not require replenishment from the circulating 
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lymphocyte pool [163]. We employed adoptive transfer studies in which CD45.2+ gB498-505-
specific CD8 memory or effector T cells were transferred to latently infected mice and their 
migration into the TG was monitored. In a first set of experiments gB498-505-specific CD8 T cells 
were obtained from the spleens of CD45.2+ gBTI1.1 mice 30 days after HSV-1 corneal infection, 
and transferred to latently infected CD45.1- mice. The transferred and endogenous gB498-505-
specific CD8 T cells were quantified in the spleen, blood, and TG of the recipient mice 2.5 and 
4.5 weeks after transfer. As illustrated in Figure 19, the gB498-505-specific CD8 T cells in the 
spleen and blood of recipient mice contained an equal or greater frequency of donor cells at all 
times tested, but no donor cells were detected in the TG. Thus there is no detectable infiltration 
of HSV-1 specific CD8+ T cells into the TG during stable latency.  
                                     
Figure 19 Adoptively transferred gB498-505-specific CD8 T cells are excluded from HSV-1-infected TG 
during stable latency 
CD8 T cells were isolated from 30 dpi gBT I.1 (CD45.2) spleens and 106 cells were intravenously (i.v.) 
injected into latently infected wild-type mice (CD45.1). At indicated times after transfer, spleens, blood, 
and TG were harvested and stained for CD8α, CD45, CD45.1, CD45.2, and gB498-505-specific T cell 
receptor. Data represent the percentage of gB-specific cells that are CD45.1+ (endogenous). Bars represent 
cumulative mean ± SEM frequency of gB498-505-specific CD8 T cells that were donor derived (n=3 from 
experiments performed by Susanne Himmelein, PhD). 
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6.4 REPOPULATION OF THE TG FOLLOWING DISRUPTION VIA STRESS AND 
CORTICOSTERONE IS NOT DEPENDENT ON PROLIFERATION  
We previously established that exposure of latently infected mice to corticosterone or restraint 
stress reduces the CD8 T cell population in the TG, and exposure to restraint stress additionally 
induces HSV-1 reactivation from latency [31] (and Freeman and Hendricks, unpublished data). 
Here we show that simultaneous exposure of latently infected mice to stress and corticosterone 
on 4 consecutive days (30-34 dpi) reduced the CD8 T cell population in the TG by >80% (Figure 
20A), but both the total CD8 T cell and the gB498-505-specific CD8 T cell populations fully 
recovered within 4 days. It is interesting to note the original 1:1 ratio of gB498-505-specific CD8 to 
non-gB498-505-specific CD8 T cells was maintained following recovery of the population. 
Treatment also resulted in HSV-1 reactivation from latency as assessed by a significant increase 
in HSV-1 genome copy number in the TG and detection of HSV-1 genomes in the ipsilateral 
cornea (Figure 20B).  
We hypothesized that recovery of the CD8 T cell population in the TG after stress and 
corticosterone treatment would involve proliferation of the remaining cells, infiltration of CD8 T 
cells from the blood, or a combination of both. We favored proliferation as re-establishing the 
original frequency of gB498-505-specific CD8 T cells through infiltration from the blood would 
seem unlikely. However, the level of proliferation in the recovered population as assessed by 
BrdU incorporation was similar to that of the unperturbed population in mock treated mice that 
were not exposed to corticosterone and stress (Figure 20C), suggesting that recovery was not 
accomplished through proliferation of remaining cells. 
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Figure 20 Following disruption of the TG-resident CD8 T cell population via stress and 
corticosterone treatment, repopulation occurs independent of proliferation 
Latenly infected mice received 4 days of restraint stress and corticosterone-treated drinking water (400 
µg/ml), followed by 1.5, 2, and 4 days of fresh water. TGs were harvested and stained with CD8α, CD45, 
and gB-specific T cells receptor. (A) The numbers of CD8α+ cells and CD8α+gB+ were quantified via flow 
cytometry. Data shown are the means and standard errors for 7 (time point 0), 5 (time point 1.5), and 12 
(time point 4) mice from two independent experiments performed by Anthony St. Leger. (B) RT-PCR of 
DNA from ganglia and corneas shows increased gH copies after stress and corticosterone treatment. gH 
copies peak in the TG at 4 days after stress and corticosterone while detectable viral burden in the cornea 
peaks at 2 days after fresh water (Fisher's exact test). RT-PCR of DNA from corneas shows increased 
detectable gH copies 2 days after stress and corticosterone treatment ended. TG data represents means and 
standard errors from 6 mice (No stress and day zero) or 2 mice (day two and four). Experiments performed 
by Alexander Rowe, PhD and Anthony St. Leger. (C) BrdU was given intraperitoneally (i.p.) 12 hours after 
fresh water. TG were then harvested 1.5 days after stress and stained for CD8α, CD45, gB-specific T cell 
receptor, and BrdU incorporation. Data represent means and standard error of 9 mice from 2 experiments 
performed by Anthony St. Leger. 
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6.5 HSV-SPECIFIC CD8 T CELLS IN THE PERIPHERAL BLOOD DO NOT 
MIGRATE INTO HSV-INFECTED GANGLIA FOLLOWING DISRUPTION OF THE 
TG-RESIDENT CD8 T CELLS  
We explored the alternative possibility that recovery of the CD8 T cell population in the TG 
following corticosterone and stress treatment was accomplished by infiltration of CD8 T cells 
from the blood. Memory and effector gB498-505-specific CD8 T cells were generated in vitro by 
pulsing gBT-1 Thy 1.1+ spleens with the gB peptide (SSIEFARL) in the presence of IL-2 for 
three days (effector cells), followed by culture with IL-15 for 10 days (memory cells) as 
previously described [128]. The effector cells were CD44high CD69+ LFA-1low VLA-4low whereas 
the memory cells were CD44 high CD69- LFA-1high VLA-4high (Figure 21A). Latently infected 
Thy1.2 mice were exposed to stress and corticosterone for 4 days followed by adoptive transfer 
of effector or memory gB498-505-specific CD8 T cells. The TG, blood, spleens, and lungs were 
obtained 4 days after transfer, and the donor (Thy1.1) and recipient (Thy1.2) gB498-505-specific 
CD8 T cells were quantified. As illustrated in Figure 21B&C the donor effector and memory 
cells comprised a significant portion of the gB498-505-specific CD8 T cells in the spleen, blood, 
and lungs of recipient mice, but were undetectable in the TG. These findings do not support the 
concept that recovery of the CD8 T cell population in the TG is through infiltration of HSV-1 
specific CD8 T cells from the blood. 
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Figure 21 Following disruption of the TG-resident CD8 T cell population via stress and 
corticosterone treatment, in vitro generated effector or memory cells do not enter the TG 
(A-C) Spleens from naïve gBT I.1 Thy 1.1 mice were pulsed with SSIEFARL (gB498-505) and incubated in 
IL-2 for three days (effector cells) and some cells were further incubated for 10 days with IL-15 replacing 
IL-2 to generate memory cells. (A) Cells were stained for CD44, CD69, LFA-1, and VLA-4 and analyzed 
by flow cytometry. Latently infected wild type mice (Thy1.2+) were subjected to 4 consecutive days of 
restraint stress and corticosterone. After the final treatment mice received an adoptive transfer of 106 
effector (B) or memory (C) CD8+ T cells (Thy1.1+). Four days after the adoptive transfer, spleens, blood, 
lungs, and TGs were harvested and stained for CD8α, CD45, Thy1.1 (Donor), Thy1.2 (Recipient), and gB-
specific T cell receptor. Data represent means and standard errors of the percentages of gB498-505-specific 
CD8 T cells that are of donor (Thy1.1) or recipient (Thy1.2) origin in the specified tissues (n = 4 mice per 
group). The experiments were performed by Anthony St. Leger and were repeated with similar results. 
6.6 REPOPULATION OF THE TG FOLLOWING STRESS AND 
CORTICOSTERONE DOES NOT DEPEND ON CD4 T CELLS  
A previous study demonstrated that CD4 T cells are required for recovery of the CD8 T cell 
population in latently infected TG following transplantation under the kidney capsule of recipient 
mice [164,165]. To determine if this is also true for recovery of the CD8 T cell population in 
latently infected TG at the orthotopic site, latently infected mice were treated with stress and 
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corticosterone on 4 consecutive days (30-34 dpi) and received anti-CD4 mAb on the first and last 
day of treatment. As shown in Figure 22A, the TG were completely depleted of CD4 T cells at 
the end of treatment and 4 days later (Figure 22B) when the CD8 T cell population had fully 
recovered. However, CD4 T cell depletion had no effect on recovery of the CD8 T cell 
population in the TG (Figure 22C). 
         
 
Figure 22 CD4 T cells are not required for the recovery of CD8 T cells within corticosterone-treated 
ganglia 
(A-C) Mice latently infected with HSV-1 received 4 days of restraint stress and corticosterone treatment 
(30-34 dpi). At 27 and 30 dpi mice received intraperitoneal injections of 0.75 mg/ml α-CD4 monoclonal 
antibody (clone GK1.5) or a control antibody. TG were excised at 38 dpi and stained for CD8α, CD4, 
CD45, and gB-specific T cell receptor. (A) Represenative dot plots demonstrate effective depletion of CD4 
T cells in the TG at 34 and 38 dpi. (B) Quantification of the CD4 depletion in mock depleted and CD4-
depleted groups. (C) TG were excised at 38 dpi and analyzed for recovery of the CD8 T cell population. 
Data are presented as means and standard errors of 15 (mock depleted) or 16 (CD4-depleted) mice from 3 
independent experiments performed by Anthony St. Leger and Susanne Himmelein, PhD. Students t test 




The frequency of HSV-1 reactivation from latency in ex vivo TG cultures is inversely 
proportional to the size of the ganglionic CD8 T cell population [29]. Based on these findings 
some have advocated that all future HSV-1 vaccines be evaluated based on their capacity to 
enhance the HSV-specific CD8 T cell population in latently infected sensory ganglia. Such an 
approach would only be feasible if the HSV-specific CD8 T cells expanded in peripheral 
lymphoid organs through immunization have access to latently infected ganglia. With our initial 
studies identifying HSV-specific CD8 T cells, we decided to investigate the ability of expanded 
HSV-specific CD8 T cells to enter the TG from the circulation. 
Evidence obtained in a model system in which latently infected DRG are transplanted 
under the kidney capsule of recipient mice suggest that HSV-specific CD8 T cells do not 
infiltrate latently infected DRG even when the resident CD8 T cell population is substantially 
disrupted [165]. However, a number of factors that may be unique to the transplanted tissue 
could have influenced CD8 T cell migration in that model. The authors suggested that the loss of 
CD8 T cells from the DRG following transplantation was likely due to death resulting from the 
trauma of transplantation. Such trauma could also induce other changes within the 
microenvironment of the latently infected ganglion such as alterations in the chemokine and 
cytokine milieu that could influence CD8 T cell infiltration. Moreover, revascularization of the 
transplanted tissue could influence T cell migration. 
Based on these concerns we sought a more physiological model in which to examine the 
HSV-specific CD8 T cell infiltration into latently infected TG. We concluded that even though 
we had identified all the CD8 T cell specificities, we decided to first investigate the ability of 
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expanded gB498-505-specific CD8 T cells to enter the TG from the circulation. This was due to the 
availability of a large pool of gB498-505-specific CD8 T cells from the gBT-I transgenic mouse.  
We first identified chemokine receptors that are used to direct CD8 T cell into acutely 
infected TG and asked if blocking these receptors during latency would result in diminution of 
the CD8 T cell population in latently infected TG. Activated CD8 T cell in human and mouse TG 
highly express the chemokine receptors CCR5 and CXCR3 and their corresponding ligands, 
CCL5 and CXCL10, have also been detected in infected ganglia [166-170]. These receptors play 
important roles in other viral models especially HIV, but the role these receptors play in CD8 T 
cell recruitment into the TG during HSV infection had not been established. In this study, we 
demonstrated using systemic treatment with the chemical non-peptide inhibitor of CXCR3 and 
CCR5, TAK-779, significantly reduced the infiltration of CD8 effector T cells into acutely 
infected TG, but did not influence the size of the CD8 memory T cell population within latently 
infected TG. Important to our studies involving subdominant CD8 T cells, we observed no 
apparent preferential influence of these receptors on various CD8 T cell specificities due to the 
unchanged frequency of gB498-505-specific CD8 T cell during and after treatment. Our latency 
studies suggest that even though these receptors aid migration into the TG during acute infection, 
CD8 T cell do not need these receptors for retention in the TG throughout latency. However, our 
results do not describe if the effects of inhibiting these receptors during acute infection persists 
into latency. If the effect of CXCR3/CCR5 inhibition becomes less apparent during latency after 
acute treatment, more support would be given to the hypothesis that once CD8 T cells enter the 
TG, they are a self-supporting population that requires no assistance from peripheral blood 
during latency.  
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 We next hypothesized that, if CXCR3 and CCR5 did not act to retain or recruit CD8 T 
cells into the TG during latent infection, an adoptive transfer of memory cells would infiltrate the 
TG and increase HSV-specific CD8 T cell numbers. Unfortunately, CD8 T cells were shown to 
not migrate into latently infected TG came from the observation that adoptively transferred 
gB498-505-specific CD8 T cells that are retained in the blood, spleen, lymph nodes, and lungs of 
recipient mice over an extended period of at least 4.5 weeks are not detectable in the TG during 
the same period. The above findings strongly suggest that TG containing an established CD8 
memory T cell population and latent HSV-1 are not permissive to CD8 T cell infiltration. We 
next asked if diminution of the resident CD8 T cell population through elevated serum 
corticosterone levels and reactivation of HSV-1 from latency through exposure of mice to 
restraint stress would change the microenvironment of the TG, rendering it permissive to CD8 T 
cell infiltration. However, adoptively transferred gB498-505-specific CD8 T cells did not enter the 
TG from the blood even when reactivation and diminution of the TG-resident CD8 T cell 
population was induced by exposure of latently infected mice to stress and corticosterone (Figure 
22). 
A caveat to these findings is that the adoptively transferred CD8 T cells obtained from 
gBT1.1 mice may not accurately reflect the migratory capability of the endogenous gB498-505-
specific CD8 T cell memory population in the lymphoid organs and blood of the host. This seems 
unlikely given that neither effector cells generated through in vitro stimulation for 3 days with 
the gB498-505 peptide, nor memory cells obtained by incubating the effector cells for an additional 
10 days in medium containing IL-15 were able to enter the TG. The transferred memory 
population expressed high levels of the LFA-1 and VLA-4 adhesion molecules typically used by 
CD8 T cells to enter infected tissue. Moreover, CD8 T cells that were isolated from spleens of 
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HSV-1 latently infected mice (30 dpi) also failed to enter the TG during recovery of the CD8 T 
cell population following stress and corticosterone treatment (data not shown). These findings 
combined with observations made with transplanted HSV-1 latently infected DRG, and with 
vesicular stomatitis virus infected brains strongly suggest that once a Trm CD8 T cell population 
is established in nervous tissue, further infiltration of cells from the blood is effectively blocked 
[163,165]. 
Since infiltration of CD8 T cells from the blood did not seem to account for recovery of 
the CD8 T cell population in the TG of stress and corticosterone treated mice, we concluded that 
recovery likely resulted from proliferation of the remaining cells in the TG. However, our results 
showed that proliferation of TG-resident cells after stress and corticosteron treatment was lower 
compared to homeostatic proliferation of control mice not exposed to stress or corticosterone. 
Conversely, it is possible that the burst of proliferation was missed, the level of proliferation in 
both the gB498-505-specific and non-gB498-505-specific CD8 T cell populations measured after 
termination of treatment could not account for the rapid recovery of the populations three days 
after treatment.  
The lack of a requirement of CD4 T cell help in the repopulation of the TG with CD8 T 
cells remains an interesting observation in comparison to the requirement of CD4 T cells in the 
transplanted DRG model. We hypothesize that the trauma associated with DRG excision and 
transplantation leads to extensive cell death, which would then require donor CD4 T cells to help 
the proliferation and re-establishment of DRG-resident CD8 T cells. Alternatively, our model 
entails no trauma and relies on female sex hormones and psychological stress to deplete the TG 
of CD8 T cells. Therefore, rather than causing death of immune cells, our treatment, we 
hypothesize, induces emigration of CD8 T cells from tissues into the blood, followed by 
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immigration back into the TG 4 days over the ensuing 4 days. This reasoning would explain the 
lack of proliferation and necessity of CD4 T cell help during repopulation of the TG. It would 
also explain the identical frequency of gB498-505-specific and non-gB498-505-specific CD8 T cells 
in the endogenous and recovered population of CD8 T cells. Moreover, the failure of adoptively 
transferred CD8 T cells to enter the TG during recovery would suggest selective re-entry of the 
original TG-resident CD8 T cells. This would suggest acquisition, by the TG-resident CD8 T 
cells, of a homing receptor that permits selective re-entry into the latently infected TG.  
Our findings suggest that at some point after establishment of an HSV-specific CD8 T 
cell population the infected TG becomes resistant to further T cell infiltration. We have shown 
that the gB498-505-specific CD8 T cells exhibit a progressively higher functional avidity (ability to 
detect a low epitope density) over time in latently infected TG, whereas their counterparts in the 
spleen and lungs showed decreased functional avidity over the same period [76]. The ability to 
detect very low levels of MHC/ peptide complexes on latently infected neurons would likely 
enhance the ability of CD8 T cells to provide immunesurveillance of latently infected ganglia, 
but be of lesser importance in the periphery. Therefore, there might be a selective advantage to 
the host to restricting infiltration of HSV-specific CD8 T cells into the TG. However, restricting 
entrance of CD8 T cells into the latently infected TG will complicate the development of 
therapeutic vaccines designed to bolster the TG-resident CD8 T cell population. 
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7.0  MANIPULATION OF HOST SUPPRESSION LEADS TO INCREASED CD8 T 
CELL FUNCTIONALITY 
Unfortunately, our findings indicated that adoptively transferred CD8 T cells into the circulation 
do not gain access to the TG. Since gB498-505-specific CD8 T cells remain fully functional 
through latent infection, we concluded that enhancing the gB498-505 response is not currently 
feasible.  Our next step concentrated on the improvement of the non-gB498-505-specific CD8 T 
cell response. Results from chapter 5 demonstrated that non-gB498-505-specific CD8 T cells 
appear chronically stimulated through latent infection. During chronic viral infections, viral 
persistence leads to chronic antigenic stimulation of CD8 T cells. Effects of constant stimulation 
through the CD8 T cell receptor leads to upregulation of inhibitory receptors such as 
programmed death (PD)-1, loss of effector function, and in extreme cases physical deletion of 
the CD8 T cell population.  An area of study gaining momentum is the development of 
techniques aimed towards reversing the effects of exhaustion, which increases CD8 T cell 
functionality to better protect from viral infections. Current strategies inhibit PD-1/PD-L1 
(currently studied in our lab), Tim-3/galectin-9 ([171,172] and currently studied), and CTLA-
4/CD28 interactions. Also, immunosuppressive cytokines such as IL-10 and TGF-β produced by 
the host have also been targeted to improve the immune response towards viral infections.  
By administering an antibody to block the IL-10 receptor, we aimed to better understand 
the state of functional compromise in the non-gB498-505-specific CD8 T cell population. 
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Additionally, we wanted to assess how the immunosuppressive cytokine, IL-10, was inhibiting 
the CD8 T cell response during latent infection. Lastly, we desired to observe whether this 
treatment, as seen in LCMV infection, correlates with reduced viral burden and presented itself 
as a possible therapy for recurrences of HSV-1 reactivation. 
7.1 IL-10R BLOCKADE ALTERS THE IMMUNODOMINANCE HIERARCHY IN 
LATENTLY INFECTED TG BY SELECTIVELY AUGMENTING EXPANSION OF 
SUBDOMINANT CD8 T CELLS.  
It was possible that the functional compromise of the subdominant population during 
latency (Chapter 5) represented a partial exhaustion as is seen in chronic viral infections [173], 
where the exhaustion can be reversed by treating mice with antibodies to the IL-10 receptor (IL-
10R) [117-119,174].  To test this possibility, mice that had established a latent HSV-1 infection 
(35 dpi) were systemically treated every three days with anti-IL-10R mAb or PBS for a period of 
3 weeks.  After treatment, the TG were excised, the cells dispersed with collagenase, and the 
number of total or immunodominant CD8 T cells was determined by flow cytometry.  The 
treated mice showed a dramatic increase in total CD8 T cells during treatment (Fig. 23A), and 
the increase was almost entirely accounted for within the subdominant CD8 T cell population 
(Fig. 23B).  As expected, the control mice did not show an increase in TG-resident CD8 T cells 
during treatment, and maintained an approximate 1:1 ratio of gB498-505-specific to non-gB498-505-
specific cells.  The increased number of non-gB498-505-specific CD8 T cells was associated with a 
significant increase in their rate of proliferation as indicated by BrdU incorporation (Fig. 23C).  
The increase in subdominant CD8 T cells in anti-IL-10R treated mice appears to be restricted to 
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the TG since the number of RR1982-989-specific CD8 T cells in the TG of anti-IL-10R-treated 
mice increased approximately 2-fold, while their numbers in the spleen remained constant (Fig. 
23D).  Since HSV-1 is confined to the TG during latency, these data are consistent with the 
notion that IL-10 regulates proliferation resulting from antigenic exposure rather than 






   

























































































Figure 23 Anti-IL-10R treatment preferentially increases proliferation of non-gB498-505 specific CD8 T cells. 
(A&B) Mice latently infected with HSV-1 were given intraperitoneal (i.p.) injection of PBS or anti-IL-10R for up to 21
days.  TGs were harvested and dispersed into single-cell suspensions and stained for CD8α (A) and gB498-505 TCR (B)
and analyzed by flow cytometry.  Symbols represent the cumulative mean ± SEM number of CD8+ T cells per TG at 7,
14, 17, and 21 days of treatment (at least 2 independent experiments, total n = 6-15). (C&D) Latently infected mice were
treated with PBS or anti-IL-10R mAb for 17 days, and then given an intraperitoneal (i.p.) injection of 2mg of BrdU. (C)
After 4 hours, TGs were dispersed into single-cell suspensions, stained for CD8α, gB498-505 TCR, and BrdU, and
analyzed by flow cytometry . Bars represent the cumulative mean ± SEM percentage of BrdU positive cells (2
experiments, total n = 10). (D) TGs and spleens were dispersed into single-cell suspensions, stained for CD8α and
RR1982-989 TCR and analyzed by flow cytometry.  Bars represent the cumulative mean ± SEM number of RR1982-989
tetramer positive cells (2 experiments, total n = 10). Statistical significance was determined using a Student’s T test. *   p
≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.0005. 
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7.2 IL-10R BLOCKADE EXPANDS BOTH FUNCTIONAL AND NON-
FUNCTIONAL SUBDOMINANT CD8 T CELLS IN LATENTLY INFECTED TG 
To determine if the function of the subdominant CD8 T cells in latently infected TG was 
also rescued by IL-10R blockade, latently infected mice were treated for up to three weeks with 
anti-IL-10R mAb as described above.  TG cells of treated and control mice were dispersed and 
CD8 T cells were either stained directly ex vivo for GrzB or the cells were stimulated with 
B6WT3 cells pulsed with pools of peptides corresponding to the three epitopes on RR1 or on 
ICP8 in the presence of anti-CD107a antibody (to detect lytic granule release) and then stained 
for intracellular IFN-γ and TNFα.  Consistent with previous findings, the immunodominant 
gB498-505-specific CD8 T cells expressed more GrzB than the non-gB498-505-specific cells prior to 
treatment (Fig. 24A).  However after a 1 week lag period, GrzB expression increased 
dramatically in the non-gB498-505-specific cells, reaching comparable levels to the gB498-505-
specific cells by the end of the 3-week anti-IL-10R treatment.  The anti-IL-10R treatment 
increased the mean number of GrzB+ gB498-505-specific during the first two weeks of treatment, 
but the difference was not statistically significant (Fig. 24A).  The number of IFN-γ+ 
subdominant CD8 T cells was significantly elevated in anti-IL-10R mAb treated mice relative to 
controls following stimulation with RR1 or ICP8 epitopes, but the frequency of IFN-γ+ cells was 
not affected (Figs 24B&C).  Moreover, anti-IL-10R mAb treatment increased the number (not 
shown) but not the frequency (Fig. 24D) of multifunctional cells capable of producing IFN-γ, 
TNFα, and releasing lytic granules when stimulated with subdominant epitopes.  Together our 
findings suggest that anti-IL-10R mAb treatment does not rescue the function of impaired 
subdominant CD8 T cells, but rather increases the rate of proliferation of both functional and 




Figure 24 Treatment with anti-IL-10R mAb increases the total number of functional non-gB498-505-
specific CD8 T cells. 
Latently infected mice were treated with PBS or anti-IL-10R mAb for 7-21 days (A), or 14 days (B-D). 
After treatment, TG cells were stained for CD8α, gB498-505 TCR, and granzyme B (GrzB) expression and 
analyzed by flow cytometry (A).  Bars represent the cumulative mean ± SEM number of GrzB+ cells (2 
experiments, total n = 6).  (B-D); TG cells were incubated for 6 hours with B6WT3 fibroblasts pulsed with 
three RRI epitopes (B&D) or three ICP8 epitopes (C & D).  Cells were monitored for surface CD8α and 
IFNγ (B&C), or surface CD8α and CD107a and intracellular IFN-γ and TNFα (D) and analyzed by flow 
cytometry.  Solid black bars represent cumulative mean ± SEM number of IFN-γ+ cells and hashed bars 
represent cumulative mean ± SEM frequency of CD8+ T cells that were IFN-γ+ (B&C, 3 experiments, n = 
11) , or percentage multifunctional (IFN γ+ , TNFα+, and CD107a+) CD8+ T cells (D, 3 experiments, n = 7-
12). Statistical significance was determined using Student’s T test. *   p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 
0.0005. 
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 7.3 THE EFFECT OF ANTI-IL-10R TREATMENT PERSISTS FOR AT LEAST 3 
WEEKS 
It was of interest to determine if the augmented functionality of subdominant CD8 T cells 
persists after anti-IL-10R treatment is terminated.  TG were excised 3 weeks after PBS or anti-
IL-10R treatment was discontinued and the number of total and GrzB+ immunodominant and 
subdominant CD8 T cells was determined by flow cytometry.  Although the total number of TG-
resident subdominant CD8 T cells and the number of GrzB+ subdominant CD8 T cells declined 
somewhat during the 3 weeks after termination of anti-IL-10R treatment (compare Fig. 22B with 
Fig. 25A, and Fig. 24A with Fig 25B), both populations remained significantly elevated 





 Figure 25 The effects of anti-IL-10R mAb are maintained for at least 3 weeks after terminating 
treatment. 
(A&B) Latently infected mice were treated with PBS or anti-IL-10R mAb for 3 weeks and were rested for 
an additional 3 weeks. After rest, TG cells were stained for CD8α, gB498-505 TCR, and granzyme B (GrzB) 
and analyzed by flow cytometry. (A) Bars represent the cumulative mean ± SEM number of CD8 T cells 
per TG (2 experiments, n = 9 – 16).  (B) Bars represent the cumulative mean ± SEM number of GrzB+ cells 
(3 experiments, n=16-20). Statistical significance was determined by a Student’s T tests. *   p ≤ 0.05, ** p 
≤ 0.005, *** p ≤ 0.0005. 
7.4 IN VIVO ANTI-IL-10R MAB TREATMENT DURING LATENCY REDUCES 
VIRAL REACTIVATION 
In untreated latently infected mice, HSV reactivation frequency in ex vivo TG cultures is directly 
proportional to the viral genome copy number, and inversely proportional to the number of CD8 
T cells in the TG [29].  The anti-IL-10R mAb treatment did not significantly alter the HSV-1 
genome copy number in latently infected TG (data not shown).  Since treatment did significantly 
increase the number of functional HSV-specific CD8 T cells, we predicted treatment would 
reduce the HSV-1 reactivation frequency in ex vivo TG cultures.  TG were excised from anti-IL-
10R treated and control mice at the end of treatment or 3 weeks after treatment was terminated, 
the cells from each TG were dispersed into cultures (the equivalent of 0.15 TG/culture), and 
supernatants of each culture were sampled every other day for 10 days and assayed for infectious 
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virus as previously described [41,43,100].  The data are presented either as the frequency TG 
cultures that reactivated (roughly an estimate of the number of neurons that reactivated in each 
TG); or as the frequency of TG with any neurons that reactivated.  Control mice that received 
PBS treatment in vivo showed a low frequency of reactivated cultures that was significantly 
increased when the function of the CD8 T cells was compromised by addition of anti-CD8 mAb 
to the cultures (Fig. 26A).  Thus, CD8 T cells that were in the TG of control mice at the time of 
excision could partly, but not completely block HSV-1 reactivation from latency in ex vivo TG 
cultures.  Compared to controls, TG that were excised immediately after 3 weeks of anti-IL-10R 
treatment showed a trend toward reduced reactivation in cultures with or without anti-CD8 mAb, 
but the differences were not statistically significant.  In contrast, TG that were excised 3 weeks 
after termination of anti-IL-10R treatment showed a significantly lower frequency of reactivation 
in cultures with and without anti-CD8 mAb compared with TG from control mice.     
Expressing the data as a percentage of TG with HSV-1 reactivation (i.e., at least one well 
of a given TG showed reactivation), all TG from control mice exhibited viral reactivation even in 
cultures where CD8 T cell function was intact (Fig. 26B).  In contrast, CD8 T cells were able to 
completely block HSV-1 reactivation in 40% of TG that were excised immediately after anti-IL-
10R mAb treatment and 45% of TG that were excised 3 weeks after treatment was terminated.  
Moreover, even when CD8 T cell function was compromised in TG cultures, we observed no 
virus reactivation in 10% of the TG that were removed immediately after anti-IL-10R mAb 
treatment and 25% of those removed 3 weeks after treatment was terminated.  Thus, the 
increased number of functional subdominant CD8 T cells in TG of anti-IL-10R mAb treated 
mice provided significantly increased protection from reactivation in ex vivo TG cultures, and 
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also appear to have completely eliminated neurons capable of reactivating virus in vivo in up to 
25% of TG. 
                             
Figure 26 Treatment with anti-IL-10R mAb reduces viral reactivation from latency. 
(A&B) Latently infected mice were treated with PBS or anti-IL-10R mAb for 3 weeks. Immediately after 
or 3 weeks after termination of treatment, TG cells from 2 mice were pooled and cultured (0.15 TG/well).  
Half of the wells were treated with either antiCD8α mAb or control IgG. Culture supernatants were serially 
sampled every 2 days, and assayed for infectious virus on monolayers of Vero cells. Bars represent the 
cumulative mean ± SEM percentage of virus positive wells per pooled TG (A) (2-4 experiments, total n = 
10-24) or the mean ± SEM percentage of TG pools that produced detectable virus (B). Statistical 
significance was determined using an unpaired Student’s T test (A) or Fisher’s Exact Test (B). *   p ≤ 0.05, 
** p ≤ 0.005, *** p ≤ 0.0005. 
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7.5 DISCUSSION 
The successful design of a therapeutic or prophylactic treatment for HSV infection 
remains elusive. Recent evidence from several laboratories suggests that strategies aimed at 
augmenting the TG-resident CD8 T cell population could inhibit HSV-1 reactivation from 
latency, potentially reducing the frequency of recurrent disease [34,41,43,86,100,165].  HSV-1 
therapeutic vaccines could be designed to increase the number and function of circulating CD8 T 
cells, but clinical trials of HSV vaccines to date have been restricted to genital infections and 
have established limited efficacy in preventing viral transmission or the frequency of recurrent 
disease [125,175,176].  Failure of therapeutic HSV vaccines might be related in part to their 
focus on increasing antibody rather than T cell responses, but our study from Chapter 6 
demonstrated limited if any access of circulating HSV-specific CD8 T cells to latently infected 
TG [9].  Therefore, alternative approaches to augmenting the TG-resident CD8 T cell population 
may be required.   
The unusually strong immunodominance of the gB498-505 epitope in B6 mice is well 
documented [53,85,152].  These cells represent 50% of the HSV-1 specific CD8 T cell repertoire 
in spleens as well as in both acutely and latently infected TG.  The remaining 50% of CD8 T 
cells in acutely infected TG are also HSV-1 specific as demonstrated by their ability to produce 
cytokines (IFN-γ and TNF-α) when stimulated with 18 different HSV-1 subdominant epitopes 
that together with the immunodominant gB498-505 epitope define the entire HSV-1 specific CD8 
TCR repertoire [50,96].  Using tetramers containing four of the subdominant epitopes that 
together constitute approximately 30% of the subdominant population; we demonstrate little if 
any change in the CD8 T cell repertoire within the memory population that is retained in the TG 
during viral latency.  However, in contrast to the immunodominant CD8 T cells that retain full 
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functionality during latency, those specific for subdominant epitopes exhibit a dramatic loss of 
functionality.   
Retention of CD8 T cells in the latently infected TG appears to require antigenic 
exposure [85]. Moreover, proliferation of the CD8 T cells in latently infected TG is less 
dependent on homeostatic proliferation signals from IL-15 than their counterparts in the spleen 
[99].  Together these findings suggest that proliferation of HSV-specific CD8 T cells in the TG is 
driven at least in part by antigenic exposure.  Our current study demonstrates anti-IL-10R mAb 
treatment dramatically and selectively increases proliferation of CD8 T cells specific for 
subdominant HSV-1 epitopes in latently infected TG, while not affecting their proliferation in 
the spleen.  This finding could indicate selective expression of IL-10R on subdominant CD8 T 
cells in the TG, and/or selective regulation of antigen driven, but not homeostatic proliferation of 
subdominant CD8 T cells by IL-10.  
Similarly, the functional compromise of CD8 T cells in the latently infected TG is not 
seen in their counterparts in the spleen, suggesting that functional compromise is also driven by 
antigenic exposure.  The similarity between the functional compromise of subdominant CD8 T 
cells in latently infected TG and functionally exhausted CD8 T cells during chronic viral 
infections is striking.  One might predict that the very low and usually undetectable levels of 
HSV-1 protein expression in latently infected TG would not elicit CD8 T cell exhaustion.  
However, the ability to produce antigens without detectable gene products via defective 
ribosomal products (DRiPs) and immunoribosomes [80,81,177], and the proposed transient 
derepression of HSV-1 genes during latency [178], may result in persistent antigenic exposure to 
HSV-specific CD8 T cells in latently infected TG.  The subdominant epitopes could be 
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expressed at a higher level than the immunodominant gB498-505 epitope, leading to selective 
exhaustion of subdominant CD8 T cells. 
During chronic LCMV infections, persistent exposure to viral antigens can lead to loss of 
functionality and ultimately to deletion of the exhausted cells [103,106,179,180].  There appears 
to be progressive functional impairment beginning with impairment of TNFα production 
followed by a loss of IFN-γ, which is seen only in cells that are at an advanced stage of 
exhaustion that occurs prior to deletion [103,157].  In these chronic viral infection models, 
functional exhaustion can be rescued by IL-10R blockade, with those cells at early stages of 
exhaustion being most readily rescued [117,118,174,181,182].  In HSV-1 latently infected TG, 
subdominant CD8 T cells exhibit a significant loss of IFN-γ, TNFα, and lytic granule release 
suggesting a late stage of exhaustion.  Treatment with anti-IL-10R mAb results in an increase in 
the number of IFN-γ producing and IFN-γ impaired subdominant CD8 T cells, such that the 
frequency of functional cells was unchanged.  It appears, therefore, that anti-IL-10R treatment 
does not rescue the function of cells that are functionally impaired, but rather induces the 
proliferation of functional and non-functional CD8 T cells in the TG. 
The in vivo anti-IL-10R treatment increased the number of subdominant CD8 T cells in 
the TG that loaded GrzB into their lytic granules in vivo, and produce IFN-γ when stimulated ex 
vivo.  The increased number of functional subdominant CD8 T cells persisted for at least 3 
weeks after anti-IL-10R treatment was terminated.  Since TG resident CD8 T cells use GrzB and 
IFN-γ to inhibit HSV-1 reactivation from latency, we predicted that the expanded number and 
TCR repertoire of functional TG resident CD8 T cells would improve the ability of these cells to 
block HSV-1 reactivation from latency in ex vivo TG cultures.  Indeed, there was a significant 
reduction of reactivation in cultures of TG from anti-IL-10R treated mice.  All of the TG from 
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control mice reactivated the virus as expected since over the past 16 years we have performed 
hundreds of these cultures and have never seen a latently infected TG that failed to reactivate the 
virus. In contrast, nearly half of TG from anti-IL-10R treated mice failed to reactivate the virus 
when CD8 T cell function was intact in ex vivo TG cultures.  Protection from reactivation was 
partially eliminated when anti-CD8α mAb was added to cultures, demonstrating that the 
enhanced number of functional subdominant CD8 T cells in TG following anti-IL-10R treatment 
provided better protection from reactivation.  However, there also appears to be an in vivo effect 
of treatment in that a significant proportion of TG from anti-IL-10R treated mice failed to 
reactivate the virus even when CD8 T cell function was compromised in ex vivo TG cultures.  
This effect was most pronounced in latently infected TG from mice that were rested for three 
weeks following 3 weeks of anti-IL-10R treatment.  Since these mice retained high numbers of 
functional subdominant CD8 T cells during this time, we hypothesize that neurons attempting to 
reactivate the virus during and after treatment were either pushed into a very stable state of 
latency, or perhaps more likely were killed by the expanded number of functional CD8 T cells.  
We saw a slight, but not statistically significant reduction in viral genome copy number in TG of 
anti-IL-10R treated mice (data not shown).  Given the small number of neurons that appear to 
require CD8 T cell protection from reactivation at any given time (approximately 6 neurons/TG) 
[183], it would likely require a very large number of TG from αIL-10R treated mice to 
demonstrate a significant reduction of viral DNA resulting from destruction of these few 
neurons.   
Based on current and previous findings we propose the following theoretical framework 
for CD8 T cell control of HSV-1 latency.  In C57BL/6 mice HSV-1 latently infected neurons in 
the TG are surrounded by HSV-specific CD8 T cells that maintain a strict 1:1 ratio of cells 
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specific for an immunodominant and subdominant epitopes.  The immunodominant CD8 T cells 
maintain full functionality during latency [14], whereas the subdominant CD8 T cells become 
functionally compromised. The functional gB498-505 specific CD8 T cells prevent HSV-1 
reactivation from latency through production of IFN-γ and release of lytic granules, while 
sparing the infected neuron [41,43,100].  Treatment of latently infected mice with anti-IL-10R 
mAb dramatically increases the number of functional, GrzB+ subdominant CD8 T cells in the 
TG.  Under these circumstances attempted HSV-1 reactivation results in attack of the host 
neuron by both immunodominant and subdominant GrB+ CD8 T cells that either overwhelm the 
neuron’s antiapoptotic mechanisms leading to neuronal death, or push the virus into a stable 
latency in which CD8+ T cell protection is no longer required.  Over time this leads to a latently 
infected TG that is completely refractory to HSV-1 reactivation even if CD8 T cell function is 
subsequently compromised.  It is not clear if this strategy would be effective in latently infected 
humans because the functional state of CD8 T cells in HSV-1 latently infected human TG is not 
known.  However, our data provide proof of principal that strategies aimed at expanding the 
repertoire of functional TG-resident CD8 T cells can reduce the likelihood of a reactivation 
event. 
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8.0  SUMMARY AND CONCLUSIONS 
The studies of this dissertation first outline the CD8 T cell repertoire of the C57BL/6 mouse from 
acute infection through latent infection. We showed that even though the CD8 T cell repertoire is 
maintained throughout infection, immunodominant CD8 T cells increase functionality and can 
effectively prevent viral reactivation from latency while subdominant CD8 T cells lose 
functionality and the ability to control viral reactivation. Our next study attempted to increase the 
number of functional cells through adoptive CD8 T cell transfer. It became evident during these 
studies that circulating CD8 T cells cannot gain access to the latently infected TG, suggesting 
that TG-resident CD8 T cells are a self-sustaining immune population. Therefore, we focused 
our efforts on attempting to enhance the TG-resident subdominant CD8 T cell response. We 
completed this task by administering anti-IL-10R mAb that blocks the IL-10R. This treatment 
increased the number of functional non-gB498-505-specific CD8 T cells. The increase in functional 
cells correlated with better protection from viral reactivation from latency. Therefore, 
diversification and expansion of the functional CD8 T cell repertoire leads to better protection 
from viral reactivation.  
We came to several conclusions from the results of these studies that can aid the 
advancement of therapies to prevent recurrent reactivations in humans. Attractive methods for 
prospective therapies have been through subunit vaccination before infection aimed at generating 
an effective antibody response. Even though clinical trials have proved these vaccinations as 
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ineffective, we feel the subunit vaccine, if aimed at generating a CD8 T cell response may still be 
efficacious. Specifically, our studies have shown that a vaccine should be directed towards 
creating a CD8 T cell response during the phase when viral proteins are expressed before DNA 
synthesis. Furthermore, it appears as if humans generate responses against the early protein, 
RR1, and other early proteins [52,140,184]. Since our studies show that increasing the 
subdominant CD8 T cell response, vaccinations that increase the diversity of functional HSV-
specific CD8 T cells may help humans prevent recurrent reactivation events.  
Conversely, the above vaccination strategy would most certainly need to be modified to 
effectively inhibit HSV-1 reactivation. Evidence for this comes from our studies showing the 
functional exhaustion of HSV-specific CD8 T cells and the exclusion of TG-resident CD8 T cells 
from being replenished from peripheral memory cells. Generation of memory cells prior to 
infection may indeed allow cells to enter the TG earlier; however, these cells appear destined for 
exhaustion. Therefore, once the TG becomes isolated from the circulating memory CD8 T cells 
during latent infection, vaccine-derived TG-resident CD8 T cells appear destined to lose 
functionality and the ability to prevent viral reactivation. To further complicate the generation of 
a prophylactic vaccine therapy, the diagnostic identifier of primary HSV-1 infection remains 
difficult to determine for some people. Therefore, we conclude that in tandem with vaccine 
development, there should also be development of therapeutic strategies that prevent or eliminate 
the effects of exhaustion on TG-resident CD8 T cells.  
With our observation of functional exhaustion in subdominant CD8 T cells, we were also 
able to substantiate the exceptional sensitivity of CD8 T cells. In combination with our previous 
studies, we corroborated the observation that viral-specific CD8 T cells receive antigenic 
stimulation throughout latent infection. With our results, we were able to deduce that different 
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CD8 T cell specificities receive varying levels of stimulation in the absence of detectable lytic 
gene expression during latency. In fact, results suggest that the level of gene expression and 
antigen generation, though not detectable, leads to functional exhaustion. It may be difficult to 
accept that an absence of gene expression would result in the vast functional exhaustion we 
observed; however, we concluded from this that the small size of the TG as well as the absence 
of CD8 T cell replenishment from the periphery significantly reduces the amount of antigen 
needed to induce exhaustion. The exquisite sensitivity of CD8 T cells has the potential to be a 
valuable tool in examining the pattern of gene expression as HSV moves in and out of latent 
infection. For example in Chapter 5, we used markers of stimulation to support our observations 
of increased copy number during a reactivation event. The dynamics of these markers on 
peptide-specific CD8 T cells may allow for detection of individual viral genes expressed as the 
virus exits latency.    
The unfortunate circumstance that prevents the entry of circulating CD8 T cells from 
entering the TG keeps the advent of adoptive CD8 T cell therapies for the prevention of HSV-1 
reactivation elusive. Due to this observation, we concluded from our studies that more 
investigation of the TG-resident CD8 T cell population must take place. For example, 
examination of tissue homing receptors on TG-resident CD8 T cells may illuminate strategies to 
manipulate the phenotype of effector/memory cells to allow for entry of CD8 T cells into the TG. 
Also, examination of the TG microenvironment such as the network of blood vessels may 
provide some much needed information that would aid understanding of factors preventing 
recruitment of viral-specific CD8 T cells into the TG.  
Lastly, we concluded from our studies that increasing and diversifying the numbers of 
functional CD8 T cells leads to a reduction in reactivation from latency. We accomplished this 
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through antibody inhibition of IL-10 signaling. We concluded that there appears to be a 
dysregulated response to IL-10 through our selective augmentation of the subdominant CD8 T 
cell population compared to the immunodominant CD8 T cell population after treatment. 
Additionally, we concluded that the increased response led to better control of viral reactivation 
from latency that can be maintained for extended lengths of time. Combining these observations 
with lack of response in uninfected tissue led the determination that increasing and broadening 
the functional repertoire of CD8 T cells results in indefinite protection from viral reactivation 
from latency. This brings us to our ultimate conclusion that the most effective therapy to protect 
from recurrent reactivation events would be a treatment that broadens and expands the functional 
CD8 T cell repertoire without having effects on the peripheral immune response such as 
treatment with anti-IL-10R mAb. 
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9.0  FUTURE DIRECTIONS 
9.1 EXAMINING EXHAUSTION 
The nature of functional exhaustion remains an interesting topic in the resolution of chronic and 
latent infections. Our studies in chapter 5 illustrate that by latent infection a great majority of 
subdominant CD8 T cells become exhausted. We still do not know at what point between acute 
infection and latent infection these subdominant CD8 T cells lose functionality. Therefore, a 
description of the kinetics of functional compromise during infection would shed light on the 
degree of functional exhaustion. Also, defining the role viral gene expression plays in functional 
exhaustion is critical for the complete understanding of the process during latency. Our 
collaboration with the Kinchington laboratory has provided the ability to express viral epitopes 
from varying viral promoters [185]. The unique properties of the gB498-505 epitope make it an 
attractive target for these studies. By moving the gB498-505 epitope to different promoters, one 
could produce epitopes resulting in exhausted CD8 T cells. Functionality of gB498-505-specific 
CD8 T cells could then depict the role viral gene expression plays in exhaustion. Similarly, 
moving exhausted epitopes to the gB promoter leading to alleviated exhaustion phenotypes 
would confirm observations.  
Our most recent data also help detail the nature of exhaustion in latently infected TG 
(Figures 29&30 in Apendix A). Results illustrate that functional subdominant CD8 T cells in the 
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TG during latency do not bind detectable amounts of fluorescently conjugated tetramers 
suggesting these cells either express TCR that binds with low affinity to peptide/MHC or express 
low amounts of surface TCR. Conversely, a large percentage of cells that do not function bind 
detectable levels of TCR. We concluded from these data that the ability to bind MHC/peptide 
directly correlates with the state of exhaustion. We can identify variations in the composition of 
the TCR by isolating functional and non-functional subdominant CD8 T cells from mice that 
express Thy1.1 concurrently with IFN-γ. Single-cell PCR analysis of TCR may show that higher 
affinity clonotypes of protein-specific CD8 T cells are more likely to become exhausted.  
9.2 CHARACTERIZING THE TG MICROENVIRONMENT DURING LATENCY 
We concluded from our CD8 T cell adoptive transfer studies that TG-resident CD8 T cells 
appear “stamped” with a surface marker that maintains their retention in the TG, which is absent 
on peripheral or circulating memory CD8 T cells. Studies by others investigating Trm CD8 T 
cells suggests a possible tissue resident marker would be CD103. Our studies discount this as a 
unique marker of Trm due to its expression on only 50% of CD8 T cells in the TG regardless of 
specificity. A marker of interest could be VLA-1 (CD49a), which is an integrin known to be 
expressed on CD8 T cells specific for HSV antigens [165]. Also, this surface marker is known to 
be important for retention of CD8 T cells in infected lung tissue during influenza infection [186]. 
Analysis of the TG microenvironment could provide insight into factors that allow entrance of 
CD8 T cells into the TG. A drawback to these studies and other studies examining the latently 
infected TG is the low numbers of CD8 T cells in the tissue. This complicates comparison of 
these cells to peripheral memory CD8 T cells. A possible way to better study TG-resident CD8 T 
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cells would be to incubate dispersed TG cells with in vitro generated memory cells. If entry is 
determined by a soluble factor in the TG, we may be able to provide exogenous cells with the 
marker capable of allowing entrance into the TG.  
9.3 FURTHER DEFINING THE EFFECTS OF ANTI-IL-10R MAB TREATMENT 
9.3.1 Are neurons dying or is HSV pushed into a more latent state? 
An important question in our studies involving the administration of anti-IL-10R mAb treatment 
asks whether neurons harboring virus capable of reactivation are killed or if HSV-1 is pushed 
into a more latent state. Our studies show that increased numbers of granzyme B expressing CD8 
T cells correlates with a lasting reduction in viral reactivation from latency. It is well 
characterized that the main role of granzyme B is to cleave and activate caspases leading to 
apoptosis of the host cell [97]. In HSV-1 infection, granzyme B has been shown to prevent viral 
reactivation not by inducing apoptosis, but by cleaving the immediate early protein, ICP4 [43]. 
With the observed increase in the number of granzyme B expressing CD8 T cells, we would 
hypothesize that the increased lytic hit would override the anti-apoptotic capabilities of ICP4 and 
LATs resulting in neuronal apoptosis. Additionally, IL-10 is a known cytokine that promotes 
neuronal survival during stress [187], so IL-10R inhibition may not only affect the immune 
system, it may also increase the neuronal susceptibility to granzyme B mediated apoptosis.  
Alternatively, granzyme B is known to bind a protein associated with heterochromatin in 
the nucleus [188]. The status of heterochromatin of viral DNA is thought to play a role in the 
reactivation from latency. Therefore, it is possible that the genetic modifications in 
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heterochromatin by granzyme B may not be inducing apoptosis but may be re-ordering the viral 
heterochromatin to a more stable form. To visualize this, it would be necessary to identify 
neuronal apoptosis during treatment. This can be accomplished using the TUNEL reagent, which 
effectively labels apoptotic cells, and confocal microscopy. The caveat of this process would be 
the extremely low frequency of infected neurons that can reactivate the virus. Confocal 
microscopy could aid in the search for apoptotic neurons due to the ability to mark hubs of 
immune cell interactions. The most effective time to glimpse apoptotic neurons would be after 
three weeks of treatment. At this point, the TG harbors the largest numbers of CD8 T cells, and it 
will be straightforward to detect clusters of CD8 T cells surrounding infected neurons. To 
confirm the first hypothesis, we would expect to observe apoptotic neurons in the centers of 
these clusters while TGs from PBS treated mice would contain clusters of CD8 T cells 
surrounding non-apoptotic neurons. Testing the state of heterochromatin would consist of 
infecting neurons in vitro in the presence of acyclovir to induce a “latent” state. We could then 
treat these neuronal cultures with perforin and granzyme B to assess changes in host 
heterochromatin as well as heterochromatin of viral DNA.  
9.3.2 What cell produces IL-10? 
In LCMV models, several cell types have been shown to produce IL-10 such as CD4 T cells, 
macrophages, DCs, B cells, and others [112,181]. Additionally, other viral models have recently 
shown that CD8 T cells can, in fact, produce IL-10 during infection to limit the inflammatory 
response slowing the kinetics of viral clearance. The role of IL-10 in viral control has not been 
investigated, so the producer of IL-10 remains unclear. The TG contains several types of cells 
that have the potential to produce IL-10 such as neurons, CD4/CD8 T cells, macrophages, B 
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cells, and DCs. Due to the difficulties of stimulating IL-10 production in immune cells. The use 
of reporter mice would be the best step to identify the main IL-10 producer during HSV-1 
infection. Specifically, performing flow cytometry on TG cells or imaging whole TG with 
confocal microscopy would allow detection of IL-10 producers in mice that express GFP 
concurrently with IL-10. 
9.3.3 What are the specificities of the increased TG-resident CD8 T cells? 
We currently hypothesize that all CD8 T cells before and after anti-IL-10R mAb treatment 
recognize HSV antigens. However, our assays have only accounted for a fraction of the HSV-
specific CD8 T cell repertoire during latency. This is primarily due to the limitation in 
fluorescently labeled tetramer technology. We have been unable to use tetramer based assays to 
identify CD8 T cell specificities due to the low level of TCR expression and/or ineffective 
labeling with the tetramer. We do have evidence that subdominant CD8 T cells that are tetramer+ 
for an HSV antigen and CD8 T cells that produce IFN-γ when stimulated with that same antigen 
are mutually exclusive (Figure 29). In other words, it appears as if tetramer+ cells are 
functionally exhausted while the functional counterparts have either low affinity TCR or express 
low amounts of surface TCR. This would suggest that we have underestimated the known 
frequency of HSV-specific CD8 T cells in a latently infected TG. To reach an appropriate 
frequency of HSV-specific CD8 T cells, we should stain latently infected TG cells with tetramer 
followed by a 6 hour stimulation with fibroblasts pulsed with peptides used in the tetramer 
pretreatment protocol. We are still faced with the problem of ineffective tetramers (for 
specificities other than RR1 and ICP8), but this process will at least provide a more accurate 
assessment of the frequency of RR1- and ICP8-specific CD8 T cells.  
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To better assess the specificities that have proven incapable of being fluorescently labeled 
with tetramer, manipulation of the peptide may allow for better binding to MHC or the TCR may 
be required. Alternatively, there has been a recent report detailing the use of photocrosslinkable 
tetramers that can label with very high efficiency [189]. These reagents have been shown to be 
able to detect peptide-specific CD8 T cells with very low numbers of surface TCR or with low 
affinity TCR. 
9.3.4 The effects of acute anti-IL-10R treatment 
We were intrigued to find a study that shows IL-10 in cooperation with IL-21 during acute 
LCMV infection actively induces memory development in the viral-specific CD8 T cell 
population [190]. Without these cytokines, the host is left with a pool of CD8 T cells retaining a 
terminal effector phenotype rather than a self-renewing memory population. While the effect of 
this on chronic viral burden was not explored, we sought to investigate the effects of acute IL-10 
neutralization in our model of HSV-1 infection due to the necessity of self-renewing memory 
cells in preventing viral reactivation.  
For these studies, we gave two i.p. injections of anti-IL-10 mAb on 0 and 5 dpi. We then 
sacrificed mice at the peak of the response (8 dpi) and latency (35 dpi) and assessed the numbers 
and phenotypes of the infiltrating lymphocytes. We notice marked effect of treatment at both 8 
and 35 dpi in regards to total CD8 and CD4 T cells in the TG. In the CD8 T cell compartment, 
we observed a 50% increase in total cells during acute infection that is maintained through 
contraction and latency. Interestingly, we saw a 200% increase in total CD4 T cells in the TG 
during acute infection and latency (Figure 27A). These data give support to our hypothesis that 
CD4 T cells are not just bystanders in the prevention of viral reactivation but do play a yet to be 
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determined role. We find it interesting that in these studies CD4 T cells are preferentially 







 Figure 27 The effects of acute anti-IL-10R mAb treatment 
(A-D) C57BL/6 mice were infected with HSV-1 RE and given an i.p. injection of anti-IL-10R mAb on 0 
and 5 dpi. TG were excised and dispersed into single-cell suspensions on (A&B) 8 and (A&C-E) 35 dpi. 
(A-D) Cells were stained for (A-D) CD8α, (A&C&D) gB498-505 TCR, (B) RR1982-929 TCR, (B) RR1822-829 
TCR and (D) granzyme B (GrzB) and analyzed by flow cytometry. (A) Symbols represent the cumulative 
mean ± SEM of total numbers of cells in the TG at 8 and 35 dpi (total n=10-14, 3 experiments). (B) Bars 
represent the cumulative mean ± SEM of the total numbers of RR1822-829 or RR1982-989 TG-resident CD8 T 
cells at 8 dpi. (total n=8-9, 2 experiments) (C) Bars represent the cumulative mean ± SEM frequency of 
gB498-505-specific CD8 T cells at 35 dpi. (total n=7-8, 2 experiments) (D) Bars represent the cumulative 
mean ± SEM total numbers of granzyme B+ gB498-505-specific or non-gB498-505-specific CD8 T cells in the 
TG at 35 dpi. (total n=7-10, 2 experiments). (E) TG cells were incubated for 6 hours with HSV-infected 
fibroblasts or B6WT3 fibroblasts pulsed with three RRI epitopes, three ICP8 epitopes, or 1 DNA Packaging 
Terminase epitope in the presence of Golgi-Plug. Cells were monitored for surface CD8α and interacellular 
+ IFN-γ and analyzed by flow cytometry. Bars represent the cumulative mean ± SEM number of IFN-γ at 35 
dpi (total n=4-10, 1 experiment). 
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We further examined the effects of CD8 T cells by characterizing the effects of acute 
antibod
mice
show a marked increase in the cellular response to HSV-1 
after IL
y treatment on the immundominance hierarchy. While we did not observe any change in 
select subdominant specificities (Figure 27B), we did notice a slight reduction in the 
immunodominance of gB498-505-specific CD8 T cells (Figure 27C). Similar to our latent anti-IL-
10 mAb treatment, we could not identify a specificity of CD8 T cells that was preferentially 
expanded. As stated earlier, granzyme B and IFN-γ secretion are absolutely required for the 
prevention of viral reactivation, so we assessed the ability of cells to produce these effector 
molecules during latency. Again, we noticed that the latent subdominant CD8 T cell population 
is significantly affected by acute anti-IL-10R mAb treatment. In the subdominant CD8 T cell 
population we detected more than a 2 fold increase in the numbers of cells expressing granzyme 
B directly ex vivo and in the numbers of cells that secrete IFN-γ upon antigenic stimulation. 
Contrary to latent anti-IL-10R mAb treatment, gB498-505-specific CD8 T cells also increased 
approximately 2 fold increase in effector function in  treated with anti-IL-10R mAb during 
primary infection (Figure 27 D&E). 
 Even though our results do 
-10 inhibition, much is needed to identify the exact role IL-10 plays in the generation of 
the cellular immune response against HSV-1. Phenotypically characterizing the increased pool of 
cells using KLRG-1, CD127, CD27, Tbet, and Eomesodermin would aid in the demarcation of 
these cells as effector or memory cells similar to previous studies. Additionally, proliferation 
assays would explain the proliferative potential of the expanded population. If the expanded 
population does exhibit an effector phenotype, it would be interesting to observe the size of the 
population for extended periods of time such as 90, 120, and 180 dpi. Due to the eventual loss of 
effector-like cells, we would hypothesize that the cells will eventually be lost from the TG. If 
 109 
indeed these cells are lost, quantification of viral burden and spontaneous reactivation from ex 
vivo cultures would convey if the boosted population was reduce the possibility of viral 
reactivation from latency. If the effector-like cell population is retained at high levels for long 
periods of time after infection, our studies would then be able to describe another unique aspect 
of the TG microenvironment that prevents the eventual contraction of effector-like cells.  
9.4 WHAT ROLE DO CD4 T CELLS PLAY DURING LATENCY? 
Even though CD4 T cells play a key role in mediating HSK, CD4 T cells enter TG, similar to 
CD8 T cells. TG CD4 T cell numbers peak between 10-12 dpi and contract to form a stable 
latency population equivalent to the TG-resident CD8 T cell population. Early in infection, TG-
resident CD4 T cells have the ability to produce IFN-γ (data not shown), but their phenotype 
during latent infection has yet to be investigated. Recently, we acquired a transgenic mouse that 
possesses CD4 T cells bearing a TCR that recognizes an HSV antigen on glycoprotein D. By 
adoptively transferring CD4 T cells of irrelevant specificities, we can determine if, similar to 
CD8 T cells, only HSV-specific CD4 T cells infiltrate and are retained in infected TG. If only 
HSV-specific CD4 T cells enter the TG, then we can assume that, similar to CD8 T cells, CD4 T 
cells require antigenic stimulation for retention in the TG. Recently, we excised TG from latently 
infected IL-10-eGFP mice and analyzed dispersed cells with flow cytometry. Intriguingly, we 
found that as many as 25% of CD4 T cells in the TG express GFP directly ex vivo (Figure 28). 
We can infer from these results that roughly a quarter of CD4 T cells are stimulated at any point 
during latency.  
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 Figure 28 TG-resident CD4 T cells produce IL-10 in latently infected ganglia 
TG from latently infected WT or IL-10-eGFP mice were excised and dispersed into single-cell suspensions 
and were immediately stained for CD45 and CD4 and analyzed by flow cytometry. Dot plots represent GFP 
expression in WT and IL-10-eGFP mice. Data represents the cumulative mean ± SEM frequency CD4 T 
cells that express GFP (total n = 1 (WT) or 3 (IL-10-eGFP) from 1 experiment).  
These results give critical and exciting evidence for further characterizing the dynamics 
of latency. Our current theory suggests that during latency, a small amount of viral gene 
expression occurs that produces peptides, which stimulate HSV-specific CD8 T cells. Our theory 
then would not support antigenic stimulation of CD4 T cells due to the apparent absence of MHC 
class II molecules on host neurons. Detection of MHC class II on latently infected neurons using 
confocal microscopy would help support our theory; however, the inability to detect MHC class 
II would require a new hypothesis. If confocal microscopy revealed that CD4 T cells clustered 
around satellite cells or other APCs such as macrophages, it would suggest that viral proteins 
have made way out of the cell to allow for cross-presentation to CD4 T cells by surrounding 
cells. Therefore, we would hypothesize that during latency, rather than intermittent viral gene 
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expression stimulating CD8 T cells, viral gene expression would produce full proteins that are 
released into the TG microenvironment to be picked up and presented to CD4 T cells. This 
process could either be due to exocytosis of viral products or the exciting possibility of DC 
networks extending nanotubes into host neurons that pick up viral peptides for antigen 
presentation to CD4 T cells. The nature of antigenic stimulation of CD4 T cells during HSV 
infection would not only help develop hypotheses related to HSV associated latency, but it will 
also help describe the dynamics of antigen presentation and the immense sensitivity of CD4 T 
cells during a viral infection.  
Our investigation of in situ production of IL-10 by TG-resident CD4 T cell response 
during HSV infection also demonstrates a role that CD4 T cells play during latency. From our 
studies, it seems as if CD4 T cells act to suppress the CD8 T cell response as described by our 
IL-10 neutralization studies in Chapter 7. Therefore, we hypothesize that TG-resident CD4 T 
cells act to prevent the destruction of non-regenerating neurons that harbor latent HSV. These 
IL-10 producing CD4 T cells resemble a Th2 CD4 T cell subset. Defining whether the rest of the 
CD4 T cells are the same or different subsets remains an intriguing avenue of research. This can 
be done by examining cytokine production and transcription factor expression after stimulation 
with antigen pulsed DCs.  
Similarly, studies should determine whether the subtypes of CD4 T cells are stable during 
various transitions of infection such as the transition from acute to latent infection, latent 
infection to reactivation/lytic infection, and reactivation/lytic infection to latent infection. It 
would be interesting to determine if CD4 T cells display a more anti-viral phenotype during a 
time of lytic infection to limit viral spread while the phenotypes are more suppressive during 
latent infection when the chance for viral spread is low or non-existent. To accomplish this, we 
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could induce reactivation using our psychological stress model and use intracellular cytokine 
detection to effector molecules produced. Additionally, flow cytometric detection of 





A.1.1 Exhaustion of RR1-specific CD8 T cells 
After our studies showing exhaustion of subdominant CD8 T cells, we wanted to begin to further 
delineate the extent of exhaustion in the subdominant CD8 T cells. We focused our efforts on 
CD8 T cells specific for epitopes on the HSV-1 protein RR1. During latency, RR1-specific CD8 
T cells lose a significant amount of functionality compared to acute infection. Nevertheless, the 
entire population does not become functionally compromised, which led to our hypothesis that 
high levels of TCR expression would lead to increased stimulation and eventual exhaustion. 
Conversely, RR1-specific CD8 T cells with little to no detectable TCR expression would be 
stimulated to a lesser degree and be less prone to exhaustion. To test this hypothesis, we first 
pretreated latently infected TG cells with pools of tetramers complexed to the 3 RR1 epitopes 
followed by a 6 hour in vitro stimulation with fibroblasts pulsed with the same 3 RR1 epitopes. 
After stimulation, we analyzed TG cells by flow cytometry for TCR expression and IFN-γ 
production.  
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Figure 29 Functioning subdominant CD8 T cells in the TG express lower amounts of TCR than non-
functional subdominant CD8 T cells 
(A&B) TGs from latently infected mice were harvested and dispersed into single-cell suspensions and were 
pretreated with pooled tetramers complexed with RR1822-829, RR1982-989, and RR1372-380 epitopes for 1 h at 
room temperature. TG cells were incubated for 6 h with B6WT3 fibroblasts loaded with 3 RR1 peptides in 
the presence of Golgi-Plug, followed by intracellular staining for IFN-γ. Samples were analyzed for 
tetramer positivity and IFN-γ production by flow cytometry. (A) Representative dot plots displaying 
tetramer staining and IFN-γ production in the CD8 T cell population after pretreatment and stimulation. (B) 
Data represents the cumulative mean ± SEM frequency of cells that were positive for the noted parameters 
(total n = 5, 1 experiment).  
These results suggest that functional exhaustion in a latently infected TG relates to either 
how well a CD8 T cell TCR can bind peptide/MHC or the level of expression of TCR. Results 
from chapter 4 show that the TCR affinity for MHC/peptide between cells that do not become 
exhausted (gB498-505) and cells that do become exhausted (RR1) are identical. Therefore, unless a 
transition occurs between acute infection and latent infection, we are left to assume that the level 
of TCR expression directly correlates to functional exhaustion during latency. Evidence to 
support this comes from data comparing stimulation and tetramer staining from acute and latent 
infection.  
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Figure 30 RR1 tetramer staining does not appear to be strictly correlative to stimulation data. 
TG cells from acute or latent TGs were either stained with pooled RR1 tetramer or stimulated with B6WT3 
fibroblasts pulsed with pooled RR1 epitopes for 6 h in the presence of Golgi-Plug. Cells were then 
analyzed for RR1-TCR expression or IFN-γ production by flow cytometry. Data represents the cumulative 
mean ± SEM frequency of CD8 T cells that were either tetramer+ or IFN-γ+.  
During acute infection, we observe that tetramer staining of RR1-specific CD8 T cells 
underestimates the cells that respond to peptide pulsed fibroblasts. Conversely, during latency we 
see that tetramer staining overestimates the cells that respond to peptide pulsed fibroblasts. In 
other word, there are RR1-specific CD8 T cells during acute infection that respond to peptide but 
do not express enough TCR to be detectable by flow cytometry. We feel that these tetramer 
negative cells that respond to peptide are cells that retain functionality in the latently infected 
TG. Further characterizing the differences between tetramer- cells that function and tetramer + 
cells that do not function during latency is an essential task to better protect from viral 
reactivation from latency.  
 116 
APPENDIX B 
LIST OF WORKS 
1) St. Leger AJ, Jeon S, Hendricks RL. Expanding the functional CD8+ T cell repertoire reduces 
HSV-1 reactivation from latency in sensory ganglia. (submitted to PLoS Pathogens). 
2) Bidula SM, Ramachandran S, St. Leger AJ, Sette A, Hendricks RL, Kinchington PR. 
Ganglionic CD8+ T cell specificity induced by herpes simplex virus type 1 lacking and 
ectopically restored for the gB498-505 C57BL/6 murine immunodominant epitope (in preparation). 
3) Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, Terry-Allison T, St 
Leger AJ, Thomson AW, Cherpes TL (2012). Dendritic cell activation and memory cell 
development are impaired among mice administered medroxyprogesterone acetate prior to 
mucosal herpes simplex virus type 1 infection. J Immunol. Aug 31. [Epub ahead of print].  
4) Kinchington PR, St. Leger AJ, Guedon JM, Hendricks RL (2012). Herpes simplex virus and 
varicella zoster virus, the house guests who never leave. Herpesviridae. 3(1):5. 
5) St. Leger AJ, Hendricks RL (2011). CD8+ T cells patrol HSV-1-infected trigeminal ganglia and 
prevent viral reactivation. The Journal of Neurovirology. 17(6):528-34. 
6) Kardava L, Yang Q, St. Leger AJ, Foon KA, Lentzsch S, Vallejo AN, Milcarek C, Borghesi L 
(2011). The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia 
(CLL) cells. International Immunology. 23: 375-384. 
 117 
7) St. Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL (2011). Defining the herpes simplex virus-
specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol. 186: 3927-3933. 
8) Himmelein S, St. Leger AJ (co-first author), Knickelbein JE, Rowe A, Freeman ML, Hendricks RL 
(2011). Circulating herpes simplex type 1 (HSV-1)-specific CD8+ T cells do not acces HSV-1 
latently infected trigeminal ganglia. Herpesviridae. 2(1):5. 
9) Yang, Q, Kardava, L, St. Leger, AJ, Martincic, K, Varnum-Finney, B, Bernstein, ID, Milcarek, C, 
Borghesi, L (2008).  E47 Controls the Developmental Integrity and Cell Cycle Quiescence of 




1. Pepose JS, Keadle TL, Morrison LA (2006) Ocular herpes simplex: changing epidemiology, 
emerging disease patterns, and the potential of vaccine prevention and therapy. Am J 
Ophthalmol 141: 547-557. 
2. Brazzale AG, Russell DB, Cunningham AL, Taylor J, McBride WJ (2010) Seroprevalence of 
herpes simplex virus type 1 and type 2 among the Indigenous population of Cape York, 
Far North Queensland, Australia. Sex Health 7: 453-459. 
3. Sauerbrei A, Schmitt S, Scheper T, Brandstadt A, Saschenbrecker S, et al. (2011) 
Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 
2006. Euro Surveill 16. 
4. Liesegang TJMD (2001) Herpes Simplex Virus Epidemiology and Ocular Importance. Cornea 
20: 1-13. 
5. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, et al. (2005) HSV-1 DNA 
in Tears and Saliva of Normal Adults. Investigative Ophthalmology & Visual Science 46: 
241-247. 
6. Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, et al. (2005) Incidence of 
herpes simplex virus keratitis in France. Ophthalmology 112: 888-895. 
7. Mortensen KK, Sjolie AK (1979) Keratitis dendritica. An epidemiological investigation. Acta 
Ophthalmol (Copenh) 57: 750-754. 
8. Young RC, Hodge DO, Liesegang TJ, Baratz KH (2010) Incidence, recurrence, and outcomes 
of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect 
of oral antiviral prophylaxis. Arch Ophthalmol 128: 1178-1183. 
9. Ribaric V (1976) The incidence of herpetic keratitis among population. Ophthalmologica 173: 
19-22. 
10. Wilhelmus KR (2010) Antiviral treatment and other therapeutic interventions for herpes 
simplex virus epithelial keratitis. Cochrane Database Syst Rev: CD002898. 
11. Knipe DM, Howley PM, Griffin DE, editors (2007) Fields' Virology. 5 ed. Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins. 
 119 
12. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, et al. (2003) Latent Herpesvirus 
Infection in Human Trigeminal Ganglia Causes Chronic Immune Response. Am J Pathol 
163: 2179-2184. 
13. Stroop WG, Schaefer DC (1987) Herpes simplex virus, type 1 invasion of the rabbit and 
mouse nervous systems revealed by in situ hybridization. Acta Neuropathol 74: 124-132. 
14. Mellerick DM, Fraser NW (1987) Physical state of the latent herpes simplex virus genome in 
a mouse model system: evidence suggesting an episomal state. Virology 158: 265-275. 
15. Sawtell NM, Thompson RL (1992) Herpes simplex virus type 1 latency-associated 
transcription unit promotes anatomical site-dependent establishment and reactivation 
from latency. J Virol 66: 2157-2169. 
16. Steiner I, Spivack JG, O'Boyle DR, Lavi E, Fraser NW (1988) Latent herpes simplex virus 
type 1 transcription in human trigeminal ganglia. Journal of Virology 62: 3493-3496. 
17. Stevens J, Wagner E, Devi-Rao G, Cook M, Feldman L (1987) RNA complementary to a 
herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science 235: 
1056-1059. 
18. Jiang X, Alami Chentoufi A, Hsiang C, Carpenter D, Osorio N, et al. (2011) The Herpes 
Simplex Virus Type 1 Latency-Associated Transcript Can Protect Neuron-Derived 
C1300 and Neuro2A Cells from Granzyme B-Induced Apoptosis and CD8 T-Cell 
Killing. J Virol 85: 2325-2332. 
19. Thompson RL, Sawtell NM (2001) Herpes Simplex Virus Type 1 Latency-Associated 
Transcript Gene Promotes Neuronal Survival. J Virol 75: 6660-6675. 
20. Li S, Carpenter D, Hsiang C, Wechsler SL, Jones C (2010) Herpes simplex virus type 1 
latency-associated transcript inhibits apoptosis and promotes neurite sprouting in 
neuroblastoma cells following serum starvation by maintaining protein kinase B (AKT) 
levels. Journal of General Virology 91: 858-866. 
21. Perng G-C, Jones C, Ciacci-Zanella J, Stone M, Henderson G, et al. (2000) Virus-Induced 
Neuronal Apoptosis Blocked by the Herpes Simplex Virus Latency-Associated 
Transcript. Science 287: 1500-1503. 
22. Margolis TP, Imai Y, Yang L, Vallas V, Krause PR (2007) Herpes Simplex Virus Type 2 
(HSV-2) Establishes Latent Infection in a Different Population of Ganglionic Neurons 
than HSV-1: Role of Latency-Associated Transcripts. Journal of Virology 81: 1872-1878. 
23. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, et al. (2008) MicroRNAs 
expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 
454: 780-783. 
 120 
24. Tang S, Patel A, Krause PR (2009) Novel Less-Abundant Viral MicroRNAs Encoded by 
Herpes Simplex Virus 2 Latency-Associated Transcript and Their Roles in Regulating 
ICP34.5 and ICP0 mRNAs. Journal of Virology 83: 1433-1442. 
25. Shen W, Sa e Silva M, Jaber T, Vitvitskaia O, Li S, et al. (2009) Two Small RNAs Encoded 
within the First 1.5 Kilobases of the Herpes Simplex Virus Type 1 Latency-Associated 
Transcript Can Inhibit Productive Infection and Cooperate To Inhibit Apoptosis. J Virol 
83: 9131-9139. 
26. Wang K, Lau TY, Morales M, Mont EK, Straus SE (2005) Laser-Capture Microdissection: 
Refining Estimates of the Quantity and Distribution of Latent Herpes Simplex Virus 1 
and Varicella-Zoster Virus DNA in Human Trigeminal Ganglia at the Single-Cell Level. 
Journal of Virology 79: 14079-14087. 
27. Cohrs RJ, Randall J, Smith J, Gilden DH, Dabrowski C, et al. (2000) Analysis of individual 
human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus 
nucleic acids using real-time PCR. J Virol 74: 11464-11471. 
28. Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The Quantity of Latent Viral DNA 
Correlates with the Relative Rates at Which Herpes Simplex Virus Types 1 and 2 Cause 
Recurrent Genital Herpes Outbreaks. J Virol 72: 2760-2764. 
29. Hoshino Y, Pesnicak L, Cohen JI, Straus SE (2007) Rates of Reactivation of Latent Herpes 
Simplex Virus from Mouse Trigeminal Ganglia Ex Vivo Correlate Directly with Viral 
Load and Inversely with Number of Infiltrating CD8+ T Cells. J Virol 81: 8157-8164. 
30. Halford WP, Schaffer PA (2001) ICP0 Is Required for Efficient Reactivation of Herpes 
Simplex Virus Type 1 from Neuronal Latency. J Virol 75: 3240-3249. 
31. Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL (2007) Psychological Stress 
Compromises CD8+ T Cell Control of Latent Herpes Simplex Virus Type 1 Infections. J 
Immunol 179: 322-328. 
32. Padgett DA, Sheridan JF, Dorne J, Berntson GG, Candelora J, et al. (1998) Social stress and 
the reactivation of latent herpes simplex virus type 1. Proceedings of the National 
Academy of Sciences of the United States of America 95: 7231-7235. 
33. Varnell ED, Kaufman HE, Hill JM, Thompson HW (1995) Cold stress-induced recurrences 
of herpetic keratitis in the squirrel monkey. Invest Ophthalmol Vis Sci 36: 1181-1183. 
34. Himmelein S, St Leger A, Knickelbein J, Rowe A, Freeman M, et al. (2011) Circulating 
herpes simplex type 1 (HSV-1)-specific CD8+ T cells do not access HSV-1 latently 
infected trigeminal ganglia. Herpesviridae 2: 5. 
35. Kubat NJ, Tran RK, McAnany P, Bloom DC (2004) Specific histone tail modification and 
not DNA methylation is a determinant of herpes simplex virus type 1 latent gene 
expression. J Virol 78: 1139-1149. 
 121 
36. Kubat NJ, Amelio AL, Giordani NV, Bloom DC (2004) The herpes simplex virus type 1 
latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency 
independently of LAT transcription. J Virol 78: 12508-12518. 
37. Knipe DM, Cliffe A (2008) Chromatin control of herpes simplex virus lytic and latent 
infection. Nat Rev Microbiol 6: 211-221. 
38. Wang QY, Zhou C, Johnson KE, Colgrove RC, Coen DM, et al. (2005) Herpesviral latency-
associated transcript gene promotes assembly of heterochromatin on viral lytic-gene 
promoters in latent infection. Proc Natl Acad Sci U S A 102: 16055-16059. 
39. Neumann DM, Bhattacharjee PS, Giordani NV, Bloom DC, Hill JM (2007) In vivo changes 
in the patterns of chromatin structure associated with the latent herpes simplex virus type 
1 genome in mouse trigeminal ganglia can be detected at early times after butyrate 
treatment. J Virol 81: 13248-13253. 
40. Amelio AL, Giordani NV, Kubat NJ, O'Neil JE, Bloom DC (2006) Deacetylation of the 
Herpes Simplex Virus Type 1 Latency-Associated Transcript (LAT) Enhancer and a 
Decrease in LAT Abundance Precede an Increase in ICP0 Transcriptional Permissiveness 
at Early Times Postexplant. Journal of Virology 80: 2063-2068. 
41. Decman V, Kinchington PR, Harvey SAK, Hendricks RL (2005) Gamma Interferon Can 
Block Herpes Simplex Virus Type 1 Reactivation from Latency, Even in the Presence of 
Late Gene Expression. J Virol 79: 10339-10347. 
42. Kramer MF, Coen DM (1995) Quantification of transcripts from the ICP4 and thymidine 
kinase genes in mouse ganglia latently infected with herpes simplex virus. Journal of 
Virology 69: 1389-1399. 
43. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, et al. (2008) Noncytotoxic 
Lytic Granule-Mediated CD8+ T Cell Inhibition of HSV-1 Reactivation from Neuronal 
Latency. Science 322: 268-271. 
44. Godowski PJ, Knipe DM (1986) Transcriptional control of herpesvirus gene expression: gene 
functions required for positive and negative regulation. Proceedings of the National 
Academy of Sciences 83: 256-260. 
45. Gao M, Knipe DM (1991) Potential role for herpes simplex virus ICP8 DNA replication 
protein in stimulation of late gene expression. J Virol 65: 2666-2675. 
46. Le Gac NT, Villani G, Boehmer PE (1998) Herpes Simplex Virus Type-1 Single-strand 
DNA-binding Protein (ICP8) Enhances the Ability of the Viral DNA Helicase-primase to 
Unwind Cisplatin-modified DNA. Journal of Biological Chemistry 273: 13801-13807. 
47. Hamatake RK, Bifano M, Hurlburt WW, Tenney DJ (1997) A functional interaction of ICP8, 
the herpes simplex virus single-stranded DNA-binding protein, and the helicase-primase 
complex that is dependent on the presence of the UL8 subunit. J Gen Virol 78 ( Pt 4): 
857-865. 
 122 
48. Tomazin R, van Schoot NE, Goldsmith K, Jugovic P, Sempe P, et al. (1998) Herpes simplex 
virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 72: 2560-2563. 
49. Goldsmith K, Chen W, Johnson DC, Hendricks RL (1998) Infected cell protein (ICP)47 
enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J 
Exp Med 187: 341-348. 
50. Salvucci L, Bonneau R, Tevethia S (1995) Polymorphism within the herpes simplex virus 
(HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for 
recognition by HSV type 1-specific cytotoxic T lymphocytes. J Virol 69: 1122-1131. 
51. Goldstein DJ, Weller SK (1988) Herpes simplex virus type 1-induced ribonucleotide 
reductase activity is dispensable for virus growth and DNA synthesis: isolation and 
characterization of an ICP6 lacZ insertion mutant. Journal of Virology 62: 196-205. 
52. Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, et al. (2012) Cross-presentation and 
genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 
1 vaccine. J Clin Invest 122: 654-673. 
53. Wallace ME, Keating R, Heath WR, Carbone FR (1999) The Cytotoxic T-Cell Response to 
Herpes Simplex Virus Type 1 Infection of C57BL/6 Mice Is Almost Entirely Directed 
against a Single Immunodominant Determinant. J Virol 73: 7619-7626. 
54. Rafield LF, Knipe DM (1984) Characterization of the major mRNAs transcribed from the 
genes for glycoprotein B and DNA-binding protein ICP8 of herpes simplex virus type 1. 
J Virol 49: 960-969. 
55. Peake ML, Nystrom P, Pizer LI (1982) Herpesvirus glycoprotein synthesis and insertion into 
plasma membranes. J Virol 42: 678-690. 
56. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB (1984) Glycoprotein C of 
herpes simplex virus 1 acts as a receptor for the C3b complement component on infected 
cells. Nature 309: 633-635. 
57. Hook LM, Lubinski JM, Jiang M, Pangburn MK, Friedman HM (2006) Herpes Simplex 
Virus Type 1 and 2 Glycoprotein C Prevents Complement-Mediated Neutralization 
Induced by Natural Immunoglobulin M Antibody. Journal of Virology 80: 4038-4046. 
58. Mardberg K, Trybala E, Tufaro F, Bergstrom T (2002) Herpes simplex virus type 1 
glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing 
gro2C cells. J Gen Virol 83: 291-300. 
59. Svennerholm B, Jeansson S, Vahlne A, Lycke E (1991) Involvement of glycoprotein C (gC) 
in adsorption of herpes simplex virus type 1 (HSV-1) to the cell. Archives of Virology 
120: 273-279. 
60. Rødahl E, Stevens JG (1992) Differential accumulation of herpes simplex virus type 1 
latency-associated transcripts in sensory and autonomic ganglia. Virology 189: 385-388. 
 123 
61. Peng W, Vitvitskaia O, Carpenter D, Wechsler SL, Jones C (2008) Identification of two 
small RNAs within the first 1.5-kb of the herpes simplex virus type 1–encoded latency-
associated transcript. Journal of Neurovirology 14: 41-52. 
62. Krug A, Luker GD, Barchet W, Leib DA, Akira S, et al. (2004) Herpes simplex virus type 1 
activates murine natural interferon-producing cells through toll-like receptor 9. Blood 
103: 1433-1437. 
63. Li H, Zhang J, Kumar A, Zheng M, Atherton SS, et al. (2006) Herpes simplex virus 1 
infection induces the expression of proinflammatory cytokines, interferons and TLR7 in 
human corneal epithelial cells. Immunology 117: 167-176. 
64. Frank GM, Buela KA, Maker DM, Harvey SA, Hendricks RL (2012) Early responding 
dendritic cells direct the local NK response to control herpes simplex virus 1 infection 
within the cornea. J Immunol 188: 1350-1359. 
65. Liu T, Tang Q, Hendricks RL (1996) Inflammatory infiltration of the trigeminal ganglion 
after herpes simplex virus type 1 corneal infection. J Virol 70: 264-271. 
66. Ghiasi H, Cai S, Perng GC, Nesburn AB, Wechsler SL (2000) The role of natural killer cells 
in protection of mice against death and corneal scarring following ocular HSV-1 
infection. Antiviral Res 45: 33-45. 
67. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA (1997) T Cell 
Receptorâ€“Î³/Î´ Cells Protect Mice from Herpes Simplex Virus Type 1â€“induced 
Lethal Encephalitis. The Journal of Experimental Medicine 185: 1969-1975. 
68. Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL (1999) Macrophage Control of 
Herpes Simplex Virus Type 1 Replication in the Peripheral Nervous System. J Immunol 
162: 2895-2905. 
69. Pereira RA, Simon MM, Simmons A (2000) Granzyme A, a Noncytolytic Component of 
CD8+ Cell Granules, Restricts the Spread of Herpes Simplex Virus in the Peripheral 
Nervous Systems of Experimentally Infected Mice. J Virol 74: 1029-1032. 
70. Minagawa H, Sakuma S, Mohri S, Mori R, Watanabe T (1988) Herpes simplex virus type 1 
infection in mice with severe combined immunodeficiency (SCID). Arch Virol 103: 73-
82. 
71. Beland JL, Sobel RA, Adler H, Del-Pan NC, Rimm IJ (1999) B cell-deficient mice have 
increased susceptibility to HSV-1 encephalomyelitis and mortality. Journal of 
Neuroimmunology 94: 122-126. 
72. Ghiasi H, Perng G, Nesburn AB, Wechsler SL (1999) Either a CD4(+)or CD8(+)T cell 
function is sufficient for clearance of infectious virus from trigeminal ganglia and 
establishment of herpes simplex virus type 1 latency in mice. Microb Pathog 27: 387-
394. 
 124 
73. Shimeld C, Whiteland JL, Nicholls SM, Grinfeld E, Easty DL, et al. (1995) Immune cell 
infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea 
with herpes simplex virus type 1. J Neuroimmunol 61: 7-16. 
74. Cantin E, Hinton D, Chen J, Openshaw H (1995) Gamma interferon expression during acute 
and latent nervous system infection by herpes simplex virus type 1. J Virol 69: 4898-
4905. 
75. Lepisto AJ, Frank GM, Xu M, Stuart PM, Hendricks RL (2006) CD8 T Cells Mediate 
Transient Herpes Stromal Keratitis in CD4-Deficient Mice. Invest Ophthalmol Vis Sci 
47: 3400-3409. 
76. Frank GM, Lepisto AJ, Freeman ML, Sheridan BS, Cherpes TL, et al. (2010) Early CD4+ T 
Cell Help Prevents Partial CD8+ T Cell Exhaustion and Promotes Maintenance of Herpes 
Simplex Virus 1 Latency. J Immunol 184: 277-286. 
77. Heiligenhaus A, Bauer D, Zheng M, Mrzyk S, Steuhl KP (1999) CD4+ T-cell type 1 and 
type 2 cytokines in the HSV-1 infected cornea. Graefes Arch Clin Exp Ophthalmol 237: 
399-406. 
78. Keadle TL, Morris JL, Pepose JS, Stuart PM (2002) CD4(+) and CD8(+) cells are key 
participants in the development of recurrent herpetic stromal keratitis in mice. Microb 
Pathog 32: 255-262. 
79. Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion 
strategies. Nat Rev Immunol 9: 503-513. 
80. Yewdell JW (2006) Confronting Complexity: Real-World Immunodominance in Antiviral 
CD8+ T Cell Responses. Immunity 25: 533-543. 
81. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR (2001) Immunoproteasomes Shape 
Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell 
Repertoire and Presentation of Viral Antigens. The Journal of Experimental Medicine 
193: 1319-1326. 
82. Kotturi MF, Peters B, Buendia-Laysa F, Jr., Sidney J, Oseroff C, et al. (2007) The CD8+ T-
Cell Response to Lymphocytic Choriomeningitis Virus Involves the L Antigen: 
Uncovering New Tricks for an Old Virus. J Virol 81: 4928-4940. 
83. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, et al. (2008) Naive Precursor Frequencies 
and MHC Binding Rather Than the Degree of Epitope Diversity Shape CD8+ T Cell 
Immunodominance. J Immunol 181: 2124-2133. 
84. Obar JJ, Khanna KM, Lefrancois L (2008) Endogenous naive CD8+ T cell precursor 
frequency regulates primary and memory responses to infection. Immunity 28: 859-869. 
 125 
85. Sheridan BS, Cherpes TL, Urban J, Kalinski P, Hendricks RL (2009) Reevaluating the CD8 
T-Cell Response to Herpes Simplex Virus Type 1: Involvement of CD8 T Cells Reactive 
to Subdominant Epitopes. J Virol 83: 2237-2245. 
86. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL (2003) Herpes Simplex Virus-
Specific Memory CD8+ T Cells Are Selectively Activated and Retained in Latently 
Infected Sensory Ganglia.  18: 593-603. 
87. Cornberg M, Chen AT, Wilkinson LA, Brehm MA, Kim S-K, et al. (2006) Narrowed TCR 
repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 116: 
1443-1456. 
88. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, et al. (2004) Limited T Cell 
Receptor Diversity of HCV-specific T Cell Responses Is Associated with CTL Escape. 
The Journal of Experimental Medicine 200: 307-319. 
89. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, et al. (2010) Effects of thymic selection of 
the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465: 
350-354. 
90. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, et al. (2007) Subdominant 
CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 
81: 3465-3476. 
91. Holtappels R, Simon CO, Munks MW, Thomas D, Deegen P, et al. (2008) Subdominant CD8 
T-cell epitopes account for protection against cytomegalovirus independent of 
immunodomination. J Virol 82: 5781-5796. 
92. Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, et al. (2011) Protective Efficacy 
of Serially Up-Ranked Subdominant CD8<sup>+</sup> T Cell Epitopes against Virus 
Challenges. PLoS Pathog 7: e1002041. 
93. Chen Y, Webster RG, Woodland DL (1998) Induction of CD8+ T Cell Responses to 
Dominant and Subdominant Epitopes and Protective Immunity to Sendai Virus Infection 
by DNA Vaccination. The Journal of Immunology 160: 2425-2432. 
94. Kim Y, Sette A, Peters B (2011) Applications for T-cell epitope queries and tools in the 
Immune Epitope Database and Analysis Resource. Journal of Immunological Methods 
374: 62-69. 
95. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, et al. (2006) A consensus 
epitope prediction approach identifies the breadth of murine TCD8+-cell responses to 
vaccinia virus. Nat Biotech 24: 817-819. 
96. St. Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL (2011) Defining the Herpes Simplex 
Virus-Specific CD8+ T Cell Repertoire in C57BL/6 Mice. The Journal of Immunology 
186: 3927-3933. 
 126 
97. Trapani JA, Smyth MJ (2002) Functional significance of the perforin/granzyme cell death 
pathway. Nat Rev Immunol 2: 735-747. 
98. Verjans GMGM, Hintzen RQ, van Dun JM, Poot A, Milikan JC, et al. (2007) Selective 
retention of herpes simplex virus-specific T cells in latently infected human trigeminal 
ganglia. Proceedings of the National Academy of Sciences 104: 3496-3501. 
99. Sheridan BS, Khanna KM, Frank GM, Hendricks RL (2006) Latent Virus Influences the 
Generation and Maintenance of CD8+ T Cell Memory. The Journal of Immunology 177: 
8356-8364. 
100. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL (2000) Cd8+ T Cells Can Block 
Herpes Simplex Virus Type 1 (HSV-1) Reactivation from Latency in Sensory Neurons. 
The Journal of Experimental Medicine 191: 1459-1466. 
101. Lekstrom-Himes JA, LeBlanc RA, Pesnicak L, Godleski M, Straus SE (2000) Gamma 
Interferon Impedes the Establishment of Herpes Simplex Virus Type 1 Latent Infection 
but Has No Impact on Its Maintenance or Reactivation in Mice. J Virol 74: 6680-6683. 
102. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB (1984) Selection of genetic 
variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. 
Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 
160: 521-540. 
103. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral 
Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in 
Distinct Stages of Functional Impairment. Journal of Virology 77: 4911-4927. 
104. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression 
on HIV-specific T cells is associated with T-cell exhaustion and disease progression. 
Nature 443: 350-354. 
105. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, et al. (2007) Liver-
infiltrating lymphocytes in chronic human hepatitis C virus infection display an 
exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J 
Virol 81: 2545-2553. 
106. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12: 492-499. 
107. Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, et al. (2010) Cooperation of Tim-3 and 
PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the 
National Academy of Sciences. 
108. Okazaki T, Okazaki I-m, Wang J, Sugiura D, Nakaki F, et al. (2011) PD-1 and LAG-3 
inhibitory co-receptors act synergistically to prevent autoimmunity in mice. The Journal 
of Experimental Medicine 208: 395-407. 
 127 
109. Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell 
exhaustion: an update on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother 56: 739-745. 
110. Riley JL (2009) PD-1 signaling in primary T cells. Immunological Reviews 229: 114-125. 
111. Oh JW, Seroogy CM, Meyer EH, Akbari O, Berry G, et al. (2002) CD4 T-helper cells 
engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and 
inflammation. J Allergy Clin Immunol 110: 460-468. 
112. Buelens C, Willems F, Delvaux A, Piérard G, Delville J-P, et al. (1995) Interleukin-10 
differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral 
blood dendritic cells. European Journal of Immunology 25: 2668-2672. 
113. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) INTERLEUKIN-10 AND 
THE INTERLEUKIN-10 RECEPTOR. Annual Review of Immunology 19: 683-765. 
114. Ng CT, Oldstone MBA (2012) Infected CD8α− dendritic cells are the predominant source 
of IL-10 during establishment of persistent viral infection. Proceedings of the National 
Academy of Sciences 109: 14116-14121. 
115. Trandem K, Zhao J, Fleming E, Perlman S (2011) Highly activated cytotoxic CD8 T cells 
express protective IL-10 at the peak of coronavirus-induced encephalitis. J Immunol 186: 
3642-3652. 
116. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, et al. (1993) Interleukin 10 
(IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural 
killer cell stimulatory factor/IL-12 synthesis in accessory cells. The Journal of 
Experimental Medicine 178: 1041-1048. 
117. Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, et al. (2010) IL-10 Restricts 
Memory T Cell Inflation during Cytomegalovirus Infection. The Journal of Immunology 
185: 3583-3592. 
118. Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, et al. (2008) IL-10 and PD-L1 
operate through distinct pathways to suppress T-cell activity during persistent viral 
infection. Proceedings of the National Academy of Sciences 105: 20428-20433. 
119. Brooks DG, Walsh KB, Elsaesser H, Oldstone MBA (2010) IL-10 directly suppresses CD4 
but not CD8 T cell effector and memory responses following acute viral infection. 
Proceedings of the National Academy of Sciences 107: 3018-3023. 
120. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S (2000) Human 
cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci 
U S A 97: 1695-1700. 
 128 
121. Stewart JP, Rooney CM (1992) The interleukin-10 homolog encoded by Epstein-Barr virus 
enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer 
cell responses. Virology 191: 773-782. 
122. Carr DJJ, Ash J, Lane TE, Kuziel WA (2006) Abnormal immune response of CCR5-
deficient mice to ocular infection with herpes simplex virus type 1. Journal of General 
Virology 87: 489-499. 
123. Koelle DM, Corey L (2008) Herpes Simplex: Insights on Pathogenesis and Possible 
Vaccines. Annual Review of Medicine 59: 381-395. 
124. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, et al. (2006) A randomized 
controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for 
the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24: 
914-920. 
125. Koelle DM, Corey L (2003) Recent Progress in Herpes Simplex Virus Immunobiology and 
Vaccine Research. Clin Microbiol Rev 16: 96-113. 
126. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, et al. (2003) The unique target 
specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 
chemokine receptors CCR5 and CXCR3. J Leukoc Biol 73: 273-280. 
127. Frank GM, Divito SJ, Maker DM, Xu M, Hendricks RL (2010) A novel p40-independent 
function of IL-12p35 is required for progression and maintenance of herpes stromal 
keratitis. Invest Ophthalmol Vis Sci 51: 3591-3598. 
128. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR (2007) Minimal activation of 
memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive 
CD8+ T cells. Nat Immunol 8: 1060-1066. 
129. Udaka K, Wiesmuller KH, Kienle S, Jung G, Tamamura H, et al. (2000) An automated 
prediction of MHC class I-binding peptides based on positional scanning with peptide 
libraries. Immunogenetics 51: 816-828. 
130. Vitiello A, Yuan L, Chesnut R, Sidney J, Southwood S, et al. (1996) Immunodominance 
analysis of CTL responses to influenza PR8 virus reveals two new dominant and 
subdominant Kb-restricted epitopes. The Journal of Immunology 157: 5555-5562. 
131. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol 22: 3099-3108. 
132. Gulukota K, Sidney J, Sette A, DeLisi C (1997) Two complementary methods for 
predicting peptides binding major histocompatibility complex molecules. J Mol Biol 267: 
1258-1267. 
 129 
133. La Gruta N, Doherty P, Turner S (2006) A correlation between function and selected 
measures of T cell avidity in influenza virus-specific CD8+ T cell responses. European 
Journal of Immunology 36: 2951-2959. 
134. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, et al. (2007) Naive CD4(+) T cell 
frequency varies for different epitopes and predicts repertoire diversity and response 
magnitude. Immunity 27: 203-213. 
135. Koelle DM, Corey L (2008) Herpes Simplex: Insights on Pathogenesis and Possible 
Vaccines. Annual Review of Medicine 59: 381-395. 
136. Rajčáni J, Andrea V, Ingeborg R (2004) Peculiarities of Herpes Simplex Virus (HSV) 
Transcription: An overview. Virus Genes 28: 293-310. 
137. Freeman ML, Lanzer KG, Cookenham T, Peters B, Sidney J, et al. (2010) Two Kinetic 
Patterns of Epitope-Specific CD8 T-Cell Responses following Murine 
Gammaherpesvirus 68 Infection. J Virol 84: 2881-2892. 
138. Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, et al. (2009) Correlates of 
protection efficacy induced by vaccinia virus-specific CD8<SUP><FONT SIZE='-
1'>+</FONT></SUP> T-cell epitopes in the murine intranasal challenge model. 
European Journal of Immunology 39: 717-722. 
139. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, et al. (1995) Antigenic 
oscillations and shifting immunodominance in HIV-1  infections. Nature 375: 606-
611. 
140. Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, et al. (2010) Uncovering the 
interplay between CD8, CD4 and antibody responses to complex pathogens. Future 
Microbiology 5: 221-239. 
141. Mikloska Z, Alison MK, Penfold MET, Cunningham AL (1996) Herpes Simplex Virus 
Protein Targets for CD4 and CD8 Lymphocyte Cytotoxicity in Cultured Epidermal 
Keratinocytes Treated with Interferon-γ. The Journal of Infectious Diseases 173: 7-17. 
142. Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, et al. (2003) Cutting Edge: 
Conventional CD8α+ Dendritic Cells Are Preferentially Involved in CTL Priming After 
Footpad Infection with Herpes Simplex Virus-1. The Journal of Immunology 170: 4437-
4440. 
143. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, et al. (2003) Epidermal Viral 
Immunity Induced by CD8{alpha}+ Dendritic Cells But Not by Langerhans Cells. 
Science 301: 1925-1928. 
144. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, et al. (2006) Migratory 
Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population 
for Efficient CTL Priming. Immunity 25: 153-162. 
 130 
145. Jirmo AC, Nagel C-H, Bohnen C, Sodeik B, Behrens GMN (2009) Contribution of Direct 
and Cross-Presentation to CTL Immunity against Herpes Simplex Virus 1. J Immunol 
182: 283-292. 
146. Sprecher E, Becker Y (1989) Langerhans cell density and activity in mouse skin and lymph 
nodes affect herpes simplex type 1 (HSV-1) pathogenicity. Archives of Virology 107: 
191-205. 
147. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG (1998) Entry of 
Alphaherpesviruses Mediated by Poliovirus Receptor-Related Protein 1 and Poliovirus 
Receptor. Science 280: 1618-1620. 
148. Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes Simplex Virus-1 Entry into 
Cells Mediated by a Novel Member of the TNF/NGF Receptor Family. Cell 87: 427-436. 
149. Chiu YG, Bowers WJ, Lim ST, Ryan DA, Federoff HJ (2009) Effects of Herpes Simplex 
Virus Amplicon Transduction on Murine Dendritic Cells. Human Gene Therapy 20: 442-
452. 
150. Mikloska Z, Bosnjak L, Cunningham AL (2001) Immature Monocyte-Derived Dendritic 
Cells Are Productively Infected with Herpes Simplex Virus Type 1. J Virol 75: 5958-
5964. 
151. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, et al. (2000) Mature Dendritic Cells 
Infected with Herpes Simplex Virus Type 1 Exhibit Inhibited T-Cell Stimulatory 
Capacity. J Virol 74: 7127-7136. 
152. Stock AT, Jones CM, Heath WR, Carbone FR (2006) CTL response compensation for the 
loss of an immunodominant class I-restricted HSV-1 determinant. Immunol Cell Biol 84: 
543-550. 
153. Blaney JE, Jr., Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, et al. (1998) 
Immunization with a Single Major Histocompatibility Complex Class I-Restricted 
Cytotoxic T-Lymphocyte Recognition Epitope of Herpes Simplex Virus Type 2 Confers 
Protective Immunity. J Virol 72: 9567-9574. 
154. Bonneau RH, Salvucci LA, Johnson DC, Tevethia SS (1993) Epitope Specificity of H-2Kb-
Restricted, HSV-1-, and HSV-2-Cross-Reactive Cytotoxic T Lymphocyte Clones. 
Virology 195: 62-70. 
155. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, et al. (2006) Diversity of the CD8+ 
T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital 
Herpes. J Virol 80: 5509-5515. 
156. Zelinskyy G, Myers L, Dietze KK, Gibbert K, Roggendorf M, et al. (2011) Virus-specific 
CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus 
infection but are highly cytotoxic and control virus replication. J Immunol 187: 3730-
3737. 
 131 
157. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. (2007) Molecular signature of 
CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684. 
158. Tal-Singer R, Lasner T, Podrzucki W, Skokotas A, Leary J, et al. (1997) Gene expression 
during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous 
system is different from that during lytic infection of tissue cultures. J Virol 71: 5268-
5276. 
159. Everett RD, Boutell C, Orr A (2004) Phenotype of a herpes simplex virus type 1 mutant that 
fails to express immediate-early regulatory protein ICP0. J Virol 78: 1763-1774. 
160. Mueller SN, Jones CM, Chen W, Kawaoka Y, Castrucci MR, et al. (2003) The early 
expression of glycoprotein B from herpes simplex virus can be detected by antigen-
specific CD8+ T cells. J Virol 77: 2445-2451. 
161. Vincent BG, Young EF, Buntzman AS, Stevens R, Kepler TB, et al. Toxin-Coupled MHC 
Class I Tetramers Can Specifically Ablate Autoreactive CD8+ T Cells and Delay 
Diabetes in Nonobese Diabetic Mice. J Immunol 184: 4196-4204. 
162. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al. (1999) A small-molecule, 
nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc 
Natl Acad Sci U S A 96: 5698-5703. 
163. Wakim LM, Woodward-Davis A, Bevan MJ (2010) Memory T cells persisting within the 
brain after local infection show functional adaptations to their tissue of residence. 
Proceedings of the National Academy of Sciences 107: 17872-17879. 
164. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, et al. (2011) Different patterns 
of peripheral migration by memory CD4+ and CD8+ T cells. Nature 477: 216-219. 
165. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, et al. (2009) Memory T cells 
in nonlymphoid tissue that provide enhanced local immunity during infection with herpes 
simplex virus. Nat Immunol 10: 524-530. 
166. Lundberg P, Openshaw H, Wang M, Yang HJ, Cantin E (2007) Effects of CXCR3 signaling 
on development of fatal encephalitis and corneal and periocular skin disease in HSV-
infected mice are mouse-strain dependent. Invest Ophthalmol Vis Sci 48: 4162-4170. 
167. Thapa M, Welner RS, Pelayo R, Carr DJJ (2008) CXCL9 and CXCL10 Expression Are 
Critical for Control of Genital Herpes Simplex Virus Type 2 Infection through 
Mobilization of HSV-Specific CTL and NK Cells to the Nervous System. The Journal of 
Immunology 180: 1098-1106. 
168. Thapa M, Carr DJ (2009) CXCR3 deficiency increases susceptibility to genital herpes 
simplex virus type 2 infection: Uncoupling of CD8+ T-cell effector function but not 
migration. J Virol 83: 9486-9501. 
 132 
169. Cook WJ, Kramer MF, Walker RM, Burwell TJ, Holman HA, et al. (2004) Persistent 
expression of chemokine and chemokine receptor RNAs at primary and latent sites of 
herpes simplex virus 1 infection. Virol J 1: 5. 
170. Wickham S, Lu B, Ash J, Carr DJ (2005) Chemokine receptor deficiency is associated with 
increased chemokine expression in the peripheral and central nervous systems and 
increased resistance to herpetic encephalitis. J Neuroimmunol 162: 51-59. 
171. Reddy PBJ, Sehrawat S, Suryawanshi A, Rajasagi NK, Mulik S, et al. (2011) Influence of 
Galectin-9/Tim-3 Interaction on Herpes Simplex Virus-1 Latency. The Journal of 
Immunology 187: 5745-5755. 
172. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, et al. (2010) Galectin-
9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. 
PLoS Pathog 6: e1000882. 
173. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in 
exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. 
174. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-
10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-1309. 
175. Cohen J (2010) Painful Failure of Promising Genital Herpes Vaccine. Science 330: 304-. 
176. Nesburn A, Ghiasi H, Wechsler S (1990) Ocular safety and efficacy of an HSV-1 gD 
vaccine during primary and latent infection. Invest Ophthalmol Vis Sci 31: 1497-1502. 
177. Lev A, Princiotta MF, Zanker D, Takeda K, Gibbs JS, et al. (2010) Compartmentalized 
MHC class I antigen processing enhances immunosurveillance by circumventing the law 
of mass action. Proc Natl Acad Sci U S A 107: 6964-6969. 
178. Du T, Zhou G, Roizman B (2011) HSV-1 gene expression from reactivated ganglia is 
disordered and concurrent with suppression of latency-associated transcript and miRNAs. 
Proceedings of the National Academy of Sciences 108: 18820-18824. 
179. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, et al. (1998) Induction and 
exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes 
visualized using soluble tetrameric major histocompatibility complex class I-peptide 
complexes. J Exp Med 187: 1383-1393. 
180. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral 
immune evasion due to persistence of activated T cells without effector function. J Exp 
Med 188: 2205-2213. 
181. Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, et al. (2007) Pathogen-Specific CD8 T 




182. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. (2006) Resolution of a 
chronic viral infection after interleukin-10 receptor blockade. The Journal of 
Experimental Medicine 203: 2461-2472. 
183. Margolis TP, Elfman FL, Leib D, Pakpour N, Apakupakul K, et al. (2007) Spontaneous 
Reactivation of Herpes Simplex Virus Type 1 in Latently Infected Murine Sensory 
Ganglia. Journal of Virology 81: 11069-11074. 
184. Dong L, Li P, Oenema T, McClurkan CL, Koelle DM Public TCR Use by Herpes Simplex 
Virus-2-Specific Human CD8 CTLs. J Immunol 184: 3063-3071. 
185. Ramachandran S, Davoli KA, Yee MB, Hendricks RL, Kinchington PR (2010) Delaying 
the Expression of Herpes Simplex Virus Type 1 Glycoprotein B (gB) to a True Late Gene 
Alters Neurovirulence and Inhibits the gB-CD8+ T-Cell Response in the Trigeminal 
Ganglion. Journal of Virology 84: 8811-8820. 
186. Ely KH, Cookenham T, Roberts AD, Woodland DL (2006) Memory T Cell Populations in 
the Lung Airways Are Maintained by Continual Recruitment. The Journal of 
Immunology 176: 537-543. 
187. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M (2009) Interleukin-10 provides direct trophic 
support to neurons. J Neurochem 110: 1617-1627. 
188. Pinkoski MJ, Winkler U, Hudig D, Bleackley RC (1996) Binding of Granzyme B in the 
Nucleus of Target Cells. Journal of Biological Chemistry 271: 10225-10229. 
189. Xie J, Huppa JB, Newell EW, Huang J, Ebert PJ, et al. (2012) Photocrosslinkable pMHC 
monomers stain T cells specifically and cause ligand-bound TCRs to be 'preferentially' 
transported to the cSMAC. Nat Immunol 13: 674-680. 
190. Cui W, Liu Y, Weinstein JS, Craft J, Kaech SM (2011) An interleukin-21-interleukin-10-
STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 
35: 792-805. 
 
 
